Mathematical modelling of tumour-immune competition tumour growth : discrete and continuum approaches by Macfarlane, Fiona Ruth
MATHEMATICAL MODELLING OF TUMOUR-IMMUNE 
COMPETITION AND TUMOUR GROWTH: DISCRETE AND 
CONTINUUM APPROACHES 
Fiona Ruth Macfarlane 
A Thesis Submitted for the Degree of PhD 
at the 
University of St Andrews 
 
  
2019 
Full metadata for this thesis is available in                                                      
St Andrews Research Repository 
at: 
http://research-repository.st-andrews.ac.uk/ 
 
 
 
Please use this identifier to cite or link to this thesis: 
http://hdl.handle.net/10023/18194  
 
 
 
This item is protected by original copyright 
 
This item is licensed under a 
Creative Commons License 
https://creativecommons.org/licenses/by-nc-nd/4.0 
Mathematical modelling of tumour-immune competition and
tumour growth: Discrete and continuum approaches
Fiona Ruth Macfarlane
This thesis is submitted in partial fulfilment for the degree of
Doctor of Philosophy (PhD)
at the University of St Andrews
March 2019

Abstract
The ability of the human immune system to detect and remove cancer cells is ex-
ploited in the development of immunotherapy techniques. However, further under-
standing of these mechanisms is required and can be achieved through the use of
mathematical models. In this thesis, we develop a simple individual-based model of
cell movement and illustrate the ability of our model to qualitatively reproduce the
migration patterns of immune cells that have been observed in single cell tracking
experiments. We then extend the model to describe the spatio-temporal interactions
between dendritic cells, cytotoxic T cells and a solid tumour. Through further exten-
sion of the model, we explicitly consider the immune recognition of evolving tumour
antigens. Computational simulations of our models further clarify the conditions for
the onset of a successful immune action against cancer cells and may suggest pos-
sible targets to improve the efficacy of immunotherapy. Mathematically, individual-
based models can be limited in their amenability to different analysis techniques
which are better suited to continuum models. To overcome this, we aim to derive
the continuum version of our described individual-based models. However, due to
the complexity of the biological mechanisms included, we first consider a simpler
biological situation. We develop an individual-based model describing the spatial
dynamics of multicellular systems whereby cells undergo pressure-driven movement
and pressure-dependent proliferation. From this, we formally derive nonlinear par-
tial differential equations that are commonly used to model the spatial dynamics
of growing cell populations. Through systematic comparison of both models, we
demonstrate that the results of computational simulations of the individual-based
model faithfully mirror the qualitative and quantitative properties of the solutions
to the corresponding partial differential equations. This method could be adapted
to more complex individual-based models, such as those we describe in this work.
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Chapter 1
Introduction
Cancer is defined as ‘a disease caused by uncontrolled division of abnormal cells in
a part of the body ’ (Oxford University Press, 2019). With over two hundred types
of cancer, each with their own causes, symptoms and treatment options, research
into this group of diseases is continually expanding and becoming more diverse.
The prevalence of these diseases is vast, in particular, in the UK around 50% of
the population will be diagnosed with some form of cancer in their life (Cancer
Research UK, 2018). Furthermore, over 18 million new cases of cancer and over 9
million deaths due to cancer were reported globally in 2018 (Bray et al., 2018; Ferlay
et al., 2018), see Figure 1.1. Consequently, most, if not all, of the UK (and global)
population will be, directly or indirectly, affected by cancer over their lifetime.
Traditionally, chemotherapy treatments, radiotherapy treatments and surgery
have been administered to manage and treat a wide range of cancers. However, side
effects of these treatment approaches can be severe. For example, they can include:
sustained damage to healthy cells, nausea, fertility issues, hair loss and psychological
issues (Carelle et al., 2002; Coates et al., 1983). More recently, the focus of cancer
therapy research has turned to developing targeted and more personalised treatment
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Figure 1.1: Global cancer incidence rates and mortality rates (2018). The
left pie chart shows the number of new cases worldwide of different types of cancer
in 2018 for both sexes and all ages. The right pie chart shows the number of cancer
deaths worldwide for different types of cancer in 2018 for both sexes and all ages.
Figure adapted from the Global Cancer Observatory website (Ferlay et al., 2019) taking data
from (Bray et al., 2018; Ferlay et al., 2018). c© International Agency for Research on Cancer 2019
against cancers. The development of these new treatment approaches relies on the
understanding of the key mechanisms, or hallmarks (Hanahan and Weinberg, 2011),
which underpin this group of diseases. One key hallmark is the ability of cancer cells
to evade the immune response, which naturally suggests that the immune system
can also control cancer to a limited extent.
The immune system is a complex collection of cells, structures and processes
which allow for the destruction of harmful foreign substances that invade the hu-
man body. Additionally, the immune system can retain memory of these substances
to allow for a prompt response in the event of re-exposure. A notable aspect of the
immune system is the ability to target only the harmful substances and not healthy
cells within the body. This makes the immune system a potentially useful mechan-
ism for controlling and treating cancers. Consequently, immunotherapy techniques
have been, and continue to be, developed to utilise these properties and offer a more
2
personalised form of cancer treatment (Coulie et al., 2014; Fesnak et al., 2016; Got-
wals et al., 2017). However, the development and testing of new therapy techniques
can be an expensive and time-consuming process.
Mathematical modelling has been used previously to describe complex biolo-
gical interactions including tumour-immune competition. These models allow for
a greater understanding of these interactions and can be used to distinguish the
key underlying mechanisms. Furthermore, mathematical models allow for the time-
efficient and inexpensive testing of potential treatment ideas that, upon success,
can be further investigated by experimentalists and clinicians. In this work, we aim
to use mathematical modelling techniques to investigate the dynamical interactions
occurring between the cells of the immune system and a solid tumour, including
biologically relevant parameters where possible.
In Chapter 2, we begin with an overview of the key biological and immuno-
logical mechanisms involved in the recognition and removal of solid tumours and
provide a short review of current immunotherapy techniques. We specifically fo-
cus on the role of dendritic cells and cytotoxic T lymphocytes which can recognise,
and respond to, antigens expressed by tumour cells. Following this, a summary of
the previously used and currently used mathematical modelling techniques within
the field of mathematical oncology is given in Chapter 3. In particular, we high-
light models and techniques used to describe the biophysical properties of cells and
tumour-immune interactions. Following these background chapters, we provide the
main body of this work.
To capture the experimentally observed migration patterns of immune cells we
develop an individual-based random walk model for cell motion in Chapter 4. In
particular, we consider a homogeneous cell population (i.e. all cells exhibit the same
phenotype) and allow the cell population to perform one of two random walks: a
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Le´vy walk or Brownian motion. Through observations of the resulting cell traject-
ories, we compare both stochastic models. We illustrate the ability of our model
to reproduce qualitatively the spatial trajectories of immune cells in the tumour
microenvironment observed in experimental data of single cell tracking. In corres-
pondence with experimental findings, a Le´vy walk appears to capture the movement
of inactive immune cells, whereas Brownian motion can describe the movement of
antigen-activated immune cells. Utilising these properties of immune cell motion we
develop the model further to consider the immune response to a solid tumour.
In Chapter 5, we extend the individual-based model to describe the interactions
between dendritic cells, cytotoxic T lymphocytes and tumour cells. We exploit the
random walk methods described in Chapter 4 to capture the movement of inactive
and active immune cells, i.e. the movement of both inactive and active dendritic cells
and cytotoxic T lymphocytes, in the tumour microenvironment. Furthermore, we
consider the activation process of immune cells, the proliferation of cancer cells, and
the destruction of cancer cells by the immune cells. The resulting computational
simulations of our model further clarify the conditions for the onset of successful
immune action against cancer cells and may suggest possible targets to improve
the efficacy of cancer immunotherapy. For the sake of simplicity, in the model we
consider a homogeneous tumour whereby all cancer cells exhibit the same phenotype.
However, solid tumours can be heterogeneous where each cancer cell can have a
unique antigen profile. In the following chapter we address this by extending the
individual-based model further to explicitly include tumour antigen expression and
further investigate the role of antigens within the immune response to cancer.
We describe, in Chapter 6, the expanded individual-based model where each
cancer cell is characterised by an antigen profile which can vary over time due to
either epimutations or mutations. Once again, the immune response against the
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cancer cells is initiated by dendritic cells that recognise the tumour antigens and
present them to cytotoxic T cells. Consequently, T cells become activated against a
particular tumour antigen and can only remove cancer cells which express a sufficient
level of the corresponding antigen. Computational simulations of the model highlight
the required conditions for the emergence of tumour clearance, dormancy or escape.
Furthermore, the model allows us to assess the impact of antigenic heterogeneity of
cancer cells on the efficacy of immune action. The results suggest that epimutations,
which alter the antigen profile of tumour cells, ultimately dictate the outcome of
tumour-immune competition. The results further indicate which other processes can
control the outcome of tumour-immune competition, and therefore suggest which
mechanisms may be exploited in the development of new immunotherapy techniques.
One potential limitation, in terms of mathematical interest, of individual-based
models is their lack of amenability to mathematical analysis. To overcome this we
aim to derive the continuum counterparts of the individual-based models introduced
in this work. However, due to the inclusion of a Le´vy walk and other complex mech-
anisms, we begin by considering a simpler cell population model in Chapter 7. We
present a simple stochastic individual-based model describing the spatial dynam-
ics of multicellular systems whereby cells undergo pressure-driven movement and
pressure-dependent proliferation. We show that nonlinear partial differential equa-
tions commonly used to model the spatial dynamics of growing cell populations can
be formally derived from the branching random walk that underlies our discrete
model. Moreover, we carry out a systematic comparison between the individual-
based model and its continuum counterparts, both in the case of one single cell
population and in the case of multiple cell populations with different biophysical
properties. The outcomes of our comparative study demonstrate that the results of
computational simulations of the individual-based model faithfully mirror the qual-
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itative and quantitative properties of the solutions to the corresponding nonlinear
partial differential equations. Although the model is not applied to a specific biolo-
gical case, the methodology and results obtained could be used to describe tumour
growth and invasion into healthy tissue.
Chapter 8 concludes this thesis with an overview of the mathematical models
we have developed and the main findings of our work. We finish by considering
the future directions and potential applications of the modelling techniques we have
developed.
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Chapter 2
Biological overview of the immune
response to cancer
2.1 Overview
In this chapter we introduce the key biological mechanisms involved in the immune
response to cancer. We begin by considering the human immune system and, spe-
cifically, how its separate components can work together. In this thesis, we will
focus on two immune cell types: dendritic cells (DCs) and cytotoxic T lymphocytes
(CTLs) and how they interact with each other to remove harmful cells and material
from the body. Additionally, we will describe some of the key aspects of tumour
growth and development, such as the expression of tumour antigens, and the ways in
which the immune system can control these processes. We will conclude the chapter
by considering some of the properties of cancer which allow for the evasion of the
immune response and the immunotherapy techniques which have been developed to
target these aspects.
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Figure 2.1: Cellular components of the human immune response. The
figure displays the key cell types involved in the innate and adaptive branches of
the human immune response. In this work, we focus on dendritic cells and how
they activate the adaptive immune response, namely CD8+ T cells ( i.e. cytotoxic T
lymphocytes), to launch an attack against cancer cells.
Reprinted with permission from Macmillan Publishers Ltd: [Nat Rev Cancer] (Dranoff, G. (2004).
Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 4(1), 11-22.), copyright
(2004) (Dranoff, 2004)
2.2 Immunology
The human immune system is a complex collection of cells, structures and processes
that work in conjunction to eliminate foreign and harmful material from within the
body. The immune system consists of two branches: the innate immune response
and the adaptive immune response, which both incorporate multiple cell types, as
shown in Figure 2.1.
The role of the innate immune response is to identify and attempt to remove
foreign material from the body. Cells which are involved in the innate response can
exhibit a range of phenotypes and perform a range of functions and they include:
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natural killer (NK) cells, macrophages and dendritic cells (DCs). Specifically, NK
cells can induce the death of target cells without requiring activation by other cells
via cell lysis (i.e. disintegration) which results in cell debris within the microenvir-
onment (Messerschmidt et al., 2016). Macrophages and DCs, on the other hand, are
phagocytic, which means that they can engulf and remove harmful particles or cells
that have been marked for removal by antibodies (Chaplin, 2010). The destruction
and removal of target cells by NK cells, DCs and macrophages can be limited, how-
ever their recognition of, and interactions with, foreign cells can initiate the adaptive
immune response (Messerschmidt et al., 2016).
Almost all cells within the human body express protein antigens on their cell
surface through major histocompatibility complex (MHC) molecules allowing them
to be recognised by the immune system (Brown et al., 2014). DCs and macrophages
can act as antigen presenting cells (APCs) where they can collect and present these
antigens to the adaptive immune cells (Weinberg, 2007a). The APCs can collect
antigens through the recognition of signals from phagocytosed cells, or living target
cells, where they then produce recognition receptors to allow for antigen collection.
Inflammatory or anti-inflammatory cytokines may also be released by the immune
cells to aid in the collection of antigens (Harshyne et al., 2001).
Once collected, the APCs can process the antigen and load them on to MHC
molecules on their cell surface (Chaplin, 2010). In particular, dendritic cells can
recognise and present multiple type of antigen (Coico and Sunshine, 2015). Once
the APCs have processed the antigen they move to the lymph nodes to present the
antigen to adaptive immune cells, specifically T cells (Laoui et al., 2016; Parlato
et al., 2017). It is interesting to note that T cells cannot bind to unprocessed
antigens which are not attached to MHC molecules.
Naive T lymphocytes within the lymph node can be activated via the antigen
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presenting cells. APCs present the antigen through an antigen-MHC complex on
their cell surface which can bind to the T cell receptor (TCR) on the surface of the
lymphocytes (Chaplin, 2010; Rohrs et al., 2019). The activation process relies on
co-stimulatory (e.g CD28) and co-inhibitory (e.g CTLA-4, PD-1) molecules (Keir
et al., 2008; Chen and Flies, 2013). Subsequently, the T cells can mature into dif-
ferent subtypes including cytotoxic T lymphocytes, T helper (Th) cells and memory
T cells (Weinberg, 2007a) depending on the antigen-MHC complex and other com-
plementary molecules. If a dendritic cell, carrying an antigen, meets an inactive T
cell the binding affinity of the T cell to the antigen-MHC complex plays a critical
role in the activation of the T cells ( Luksza et al., 2017). If the binding affinity of
the T cell is too low they cannot interact with the APC. On the other hand, if the
binding affinity is too high then the immune cells may be able to bind to nonharm-
ful cells causing autoimmune reactions (Engelhardt et al., 2012; Tan et al., 2015).
CD8 glycoproteins on the surface of naive T cells strengthen the interaction with
the APC and results in the maturation to CD8+ T cells, also known as cytotoxic T
lymphocytes (CTLs) (Chaplin, 2010). Through this interaction with APCs, CTLs
become activated and subsequently can recognise and destroy any cells or particles
that express the target antigen (Weinberg, 2007a). However, T cells only produce
one type of antigen receptor and therefore can only target cells expressing that par-
ticular antigen (Brenner et al., 2008; Coico and Sunshine, 2015). Not all target
cells will express the same target antigens and therefore, it has been suggested that,
a repertoire of T cells activated against a range of antigens will result in a more
successful immune response (Chaplin, 2010). The activated T cells will then travel
to the site of infection, or the site of the target cells (Halle et al., 2016), where
they can then recognise these cells through the interaction of their TCR with an
antigen-MHC complex on the surface of the target cell (Messerschmidt et al., 2016).
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Once the T cell has recognised the target cell, there are two mechanisms which
can be used to cause apoptosis (programmed cell death). These are the perforin-
granzyme mechanism or the Fas-FasL mechanism, which may be used independently
or together to remove harmful cells. The former mechanism is where perforin is
injected directly into the target cell, through a synapse, creating small holes in the
cell membrane. Subsequently, granzyme B can enter the target cell through these
small holes and activate the apoptotic cascade within the target cell (Basu et al.,
2016; Lawrence, 2016; Messerschmidt et al., 2016). The second mechanism that the
CTL can use to cause apoptosis utilises necrosis factors like the Fas ligand (FasL).
Generally, FasL is present on the cell surface of the CTL which allows direct contact
between the CTL and cells that produce the Fas receptor. Most cells will produce
Fas receptors on their cell surface. Once FasL or sFasL binds to the Fas receptor,
they aggregate to form an adaptor protein known as FADD (Fas associated death
domain) which can trigger apoptosis, resulting in target cell death (Hersey and
Zhang, 2001).
After all target cells are removed, CTLs must be deactivated or removed to pre-
vent any damage being done to normal cells. This response has three stages: an
inactivation phase, a self-apoptosis stage, and the formation of a subset of memory
cells (Klebanoff et al., 2006). The deactivation process prevents the risk of autoim-
mune diseases occurring and the formation of a memory population allows for a
faster response if the same antigen is recognised in future.
In this thesis, we focus on DCs and CTLs in particular and how they interact
together through the antigen presentation process. We utilise the properties of
these cell types in the individual-based models described in Chapter 4, Chapter 5
and Chapter 6.
11
Figure 2.2: The ten hallmarks of cancer and their potential treatment
options. The figure describes the ten key characteristics of a tumour and highlights
therapies which target each characteristic. In this work we specifically focus on the
ability of the immune system to control the tumour and subsequently, the ability of
tumours to evade immune destruction.
Reprinted from Cell, 144 (5), D Hanahan, RA Weinberg, Hallmarks of Cancer: The Next Gener-
ation, 646-674, Copyright (2011), with permission from Elsevier (Hanahan and Weinberg, 2011)
2.3 Tumour development
Hanahan and Weinberg (2011) (re)defined the ten hallmarks, or key characteristics,
of cancer, which are displayed in Figure 2.2. These include the ability of cancer cells
to sustain/enhance replication and growth (cell proliferation), avoid growth sup-
pressors, avoid the immune response, be able to divide/replicate indefinitely, recruit
immune cells to cause inflammation, invade another area of the body (formation
of metastasis), create new blood vessels (angiogenesis), mutate, resist cell death
(apoptosis) and alter their metabolic processes to avoid the need for oxygen.
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Mutations, or epimutations, within healthy cells, which alter the antigen ex-
pressed by the cell, can lead to the emergence of cancer cells. Through cell division,
the altered cells cluster together to form a growing tumour. In the early stages of
tumourigenesis, cancer cells stay close to the original site of the tumour (Hanahan
and Weinberg, 2011). However, once the tumour has developed and is large enough
it can begin to create a blood supply through angiogenesis. This allows single cells
to leave the tumour mass and travel to other sites of the body, through the blood
stream, and form metastasis (Weinberg, 2007b). Furthermore, the process that
leads human cells to induce their own cell death depends on the shortening of the
telomeres at the end of chromosomes through each cell division. Therefore, once
the telomeres shorten significantly the cell can no longer replicate and will initiate
apoptosis leading to cell death. However, most cancer cells express high levels of
telomerase, an enzyme that prevents the shortening of the telomeres allowing for
a longer or infinite survival of cells (Shay et al., 2001). In our work we focus on
tumours in the early stages of development (i.e. small pre-angiogenic tumours).
Cancer cells within the tumour can exhibit a distinct set of phenotypes and
antigens making the tumour heterogeneous. These tumour antigens dictate which
genes and proteins that the tumour cell expresses. There are three main types of tu-
mour antigen: (i) tumour associated antigens (TAAs), (ii) tumour specific antigens
(TSAs) or (iii) cancer-testis antigens (CTAs). Tumour associated antigens are over
expressed in cancer cells but can also be found in normal healthy cells, whereas tu-
mour specific antigens are only expressed by cancer cells. Furthermore, cancer-testis
antigens are expressed in cancer cells but also in the normal reproductive tissues at
low levels (Yarchoan et al., 2017). One potential drawback to the development of
new cancer therapies is the ability to identify these tumour antigens. Recently, with
this aim extensive cell-based studies have been carried out and used to successfully
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identify tumour antigens (Brown et al., 2014; Joglekar et al., 2019).
Furthermore, through epimutations or mutations the antigen profile of cancer
cells may evolve over time. Epimutations are spontaneous ‘heritable changes in
gene expression that leave the sequence of bases in the DNA unaltered ’ (Oey and
Whitelaw, 2014), whereas mutations take place during cell division and may cause
the antigen profile of one progeny cell to be different from that of the parent cell.
One of the first epimutations to be identified, in cancer cells, was the loss of DNA
methylation at the CpG dinucleotides. DNA methylation is an important mechan-
ism in gene regulation where the addition of methyl groups to DNA can repress gene
expression (Coulie et al., 2014). In normal cells 70-80% of all CpG dinucleotides are
methylated. However, hypomethylation in cancer cells can lead to gene activation,
mismatch repair, chromosomal instability and mechanisms of viral effects in can-
cer (Feinberg and Tycko, 2004). Generally, epimutations are reversible and occur
much more frequently than mutations, which are generally not reversible (Feinberg,
2004; Peltoma¨ki, 2012).
Notably, one tumour antigen gene family of interest are the melanoma asso-
ciated genes (MAGE) which are cancer-testis antigens. MAGE-A genes are fre-
quently expressed in cancers of different types and originating from different tissues
and are linked to poor prognosis. In regards to DNA methylation, MAGE genes
are methylated in normal cells but in cancer cells are not, allowing for their ac-
tivation and expression (Boon et al., 2006; Chalitchagorn et al., 2004; Chinnasamy
et al., 2011; Mu¨ller-Richter et al., 2009; Zajac et al., 2017). Demethylation becomes
more prominent as the cancer develops, suggesting that these epigenetic events
are important in tumour progression (Coulie et al., 2014). Furthermore, MAGE-
A proteins are involved in processes which reduce apoptosis of tumour cells and
enhance tumour proliferation, therefore benefiting tumour progression if they are
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expressed (Van Tongelen et al., 2017). Common cancers that they are expressed in
are melanomas (Boon et al., 2006; Connerotte et al., 2008; Coulie et al., 2014; Uro-
sevic et al., 2005), oesophageal cancers (Zajac et al., 2017), lung, breast, prostate and
colorectal carcinomas (Coulie et al., 2014) and head and neck cancers (Hartmann
et al., 2016; Mu¨ller-Richter et al., 2009). Moreover, there can be high variabil-
ity of specific antigen expression between patients with the same cancer and even
within samples from the same patient (Hartmann et al., 2016; Mu¨ller-Richter et al.,
2009; Urosevic et al., 2005). In this thesis, we focus on these MAGE-A antigens in
particular and how their expression varies over time through epimutations. These
mechanisms are utilised in the individual-based model described in Chapter 6.
2.4 Tumour immunology
Early experimental studies highlighted that immunodeficient mice were more likely
to develop cancers than those with a healthy immune system (Hanahan and Wein-
berg, 2011). Furthermore, the presence of T lymphocytes within the tumour mi-
croenvironment can be used as a marker to predict the success of cancer treat-
ments (Spranger and Gajewski, 2018). These findings indicate that the immune
system is capable of controlling and preventing tumour development. The mechan-
isms of the immune response against cancer have been studied in depth to provide
an understanding of the key mechanisms involved. In general, tumour cells are
poor antigen presenting cells (Dhodapkar et al., 2008) and therefore innate immune
cells are required to act as antigen presenting cells (APCs) to initiate a success-
ful response against tumours. Specifically, dendritic cells (DCs) can collect tumour
antigens to become activated APCs (Bianca et al., 2012; Dhodapkar et al., 2008;
Harshyne et al., 2003). The activated DCs can then subsequently activate cytotoxic
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T lymphocytes (CTLs) to initiate a response against the tumour. Since tumour
cells express MHC (Algarra et al., 2000), they can be recognised by the activated
T cells, which may result in tumour cell death (Boissonnas et al., 2007; Christophe
et al., 2015; Engelhardt et al., 2012; Phan and Rosenberg, 2013; Spranger, 2016).
Notably, cancer cells normally produce Fas receptors at higher levels than noncan-
cer cells, making them more susceptible to removal by CTLs through the Fas-FasL
mechanism (Modiano and Bellgrau, 2016).
In recent years, cell imaging techniques have improved greatly permitting single
cell tracking of immune cells and tumour cells in real time in both in vitro and in
vivo situations. This allows for a greater understanding of cell movement, velocity
and spatial distributions within the tumour microenvironment. These imaging tech-
niques generally involve the labelling of cells with fluorescent proteins, or genetically
engineering cells to produce specific reporter proteins (Liu and Li, 2014). For ex-
ample, Boissonnas et al. (2007) used individual cell tracking to study the movement
of CTLs, in vivo, in the presence and absence of a tumour antigen, and verified a
change in their patterns of migration between these situations. In the case where no
antigen was present, the cells moved actively in a search-like pattern. On the other
hand, when the tumour antigen was present, the cells switched to a more restricted
form of movement. Engelhardt et al. (2012) discovered similar results when studying
the movement of DCs in response to a solid tumour, where the change in movement
was linked to the presence or absence of tumour antigen.
Overall, many experimental studies have concluded that the immune system is
able to remove early stage tumours and cancer cells, however through antigenic
changes and other evolutionary mechanisms the disease can adapt to evade the
immune response through a process known as immunoediting (Aguirre-Ghiso, 2007).
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2.5 Immunoediting
2.5.1 Tumour dormancy
At the initial stages of immunoediting the tumour can undergo a period of dormancy
where there is no change in size of the tumour. There are three types of dormancy:
(i) tumour mass dormancy, (ii) cellular dormancy or (iii) immunological dormancy.
In more detail, tumour mass dormancy is where the tumour does not grow due to the
environmental conditions, such as lack of blood flow or nutrients. On the other hand,
cellular dormancy is where the tumour cells do not undergo growth phases (Aguirre-
Ghiso, 2007; Wang and Lin, 2013). Furthermore, immunological dormancy is where
the tumour is maintained at a reduced size by the immune system (Manjili, 2018;
Yeh and Ramaswamy, 2015). During tumour dormancy, mutations and epimutations
can allow the tumour cells to become less susceptible to the immune response (Teng
et al., 2008). This accumulation of favourable changes within the tumour cells
may result in relapse and a more aggressive disease. Additionally, single cells may
migrate away from the dormant tumour and form a secondary tumour (i.e. meta-
stasis) (Gomis and Gawrzak, 2017). We describe the biological settings required for
the onset of tumour dormancy in the individual-based model described in Chapter 6.
2.5.2 Immune evasion
It is clear that some tumour cells must evade the immune response to develop a solid
tumour and eventually cause damage within the body. There are several mechan-
isms that tumour cells can use to do this. Generally, if tumour-infiltrating CTLs
are present along with chemokines, such as interferons, the tumour cells generally
use immune suppression pathways to inhibit and attack the immune response. If
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tumour-infiltrating CTLs are not present, then cancer cells are more likely to use
evasion mechanisms that allow them to avoid physical interaction with the immune
cells (Gajewski et al., 2013). In the remainder of this sub-section we highlight some
of these key evasion mechanisms used by the tumour to avoid immune destruction.
It has been shown that both genetic and epigenetic mutations within tumour
cells can aid in immune resistance and immune evasion (Sadikovic et al., 2008).
These mutations may alter the antigens expressed by the tumour cells, potentially
preventing CTLs from recognising them as they no longer express the targeted an-
tigen. Even if tumour cells produce the target antigen, they are generally expressed
in low numbers with around 50 copies per cell (Tan et al., 2015), which can prevent
immune recognition. Similarly, if the antigen profiles of the cancer cells are still sim-
ilar enough to healthy cells, the cancer cells may not be recognised by the immune
system (Messerschmidt et al., 2016).
Tumour cells can evade cell-cell recognition by immune cells through manipulat-
ing the binding process. The binding between the MHC molecule and the tumour
antigen is the first step in antigen recognition. However tumour cells can cause ge-
netic or epigenetic downregulation of MHC molecules within themselves preventing
presentaion of the antigen (Agrawal and Kishore, 2000; Boon et al., 2006; Garrido
et al., 2010; Igney and Krammer, 2002; Leone et al., 2013). This may limit the
ability of the immune cells to recognise the tumour cells and allows the tumour cells
to survive. Furthermore, tumour antigen and T cell receptor binding is generally
weak and even a slight reduction in affinity, through tumour mutation or T cell ex-
haustion, can lead to the immune cells not being activated by the APCs (Mckeithan,
1995; Messerschmidt et al., 2016; Tan et al., 2015).
After the CTLs are activated, the tumour cells can use direct contact mechanisms
to prevent apoptosis and downregulate the immune response. For example, increased
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expression of PD-L1 (programmed death ligand 1) allows the tumour cell to bind to
the PD-1 (programmed death 1) receptor on the immune cells causing immune cell
death or inhibition (Gajewski et al., 2013; Restifo et al., 2016). Similarly, the Fas
ligand and receptor response can be inhibited by either tumour cells downregulating
the level of Fas receptors on their cell surface, or by producing FasL and sFasL
themselves. The FasL produced can then bind to Fas receptors on the immune cells
causing the immune cells to undergo apoptosis (Stewart and Abrams, 2008; Modiano
and Bellgrau, 2016).
With the aim of targetting the immune resistant mechanisms of cancer, immun-
otherapy techniques have been developed as a method of treatment to allow for a
stronger immune response.
2.6 Cancer treatment and therapies
Traditional treatments for cancer include chemotherapy and radiotherapy, which
have proven to be beneficial in many cases and are used widely to treat most types
of cancer. However these methods can have potentially severe side effects. For
example, the damage caused to healthy cells as well as the cancer cells can result in
further illness or even fatalities (Carelle et al., 2002; Coates et al., 1983). Targeted
therapies, like immunotherapy, may be able to reduce the damage to normal cells.
Generally, immunotherapies aim to boost the natural immune system in the body
and specifically within the microenvironment of the tumour. There are three main
types of immunotherapy: cancer vaccines; antibody therapies; and adoptive cell
therapies.
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2.6.1 Cancer vaccines
The successful HPV preventive cancer vaccine (Einstein et al., 2009), led to research
into the development of other vaccines to be used a preventative measures, as well as
treatment choices for cancer. There are currently a small number of FDA (American
Food and Drug Association) approved cancer vaccines for public use. In particular,
the Sipuleucel-T protocol exposes immune cells of prostate cancer patients to the
protein PAP (prostatic acid phosphotase), which induces the maturation of dendritic
cells and, upon reinjection, a more successful immune response (American Cancer
Soceity, 2018). Furthermore, the Bacille Calmette-Guerin (BCG) vaccine has been
approved for use in early stage bladder cancers or melanomas. The BCG bacterium
can infect human tissue and induce an immune response without causing tissue
damage. It is generally used post-surgery and has been shown to reduce tumour
recurrence in 50-70% of patients (Bunimovich-Mendrazitsky et al., 2015). Recently,
clinical trials where nanoparticles carrying tumour RNA are injected into the patient
have proven to enhance CD8+ T cell activity in both mouse and human experiments,
although the treatment is not yet approved (Bialkowski et al., 2016; Kranz et al.,
2016).
2.6.2 Antibody therapies
Antibody-based therapies involve the administration of drugs to target specific pro-
teins within the cancer cells. Multiple types of tumour antigen have been identified
through experimental research which allows these to become targets for immuno-
therapy. However, when targeting TAAs care must be taken as healthy cells may
be recognised as foreign and destroyed along with the cancer cells. The drugs ad-
ministered for treatment may be attached to radioactive particles or used in con-
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junction with chemotherapy drugs. Approved treatments include drugs that: target
growth factors in head and neck cancers (American Cancer Soceity, 2018); inhibit
the anti-apoptosis mechanism in leukaemia (Delbridge et al., 2016; Hua et al., 2016;
Leverson, 2016); inhibit programmed death receptor 1 (PD-1) in melanoma and
lymphoma (Huang et al., 2017; Littman, 2015; Moreno et al., 2015) and combine
PD-1 inhibition with other antibody treatments (Keir et al., 2008; Larkin et al.,
2015; Postow et al., 2015).
A particular therapy approach utilizing monoclonal antibodies is to increase the
expression of particular tumour antigens. For example, Yarchoan et al. (2017) found
experimentally that a higher expression of tumour antigens led to the tumour being
increasingly recognised by the immune system. It has also been shown experiment-
ally that epigenetic alterations can be both beneficial and detrimental to tumour
development, small levels of alteration can increase the tumour’s evolutionary fitness.
However, too much alteration leads to increased immune recognition (Chen and Mell-
man, 2017). These properties have been exploited through treatment approaches,
in particular it was shown that 5-aza-2’-deoxyctidine and histone deacetylase inhib-
itors could increase the expression of MAGE genes through decreased methylation
of their promoters, allowing for the recognition of tumour cells (Chinnasamy et al.,
2011; Wischnewski et al., 2006).
Although using monoclonal antibodies is a promising method of treating a variety
of cancers there is a potential for resistance and tumour recurrence to occur (Restifo
et al., 2016). Furthermore, some of these drugs can have severe side effects such as
risk of autoimmune diseases and can even enhance cancer progression (Champiat
et al., 2016; Kato et al., 2017). The main cause of this resistance or relapse is
thought to be evolution of the antigenic profiles of the cancer cells. For example,
in a PD-1 therapy trial 10% of patients showed resistance due to loss of tumour
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antigens through mutation (Anagnostou et al., 2017). T cell therapies can lead to
inflammation of the tissue, promoting the mutation of cancer cells, like melanoma
cells, to become more resistant to T cell induced death (Baar et al., 2016).
2.6.3 Adoptive cell therapy
Adoptive T cell therapy: Adoptive T cell therapies rely on T cells from the pa-
tient, or from donor patients, to be modified and then (re)injected into the patient’s
blood stream (Fesnak et al., 2016). The use of the patient’s own T cells, allows
this therapy to become more adaptable for each patient, i.e. personalised. These
therapies were shown to be of potential use through mouse models, demonstrating
that immunity could be acquired adoptively (Billingham et al., 1954). The standard
method is that cells are removed from the body, modified and undergo incubation
with cytokines to allow for expansion ex vivo (outwith the body). For example,
the cells may be activated against a certain antigen. They are then transferred
back into the patient and are able to initiate a specific immune response against
the cancer (Gross and Eshhar, 2016; Weinberg, 2007a). Traditionally, adoptive T
cell therapies have been used to treat B-cell malignancies and have proved beneficial
with high response rates (Brentjens et al., 2013; Davila et al., 2014; Grupp et al.,
2013; Maude et al., 2014). However, there is a large amount of work on the develop-
ment of therapies against solid tumours (Andersen et al., 2016; Frigault and Maus,
2016; Gross and Eshhar, 2016; Ikeda, 2016; Johnson et al., 2015; Perez et al., 2015).
Adoptive cell therapies which target solid tumours have, generally, been nonspe-
cific in the past, targeting common antigens such as EGFR (epidermal growth factor
receptor) and its variants (Feng et al., 2016; Johnson et al., 2015; Morgan et al.,
2012; O’Rourke et al., 2016) and NY-ESO-1 (New York oesophageal squamous cell
carcinoma 1) (Rapoport et al., 2015; Robbins et al., 2011, 2015). However, not all
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patients respond well to treatment, or at all, and those who do respond can experi-
ence a limited effect (Dudley et al., 2001; Feng et al., 2016; Mackensen et al., 2006).
Additionally, by targeting common antigens there is a risk of attacking healthy cells.
However, germline cells do not contain MHC and therefore cannot produce anti-
gens that T cells could then recognise. Hence, there is little risk of T cells recognising
normal cells when targeting cancer-testis antigens, (e.g. the MAGE antigens) (Boon
et al., 2006; Connerotte et al., 2008). This makes cancer-testis antigens a useful
target in immunotherapy. Clinical trials of treatments which target MAGE-A anti-
gens have proven somewhat successful, for example, targetting MAGE-A3 has been
found to be successful in mouse model tests (Chinnasamy et al., 2011) and in treat-
ing human melanoma cases (Connerotte et al., 2008; Lu et al., 2015; Zhang et al.,
2003). Additionally, MAGE-A4 has also been a successful target in oesophageal can-
cers (Kageyama et al., 2015; Zhang et al., 2002). However, these can lead to partial
responses and when similar methods have been applied to a wider range of cancers,
severe side effects, such as cardiogenic shock and neural toxicity, lead to fatalities.
It is thought that these deaths were caused by the high affinity of the receptors for
normal human antigens (Linette et al., 2013; Morgan et al., 2013). Further studies
have enhanced T cells that target MAGE genes in vitro (Gerdemann et al., 2011;
Graff-Dubois et al., 2002).
An effective modification to T cells, in the adoptive therapy setting, is the attach-
ment of chimeric antigen receptors (CARs) which allow T cells to better recognise
and destroy cancer cells. A CAR is a recombinant protein combined with a specific
tumour associated antigen that can activate other T cells (Sadelain et al., 2013).
These CARs can be used universally, regardless of the patient’s MHC profile, as the
CAR-T cells do not require activation through antigen presentation. Furthermore,
CAR-T cells have been shown to be functional up to four years after a single treat-
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ment, and even over ten years in some cases (Porter et al., 2015; Scholler et al.,
2012). There have been extensive experiments and clinical trials based on CAR-T
cell therapies with successful initial results, however very few have been approved as
viable options for cancer treatment. In particular, Phase I trials using CAR-T cells
to treat non-Hodgkins lymphoma (NHL), chronic lymphocytic lymphoma (CLL) and
acute lymphoblastic leukaemia (ALL) proved successful, with overall response rates
of over 60% (Gross and Eshhar, 2016). Similar trials targeting ALL also had high
remission rates of around 90% (Bonini and Mondino, 2015; Walker and Enderling,
2016). Furthermore, when used to treat leukaemia, clinical trial results highlighted
that one CAR-T cell can kill up to 1000 leukaemia cells, with the CAR-T cell levels
expanding over 1000 times in vivo (i.e. within the body). These highly effective
CAR-T cells also survived in the body for at least 6 months after insertion, allowing
for prolonged defense against cancer and also allowed for stronger binding to tumour
associated antigens (Kalos et al., 2011; Tan et al., 2015).
However, there have been safety concerns and a potential risk of CAR-T cells
attacking non-tumour cells that express the target antigen has been suggested. This
could explain situations where CAR-T cell treatments became fatal (Morgan et al.,
2010). To combat this, mechanisms have to be put in place to prevent the CAR-T
cells from attacking normal cells. ‘Suicide switches’ allow the modified T cells to be
deactivated or destroyed when exposed to certain molecules or drugs (Ikeda, 2016).
Contrastingly, modifying the receptors so that they are only active in the presence
of certain drugs has also been investigated (Rodgers et al., 2016; Wu et al., 2015).
The standard protocol of adoptive cell therapy is to inject the enhanced cells into
the blood, where they then travel through the blood stream to the lungs and later
the liver and spleen. However, some issues with extravasation from the blood vessels
and intravasation into tumours have been found (Frigault and Maus, 2016; Kershaw
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et al., 2006). Solid cancers can be difficult to infiltrate, as cells must overcome
abnormal vasculature that can restrict their movement. This could potentially be
overcome by combining adoptive cell therapy with other techniques such as: those
that target growth factors (Gotwals et al., 2017; Yong et al., 2017) or using viruses to
reduce the cancer mass (VanSeggelen et al., 2015; Walker et al., 2016). By injecting
the adoptive cells directly into the tumour, if possible, the restriction on these cells
moving to the site of tumour would also be reduced (Gross and Eshhar, 2016).
Another potential limitation to using T cell and CAR-T cell therapies is that
these modified cells can also be immunosuppressed by the tumour, through the
mechanisms described in the previous section (Beatty and Moon, 2014). In par-
ticular, CAR-T cells can be suppressed by tumour cells via the PD-1 and PD-L1
mechanism, and by using a PD-1 monocloncal antibody a more successful immune
response can be initiated (John et al., 2013). Additionally, to combat this there is
an aim to develop CAR-T cells that would be resistant to PD-L1 suppression (Ren
et al., 2017). Notably, the expression of PD-L1 by tumour infiltrating cells can be
a strong predictor of clinical response to immunotherapies (Hui et al., 2017; Perez
et al., 2015).
A further limitation to T cell therapies may be that only one antigen is focused
on. However, clinical trials using multiple TCRs in adoptive T cell therapy, to
target multiple tumour antigens, have proved successful (Verdegaal et al., 2016).
Furthermore, it has been shown that targeting only specific antigens within a tumour
could lead to untargeted antigens becoming prevalent ( Luksza et al., 2017) and
therefore it would be beneficial for a T cell population to be able to target more
than one tumour antigen.
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Dendritic cell therapy: Using a similar approach to adoptive T cell therapy,
dendritic cells can be removed from the body and expanded or activated using
tumour antigens ex vivo. This may subsequently induce an enhanced response by
T lymphocytes, once the DCs are reinjected into the patient. For example, several
clinical trials where extracted DCs of melanoma patients were pulsed with tumour
antigens proved successful in inducing an enhanced CTL response (Carreno et al.,
2015; Schreibelt et al., 2016; Tel et al., 2013; Wilgenhof et al., 2011, 2016). In
particular, Gerdemann et al. (2011) produced high affinity CTL populations through
dendritic vaccines that were capable of targeting multiple tumour antigens. The
enhanced cells showed improved responses in vitro when using heterogeneous human
lymphoma samples.
2.6.4 The role of interdisciplinary research
Immunotherapy techniques can take an extensive amount of time to develop and
test. Once an initial hypothesis is set, it can be several attempts before a successful
and viable result is obtained. Computational and mathematical oncology modelling
can be useful in removing some of the ‘testing time’ and providing more accurate
predictions of the model. If we can predict whether a certain treatment will have
a beneficial effect on a certain type of cancer, this can then be developed further,
thereby hopefully reducing the time to develop immunotherapies. We briefly re-
view a selection of the mathematical and computational methods used previously to
model tumour growth and the immune response to cancer in the following chapter.
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Chapter 3
Review of modelling strategies
3.1 Overview
In this chapter, we provide a short review of the mathematical modelling approaches
which have previously been used to describe cell motion, tumour growth and tumour-
immune competition. We begin with a discussion on the multiple scales considered in
modelling and some of the general approaches to mathematical modelling biological
phenomena.
3.2 Methods of mathematical modelling
Biological processes exhibit multiscale properties where interactions occur across
various spatial and temporal scales. Generally, there are three spatial scales poten-
tially considered in modelling: the molecular scale, the microscopic scale and the
macroscopic scale. Intracellular processes, such as mutations and cell signalling,
may occur at the molecular scale, i.e. nm-µm. Whereas, extracellular interactions,
e.g. interactions between cells, may occur at the microscopic scale, i.e. µm-mm.
Furthermore, tissue level processes may occur at the macroscopic scale, i.e. mm-
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cm (Deisboeck et al., 2011). All of these processes and mechanisms may also occur
across various temporal scales, e.g. ns, µs, s, mins, hrs, days, years. The scale that
is considered within mathematical descriptions of these processes depends on the
level of detail required. Often, the dynamics from each scale can feed into the de-
scription and cause variation in the mechanisms of other scales. In these situations
it is important to consider multiscale models, where these multiscale properties of
the biological system are described.
Furthermore, mathematical models can have discrete or continuous approaches
and can relate to discrete and continuous biological mechanisms. Although, discrete
models can be stochastic and capture small scale dynamics, they are less tractable
towards mathematical analysis. Continuous models are, generally, less computa-
tionally expensive than discrete models and allow for the investigation of large cell
densities. By using hybrid models with both discrete and continuous parts a bet-
ter understanding of the situation as a whole can be obtained, but these can also
be computationally expensive due to complexity (Lowengrub et al., 2009). Various
mathematical methods are used to model biological phenomena including differential
equations, stochastic models and combinations of these. In these models there can
be a correlation between the complexity of the model and the biological relevance,
although often, due to limitations of mathematical methods, a balance between these
must be found.
3.2.1 Differential equations
Differential equations are used to describe the change of continuous variables over
time and/or space. Ordinary differential equation (ODE) models consider the change
over either time or space, and can vary in complexity from a simple one variable
model to multi-variable systems. However, ODEs cannot incorporate both spatial
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and temporal dynamics, which can both be important in biological processes. On
the other hand, partial differential equations (PDEs) can be used to describe the
change in variables which depend on both space and time and therefore can be used
to describe the spatio-temporal dynamics of biological systems (Eftimie et al., 2011).
3.2.2 Discrete models
Computational models can be used to describe discrete properties of biological sys-
tems in multiple dimensions. These models can be grid (lattice) based or be de-
scribed on an non-uniform grid (mesh) (Macklin and Edgerton, 2010; Van Liedekerke
et al., 2015). Generally, a set of rules that describe the potential mechanisms or in-
teractions that each individual can undergo are defined. These rules depend on the
probability of events occurring and allow for the observation of any patterns in the
dynamics of the biological system (An et al., 2009). Individual-based (IB) models,
or agent-based models (ABM), track each individual over time and allow them to
move or interact with other individuals independently (Grimm and Railsback, 2005).
Although we will focus on these individuals being cells in our work, particles, an-
imals and social interactions can also be modelled in this way. Specifically, cellular
automata (CA) models are a type of grid based IB model where, often, only one
cell can occupy each grid position through volume exclusion. The cell’s movement
and interactions with other cells within the system then depends on the rules of
the model and the number of cells occupying the neighbouring grid positions of the
cell (Wolfram, 1983). Lattice gas CA (LGCA) models are similar, however, multiple
cells may occupy one grid position. Contrastingly, cellular potts models use multiple
grid positions to describe the location of one cell (Lowengrub et al., 2009). Other
methods can include more physical representations of cells via masses and springs
models (Murray et al., 2009). The development of multiple modelling approaches
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has led to the development of many computational tools and packages that can be
used to implement these models, and a review of several of these tools can be found
in Metzcar et al. (2019). Although using previously developed software can be bene-
ficial, in this work we develop our own computational techniques to allow for deeper
understanding and control over the model.
3.2.3 Multiscale and hybrid models
In recent years, it has become more common to combine discrete and continuous
models to provide a more in-depth description and analysis of the biological sys-
tems. By combining computational models with differential equations a greater
understanding of the biological relevance can be obtained through both the dynam-
ics of the system emerging. Additionally, through this hybrid approach a wider
range of tools can be used to analyse the model.
In this thesis, we will develop individual-based (IB) modelling techniques to
describe tumour-immune competition in Chapter 4, Chapter 5 and Chapter 6, and
consider the derivation of a PDE model from an IB model of cell populations in
Chapter 7.
3.3 Modelling random walks
In both differential equation and computational models the movement of organisms
or cells can be described through random walk methods. The theory of random
walks was studied and developed independently in the areas of biology (Brown,
1828), probability theory (Bernoulli, 1713), finance (Bachelier, 1900) and phys-
ics (Pearson, 1905; Rayleigh, 1880). In particular, the rigorous connection between
the microscopic dynamics of particles and the macroscopic processes of diffusion was
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described in the seminal work of Einstein (1905).
One of the first types of walks to be described is Brownian motion, where cells
have equal probability of moving in any direction at any time. The Brownian discrete
random walk can be used to formally derive the standard, continuous, diffusion equa-
tion (Nava-Sedeno et al., 2017). However, issues arise with the diffusion equation due
to the implied infinite, and unrealistic, propagation speed of cells (Zaburdaev et al.,
2015). In an attempt to overcome these issues several methods were introduced, such
as, the use of ballistic cones defining the maximal velocity of particles (Taylor, 1922),
persistent Brownian motion with finite velocity (Furth, 1920) and the development
of the telegraph equation which included an additional second order time derivat-
ive (Bakunin, 2003; Davydov, 1934). The continuous time random walk (CTRW)
was introduced by Montroll and Weiss (1965) to include waiting times of cells which
allowed for the derivation of anomalous diffusion, where the spreading of cells was
slower than standard (i.e. Fickian) diffusion, also known as subdiffusion. Further-
more, situations where particles can spread faster then Brownian motion, also known
as superdiffusion, were observed in turbulent flows (Richardson, 1926).
To allow for the inclusion of superdiffusive behaviour, random walk methods were
developed to allow particles and cells to travel for longer periods of time in a given
direction. To achieve this, Le´vy stable distributions (Gnedenko and Kolmogorov,
1954; Le´vy, 1937) were considered and Le´vy flights were introduced (Mandelbrot,
1982). These consist of instant jumps characterised by infinite mean squared flight
lengths which allow particles to travel a longer distance, faster (Dybiec and Gudowska-
Nowak, 2017). However, infinite propagation speeds are still possible and this form
of motion (Shlesinger et al., 1986) is generally not biologically realistic. Le´vy walks,
on the other hand, impose finite propagation speeds on cells (Shlesinger et al., 1982)
and have two general approaches. Firstly, cells still exhibit waiting times. However,
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once the waiting time has elapsed the cells move with a constant speed in the re-
quired direction towards their destination (Klafter and Zumofen, 1994; Zaburdaev
and Chukbar, 2002). The second method is more commonly used, and eliminates the
waiting time of cells allowing them to move continuously (Humphries et al., 2013;
Klafter and Zumofen, 1994; Shlesinger et al., 1986; Zumofen and Klafter, 1993).
More formally, a Le´vy walk is a scale invariant motion characterised by a power-law
run length distribution function:
L(s) ∼ s−(α+1),
where 0 < α < 2 is a scaling factor and s is the length of a step that they will
take in the chosen direction. Therefore, the frequency of steps of length s will be
proportional to s−(α+1) (Mattha¨us et al., 2011).
Since their introduction, Le´vy walks have been used to successfully describe and
capture the migration patterns of a wide range of organisms, such as; soil amoebae
(Levandowsky et al., 1997), eukaryotic cells (Li et al., 2008), bacteria (Zaburdaev
et al., 2014) and even humans (Rhee et al., 2011; Raichlen et al., 2014). For example,
Mattha¨us et al. (2011) considered a model of the chemotaxis signalling pathway of
E. coli and demonstrated that stochastic fluctuations and the specific design of the
signalling pathway together enable the generation of Le´vy walks. The E. coli ex-
hibited a chemotactic run and tumble motion, where the flagella of the bacteria
rotated counter clockwise, formed a bundle and propelled the cell in a straight
line. If the flagella rotated clockwise the bundle opened and the bacteria randomly
changed their angle without forward propagation. Furthermore, recent literature,
based on experimental data, suggests that T cells may move in a superdiffusive or
Le´vy like motion (Agliari et al., 2014; Fricke et al., 2016; Harris et al., 2012; Krum-
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mel et al., 2016; Weninger et al., 2014). We note that, although Le´vy processes have
been investigated through more generalised one dimensional continuous mathemat-
ical models (Fedotov, 2016; Fedotov and Korabel, 2017; Gan et al., 2015; Golovin
et al., 2008; Hanert, 2012; Stage et al., 2016), it has been suggested that stochastic
individual-based models may be more appropriate methods of capturing these com-
plex migration patterns (Nava-Sedeno et al., 2017). In Chapter 4 of this thesis,
we will develop an individual-based model of Brownian and Le´vy walk methods to
describe immune cell motion.
3.3.1 Mathematical models of cell population migration and
growth
As mentioned above, random walks can be used to model cell migration and from
these methods continuous descriptions of the cell population can be obtained. One
particular area of interest, is the use of nonlinear partial differential equation models
to describe the movement and growth of populations of cells. For example, models
that describe the evolution of cellular densities in response to pressure gradients
generated by population growth have been particularly popular (Ambrosi and Mol-
lica, 2002; Ambrosi and Preziosi, 2002; Araujo and McElwain, 2004; Bresch et al.,
2010; Byrne, 2010; Byrne and Chaplain, 1995, 1996, 1997; Byrne and Drasdo, 2009;
Byrne et al., 2003; Byrne and Preziosi, 2003; Chaplain et al., 2006; Chen et al.,
2001; Ciarletta et al., 2011; Greenspan, 1976; Lowengrub et al., 2009; Perthame,
2014; Preziosi, 2003; Ranft et al., 2010; Roose et al., 2007; Sherratt and Chaplain,
2001; Ward and King, 1999, 1997). Models of this form have been widely used to
complement empirical research in developmental biology and cancer research.
Further to the biological and clinical insights into the underpinnings of tissue
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development and tumour growth they can provide, these continuum models exhibit
a range of interesting qualitative behaviours. For example, travelling-wave solu-
tions with composite shapes and discontinuities (Tang et al., 2014). Moreover, in
analogy with reaction-diffusion systems arising in the mathematical modelling of
other biological and ecological problems (Dancer et al., 1999; Mimura et al., 2000),
these models can give rise to sharp interfaces, which bring about spatial segregation
between cell populations with different biophysical properties (Lorenzi et al., 2017).
A key advantage of continuum models for the spatial dynamics of growing cell
populations over their individual-based counterparts, i.e. discrete models that track
the dynamics of individual cells (Drasdo, 2005; Van Liedekerke et al., 2015) is that
they are amenable to mathematical analysis and they are computationally inexpens-
ive. Mathematical analysis enables a complete exploration of the model parameter
space, which ultimately allows more in-depth conclusions to be drawn. Further-
more, compared to individual-based models, continuum models offer the possibility
to carry out numerical simulations at the level of larger portions of tissues or even
of whole organs, while keeping computational costs within acceptable bounds.
However, continuum models are defined at the scale of whole cell populations
and, as such, they are usually formulated on the basis of phenomenological consider-
ations, which can hinder a precise mathematical description of crucial biological and
physical aspects. On the contrary, stochastic individual-based models that describe
the dynamics of single cells in terms of algorithmic rules can be more easily tailored
to capture fine details of cellular dynamics, thus making it possible to achieve a
more accurate mathematical representation of multicellular systems. Furthermore,
individual-based models are able to reproduce the emergence of population-level
phenomena that are induced by stochastic fluctuations in single-cell biophysical
properties, which are relevant in the regime of low cellular densities and cannot
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easily be captured by continuum models. Therefore, it is desirable to derive con-
tinuum models for the spatial dynamics of cell populations as the appropriate limit
of individual-based models for spatial cell movement and proliferation, in order to
have a clearer picture of the modelling assumptions that are made and guarantee
that they correctly reflect the essentials of the underlying application problem.
For this reason, the derivation of continuum models formulated in terms of par-
tial differential equations or partial integrodifferential equations from underlying
individual-based models has attracted the attention of a considerable number of
mathematicians and physicists. This is generally done by considering the limit of
the discrete models as the dependent variables go to a certain value, usually 0 or∞.
Examples in this active field of research include the derivation of continuum models
of chemotaxis from velocity-jump process (Hillen and Painter, 2009; Othmer et al.,
1988; Hillen and Othmer, 2000; Painter and Sherratt, 2003) or from self-attracting
reinforced random walks (Stevens, 2000; Stevens and Othmer, 1997); the derivation
of diffusion and nonlinear diffusion equations from underlying random walks (Oth-
mer and Hillen, 2002; Penington et al., 2011, 2014), from systems of discrete equa-
tions of motion (Fozard et al., 2010; Murray et al., 2009, 2012), from discrete lattice-
based exclusion processes (Binder and Landman, 2009; Dyson et al., 2012; Fernando
et al., 2010; Johnston et al., 2017, 2012; Landman and Fernando, 2011; Lushnikov
et al., 2008; Simpson et al., 2010) or from cellular automata (Deroulers et al., 2009;
Drasdo, 2005; Simpson et al., 2007); and, most recently, the derivation of nonlocal
models of cell-cell adhesion from position-jump processes (Buttenschoen et al., 2018).
In Chapter 7 of this thesis, we develop a simple individual-based model of growing
cell populations and formally derive the corresponding continuous PDE model.
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3.4 Mathematical oncology
Mathematical oncology is an ever increasing field and many models have been de-
veloped and used to describe the growth, development and treatment of cancer.
Within these mathematical models specific areas of tumour development, or spe-
cific hallmarks of cancer, can be investigated. These include models of tumour and
immune interactions. In this section we will discuss some of the key models, from
the literature, that have been developed previously to describe tumour development
and the immune response to cancer.
3.4.1 Mathematical modelling of cancer growth and devel-
opment
In particular, partial differential equations have been used in various cases to under-
stand the spatial aspects of the mechanisms of cancer. In this regard, reaction-
diffusion equations have been used in cancer models to describe: cancer inva-
sion (Chaplain and Lolas, 2006; Gatenby and Gawlinski, 1996; Peng et al., 2017;
Ramis-Conde et al., 2008); spherical tumour growth in the presence of nutrients,
growth factors and inhibitors (Byrne and Chaplain, 1995; Chaplain, 1995; Chap-
lain et al., 2001; Ferreira et al., 2002); angiogenesis (Ambrosi et al., 2004; Anderson
and Chaplain, 1998; Bauer et al., 2007); cell adhesion (Ambrosi et al., 2009; Am-
brosi and Preziosi, 2009; Armstrong et al., 2006); or combinations of these mech-
anisms (de Pillis et al., 2006b). Generally, individual-based (IB) models have been
used to describe mechanisms such as: tumour growth and development (Enderling
et al., 2009; Poleszczuk et al., 2016; Wang et al., 2015); cell adhesion and variance
in tumour cell movement (Frascoli et al., 2016).
Furthermore, many mathematical models have consider tumour heterogeneity
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and the role of tumour antigens (Balachandran et al., 2017; Cho and Levy, 2017;
Lorz et al., 2015). In particular, tumour antigen expression and the effects of epi-
genetic and genetic events have been modelled through differential equation mod-
els (Cho and Levy, 2017; Lorenzi et al., 2016; Lorz et al., 2015; Johnston et al., 2007,
2017; Tomasetti and Levy, 2010), stochastic computational models (Bouchnita et al.,
2017; Ghaffarizadeh et al., 2018; Manem et al., 2014) or hybrid approaches (Ander-
son et al., 2006). For example, Asatryan and Komarova (2016) developed ordinary
differential equation (ODE) models to investigate the effects of genetic instability
on the competition between sub-populations within a heterogenous tumour. Their
model highlighted several patterns of genetic instability which corresponded to dif-
ferent stages of tumour development.
3.4.2 Modelling of tumour-immune dynamics
The use of mathematical modelling to capture the specific interactions between the
immune system and cancer has been widely examined over the past few decades.
The majority of the models use ordinary differential equations or integro-differential
equations (IDEs) to describe cellular level dynamics, with many of them focusing on
tumour cells interacting with cytotoxic T lymphocytes (Bunimovich-Mendrazitsky
et al., 2008; Cattani et al., 2010; Delitala and Lorenzi, 2013; Frascoli et al., 2014;
Kolev, 2003; Kuznetsov and Knott, 2001; Lin Erickson et al., 2009; Lorenzi et al.,
2015). These nonspatial models can vary in complexity and include specific aspects
of the immune system such as: the specific chemicals involved in the apoptosis cas-
cade (Calzone et al., 2010; Eissing et al., 2004; Fussenegger et al., 2000; Galante
et al., 2012; Legewie et al., 2006; Lejeune et al., 2008); the tumour antigen re-
cognition process (Cattani and Ciancio, 2012; De Boer et al., 1985); cooperation
between immune cell types (de Pillis and Radunskaya, 2003; de Pillis et al., 2005;
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Fishman and Perelson, 1993); and the immune cells’ ability to attack the cancer
cells (Bellomo and Delitala, 2008; Takayanagi and Ohuchi, 2001; Wilkie and Hahn-
feldt, 2013). From nonspatial models, the effect of immune evasion by the cancer
cells has been well described, with the parameter values of the models being derived
either from experimental data or estimated logically. Many models which focus
on tumour immune competition are based on the pivotal work of Kuznetsov et al.
(1994), where the authors developed a system of ODEs to describe the interactions
between cytotoxic T lymphocytes and a growing B-lymphoma. The model predicted
the experimentally observed oscillations in tumour growth and the parameter values
used were validated using experimental data.
Key dynamics can be confirmed or expanded in a wider range of biologically
relevant situations by extending these ODE and IDE models into partial differential
equation models through the inclusion of spatial phenomena, e.g. random motil-
ity or chemotaxis, of the cells (Al-Tameemi et al., 2012; d’Onofrio and Ciancio,
2011; Kolev, 2003). In particular, following the work of Kuznetsov et al. (1994),
Matzavinos et al. (2004) developed a system of four partial differential equations
(PDEs) to describe the interactions between tumour-infiltrating CTLs, tumour cells,
CTL-tumour complexes and chemokines. Through stability analysis techniques and
numerical simulations, their model revealed the key parameter spaces required for
the onset of tumour dormancy. Furthermore, the authors proved the existence of
travelling wave solutions which can replicate tumour invasion patterns (Matzavinos
and Chaplain, 2004).
By using computational models such as cellular automata (CA) and IB models a
wider spectrum of biological phenomena can be translated into mathematical terms
and described. These models can be posed on a spatial domain (e.g. a grid), and
a set of rules can be given to each cell with certain probabilities to achieve a more
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detailed description of cancer-immune competition (Chowdhury et al., 1991; Hu
et al., 2012; Kather et al., 2017; Pappalardo et al., 2008). For example, Christophe
et al. (2015) used an individual-based approach to study the interactions between
cytotoxic T lymphocytes (CTLs) and a genetically evolving melanoma. Their results
indicated that the initial time of interaction between the CTLs and melanoma cells
determines the outcome of their competition, as highly mutated tumour cells became
less susceptible to immune action.
Hybrid or combination models have been used to a great extent to study the
immune response to cancer. Tumour-immune dynamics have been considered in
this way using: PDE-CA combination models (Alemani et al., 2012; Mallet and
de Pillis, 2006); ODE-IB combination models (Wu et al., 2018); DDE-ABM com-
bination models (Kim and Lee, 2012) and PDE-IB combination models (Anderson
and Chaplain, 1998; Bauer et al., 2007). In particular, de Pillis et al. (2006b) used
a hybrid PDE-CA approach to describe tumour-immune competition. They used
PDEs to describe the evolution of pro-tumour nutrients within the tumour microen-
vironement and described tumour cell, CTL and natural killer (NK) cell movement
and interactions through the CA approach. Using this framework they explored
the role of nutrients, cell-cell adhesion and immune cell capabilities on the growing
tumour.
Mathematical approaches have additionally been used to describe the role of
tumour antigen expression within tumour-immune interactions. Traditionally, tu-
mour antigen expression and recognition by the immune system have been implicitly
modelled by tuning the rates of T cell recruitment, T cell proliferation or tumour
cell removal (Arciero et al., 2004; Balea et al., 2014; Besse et al., 2018; De Boer
et al., 1985; de Pillis et al., 2009; Ko¨se et al., 2017; Mallet and de Pillis, 2006).
More recently, these processes have been explicitly captured by mathematical mod-
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els formulated in terms of either ordinary differential equations (Balachandran et al.,
2017; d’Onofrio and Ciancio, 2011;  Luksza et al., 2017) or integro-differential equa-
tions (Delitala et al., 2013; Delitala and Lorenzi, 2013; Kolev et al., 2013; Lorenzi
et al., 2015). In Chapters 5 and 6 of this thesis, we develop individual-based models
to describe the interactions between solid tumour and the immune system and in
Chapter 6, we explicitly consider tumour evolution through epimutations.
3.4.3 Mathematical modelling of immunotherapies
Prediction of the success of cancer treatment protocols, especially immunotherapies,
can be achieved through the use of mathematical models. Models of immunotherapy
have been used to investigate the conditions of therapies which lead to tumour
dormancy or tumour removal without an overactive immune response (d’Onofrio,
2005; Frascoli et al., 2014). In particular, ODE models have been used to predict
the effects of immunotherapy techniques by allowing the user to vary the dose,
administration and timing of a variety of treatments to find the hypothetical optimal
situation, which can then be further investigated through experiments and clinical
trials (Walker and Enderling, 2016). Furthermore, predator-prey like models have
been used to describe dynamics of the immune and tumour cells, where the number
or properties of competing immune cells change due to therapy (Arciero et al., 2004;
Babbs, 2012; Bunimovich-Mendrazitsky et al., 2015; Burden et al., 2004; Cappuccio
et al., 2006; Radunskaya et al., 2013; d’Onofrio and Ciancio, 2011; Frascoli et al.,
2014; Hu et al., 2012; Konstorum et al., 2017; Ko¨se et al., 2017; Kuznetsov and
Knott, 2001; Nani and Freedman, 2000; Sotolongo-Costa et al., 2003). Additionally,
key markers for therapies to target, such as tumour antigens, can also be discovered
through ODE models (Balachandran et al., 2017;  Luksza et al., 2017). Moreover, a
combination of PDE and IB models has been used, for example, to describe tumour
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growth in the presence of cytotoxic and cytostatic drugs, highlighting that the local
tumour cell environment plays a key role (Lorenzi et al., 2015; Lorz et al., 2015; Cho
and Levy, 2017). Contrastingly, computational models have also been utilized to
predict the success of immunotherapy techniques (Chowdhury et al., 1991; Mallet
and de Pillis, 2006), such as PD-L1 inhibition therapies (Gong et al., 2017).
Mathematical approaches may focus on immunotherapy alone, or the combina-
tion of immunotherapy with other forms of therapy, e.g. chemotherapy or cytokine
therapy (de Pillis et al., 2006a; Kirschner and Panetta, 1998) which generally lead
to a more successful response and can block immunosuppression (Dritschel et al.,
2018). For example, Joshi et al. (2009) describe adoptive cell therapy and cancer
vaccine therapy against a solid tumour using an ODE model. They found that
adoptive cell therapy could actually enhance tumour growth, which has been ob-
served experimentally. However, cancer vaccines that targeted antigen presenting
cells were able to reduce tumour growth and prevent tumour relapse once dormancy
was established.
Model validity and interdisciplinary research
Due to the difficulty in estimating parameter values, many models consider simple
systems of equations and instead identify potential parameter spaces of interest (Besse
et al., 2018). More in-depth communication between experimentalists, clinicians,
statisticians and mathematicians means that more in-depth models can be de-
veloped. A key trait of a mathematical model of biological phenomena is that it is
biologically relevant. Several models attempt the validation of results with clinical
data (Cappuccio et al., 2006; Gatenby and Gawlinski, 1996). However, many models
have only estimated parameters or use nonhuman data. Therefore there is a great
need for the collaboration of biologists, clinicians and mathematicians to ensure
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that models are more in-depth. Interdisciplinary groups can increase the success of
research into the development of new cancer therapies (Masoudi-Nejad and Wang,
2015; McGuire et al., 2013). Interdisciplinary work has become more common in
cancer research where biological experiments can feed into the model, which can
then predict the next step for the experiments, that can then be tested (Christophe
et al., 2015; Hua et al., 2016; Walker and Enderling, 2016).
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Chapter 4
A simple individual-based model
describing immune cell motion
4.1 Overview
In this chapter we introduce the modelling approaches used to capture active and
inactive immune cell migration in the tumour microenvironment. Here, the terms
inactive and active refer to the interactions of the immune cells with tumour anti-
gens. Therefore, an active dendritic cell has recognised and collected the antigen,
whereas an active cytotoxic T lymphocyte has been presented the antigen by the
dendritic cell. The work we describe in this short chapter will provide a foundation
for the development of the more detailed individual-based (IB) models described in
subsequent chapters.
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4.2 Background
Boissonnas et al. (2007) used individual cell tracking to study the movement of
cytotoxic T lymphocytes (CTLs) in the presence and absence of tumour antigen,
and verified a change in the mechanisms of movement between these two situations.
In the instance where tumour antigen was absent the cells migrated in a search-
like pattern. On the other hand, when the tumour antigen was present the cells
exhibited a restricted form of motion whereby they could only travel short distances
in any direction. Therefore, these results can be used to describe the migration of
CTLs which are in an inactive state or the migration of CTLs which are activated
by tumour antigen. Engelhardt et al. (2012) observed that dendritic cells (DCs)
alter their migration pattern in a similar manner to CTLs when exposed to tumour
antigen.
In this chapter, we aim to capture these two forms of cell motion using mathem-
atical modelling techniques. As mentioned in Section 3.3, stochastic models, such as
individual-based (IB) models, are appropriate for describing complex spatial migra-
tion patterns. Therefore, we develop an IB model of cell motion based on random
walk methods to describe the experimental results of Boissonnas et al. (2007). The
code was developed and the simulations were run in Matlab. The model described
in this chapter and some of the results shown have been published in Macfarlane
et al. (2018).
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4.3 Determining the appropriate form of random
walk
To determine which form of random walk is appropriate to capture the migration
patterns of immune cells in the absence and presence of tumour antigen we extract
the key properties of the migration patterns observed in the experimental works
mentioned previously. Immune cells, when tumour antigen is absent, appear to per-
sist in one direction for a period of time before changing direction and repeating the
process. These search-like patterns have been observed in other areas of cell bio-
logy and have been mathematically described as Le´vy processes (Ariel et al., 2015;
Detcheverry, 2017; Miller et al., 2002; Wolf et al., 2003). We refer the reader to Sec-
tion 3.3 for further information on Le´vy processes and how they have previously been
modelled. Following these methods, we hypothesise that a Le´vy walk implemented
into an individual-based model may be suitable to represent the migration patterns
of inactive immune cells in the tumour microenvironment. Interestingly, recent lit-
erature, based on experimental data and fitting the data to mathematical models,
suggests that T cells may move in a superdiffusive or Le´vy like motion (Agliari et al.,
2014; Fricke et al., 2016; Harris et al., 2012; Krummel et al., 2016; Weninger et al.,
2014). Therefore, we hypothesise that a Le´vy walk will capture the migration of
inactivate immune cells in the tumour microenvironment.
In contrast to the immune cells when no antigen is present, from the experi-
mental observations of Boissonnas et al. (2007), immune cells in the presence of
tumour antigen appear to have a limited migration pattern. That is, the cells do
not move in one direction for significant periods of time, suggesting that they change
direction very frequently. Brownian motion is a standard form of diffusion and is
used regularly in modelling cell motion, including that of T cells (Casal et al., 2005;
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Celli et al., 2012; de Pillis et al., 2006b; Matzavinos et al., 2004). Each cell that
undergoes Brownian motion moves randomly where each step is unrelated to the
previous one. This generally leads to cells staying within a smaller area over time
and therefore we choose this to represent the active immune cells that were shown
to have restricted movement in Boissonnas et al. (2007). Therefore, we hypothesise
that Brownian motion will capture the migration of activated immune cells in the
tumour microenvironment.
4.4 The individual-based model
The individual-based model is designed on a 2D spatial domain, which we separate
into a grid with sites of length ∆x in the x direction, and ∆y in the y direction. Each
time-step of the simulations of the model will have length ∆t. We will consider a
number of cells, N , on the grid and allow them to move using either a Le´vy walk or
Brownian motion, as described above. To consider a biologically realistic situation,
we additionally impose a volume exclusion limit whereby only one cell can occupy
any grid-position at any one time. We set up the two forms of random walk utilising
the probabilities of moving to one of the eight neighbouring grid positions, as shown
in Figure 4.1a.
4.4.1 The Le´vy walk mechanism
If a cell is following a Le´vy walk process, the direction of movement is initially
chosen randomly, with equal probability, from one of the eight possible directions.
The probability of choosing a step-length s is determined by the Le´vy distribution,
L(s) ∼ s−(α+1), (4.1)
46
Figure 4.1: Cell neighbourhood and example immune cell trajectories
using the random walk mechanisms. a At each time-step, immune cells can
move to one of the eight neighbouring grid-sites provided it is unoccupied. b Immune
cells which move via a Le´vy walk have probabilities of moving in a given direction
for s time-steps which is taken from the Le´vy distribution given by equation (4.1).
c Immune cells which move via Brownian motion have an equal probability of moving
to neighbouring grid-sites at each time-step.
where s is the number of time-steps the cell will move in a given direction and α is the
walk exponent (see Harris et al. (2012) for full details). If the number of steps is one,
i.e. s = 1, then the process repeats at the next time-step, otherwise the cell will keep
moving in the initially chosen direction until all steps have been taken. Once the
step-number is completed the process begins again. The Le´vy distribution for step-
length results in a high probability that cells will choose a short step-length, however
longer step-lengths can still be chosen. These properties ensure that cells whose
motion is governed by a Le´vy walk have a larger probability of moving in a given
direction for longer, compared to a Brownian motion, as shown by Figure 4.1b. We
make the assumption that cells cannot move to a grid-site outside the boundary of
the domain, that is, we impose reflective boundary conditions. Although boundary
conditions are imposed, the time-step we consider throughout simulations is small
enough that cells will remain well within the boundary. Therefore, the boundary
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conditions will not alter the movement trajectories of the cells.
4.4.2 The Brownian motion mechanism
When undergoing a random walk which follows Brownian motion, at each time-step
each cell will have the capacity to change direction and move to any of the eight
neighbouring grid positions, as shown in Figure 4.1c. That is, cells have an equal
probability of moving to any neighbouring grid position at any one time, independent
of previous movements, and the process repeats at the next time-step. As in the
case of the Le´vy walk, we impose reflective boundary conditions to ensure all cells
remain within the domain, however the time-step is small enough that these do not
effect cell movement. Cells can then move within the grid using either a Brownian
motion or Le´vy walk mechanism, which we describe below.
4.5 Model set up and results
4.5.1 Set up of simulations
We set up the 2D grid by assigning the step-lengths ∆x and ∆y as well as the time-
step-length ∆t. To be consistent with the average cell size of immune cells (Goya
et al., 2008; Rozenberg, 2011), we choose our spatial step-lengths to be ∆x = ∆y =
10 µm. Note that, since we consider the diagonal neighbourhoods of cells the grid-
spacing can increase if moving diagonally to
√
2 ∆x/y, with these values still within
the biological ranges of immune cell diameter. Furthermore, to satisfy the immune
cell speed and set up given in Boissonnas et al. (2007), we consider: a time-step
of ∆t = 1 min, define a 200 × 200 µm2 grid and consider N = 50 cells within the
system.
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The Le´vy walk mechanism: For cells moving via the Le´vy walk mechanism,
the probability of changing direction depends on the number of steps that the cell
had taken in the current direction s. The probability of moving in any direction, Di
of the eight possible directions, i = 1, . . . , 8, at any one time can be calculated as,
P(Di) =

1
8
, if s = 0,
1, if s > 0 and i is the previous direction taken,
0, if s > 0 and i is not previous direction taken,

for i = 1, . . . , 8.
For the Le´vy walk we also need to consider the exponent α of the step-length distri-
bution given in equation (4.1). Following work by Harris et al. (2012) we consider
an exponent of,
α = 1.15.
Using this exponent and allowing only integer step-lengths we define a Le´vy distri-
bution. From this distribution we calculate the probability of choosing a step-length
of at least length s. As we consider only integer step-lengths we obtain the probab-
ilities of choosing a certain step-length, represented in Figure 4.2, where cells choose
a step-length of s ∈ {1, . . . , 11}.
The Brownian motion mechanism: For cells which undergo the Brownian mo-
tion random walk, each movement is independent of the previous movement choices.
The probability of moving in any direction, Di of the eight possible directions,
i = 1, . . . , 8, at any one time can be calculated as,
P(Di) =
1
8
for i = 1, . . . , 8.
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Figure 4.2: Probability of choosing step-lengths for cells undergoing a
Le´vy walk. The bars represent the probability of choosing a step-length of length
s for each cell undergoing a Le´vy walk. These values are calculated using the Le´vy
distribution given in equation (4.1) and using the exponent α = 1.15.
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4.5.2 Comparison of the models with experimental data of
single CTL tracking
To test that using Le´vy walk and Brownian motion mechanisms are appropriate for
modelling immune cell motion in the absence and presence of tumour antigen, we
attempt to qualitatively replicate the experimental observations of Boissonnas et al.
(2007). In this experimental work they considered cytotoxic T lymphocyte (CTL)
motion over time in the presence or absence of a tumour antigen. The experimental
results indicated that if tumour antigen is present the CTLs cover a more restricted
area moving at a speed of around 5µm min−1, whereas in the absence of antigen
CTLs move in a search type pattern exploring a wider portion of space over the
same time interval, moving at a faster speed of around 10µm min−1. To reproduce,
in silico, the experimental setting used in Boissonnas et al. (2007), we considered 50
cells with their starting positions aligned and tracked each individual cell’s trajectory
over time in the case where cell movement was modelled by the two afore mentioned
random walks. Initially, we consider the case where there is no tumour antigen
present and wish to compare our model to the experimental observations, displayed
in Figure 4.3a. As mentioned previously, we hypothesised that a Le´vy walk would be
an appropriate method of describing the search-like pattern of the CTLs. Therefore,
we ran simulations, for a time consistent with the time-frame of the experimental
data, allowing 50 cells to undergo a Le´vy walk. Furthermore, to align with the
experimental data we allowed each cell to move at a speed of 10µm min−1. Each cell
was tracked over time and the resulting movements are displayed in Figure 4.3c. A
good qualitative match is observed between Figure 4.3a and Figure 4.3c, where cells
can move a significant distance from the origin and appear to be able to persist in one
direction for a period of time before changing direction. We then turn our attention
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to the case where tumour antigen is present and again wish to compare our model
to the experimental observations, displayed in Figure 4.3b. In this situation, we
hypothesised that Brownian motion would be an appropriate method of describing
the restricted motion of the CTLs. To investigate this we ran simulations, for
a time consistent with the time-frame of the experimental data, allowing 50 cells
to move via Brownian motion. Again, to align with the experimental data we
allowed each cell to move at a speed of 5µm min−1. Each cell was tracked over
time and the resulting movements are displayed in Figure 4.3d. When comparing
Figure 4.3b and Figure 4.3d we can conclude that Brownian motion is an appropriate
modelling method here, as we capture the restricted motion of the cells where they
change direction frequently. To confirm that these qualitative matches between the
experimental data and computational results are not dependent on the speed at
which cells travel, we also consider a faster version of Brownian motion and a slower
version of the Le´vy walk. We consider cells moving via Brownian motion at a cell
speed of 10µm min−1, displaying the results in Figure 4.3e and compare these to
the results in Figure 4.3a. Here, we observe that the faster Brownian motion does
not capture the persistance of the cells when there is no tumour antigen present.
Similarly, we consider cells moving via a Le´vy walk at a cell speed of 5µm min−1,
displaying the results in Figure 4.3f and compare these to the results in Figure 4.3b.
Here, we demonstrate that the slower Le´vy walk does not capture the restricted
motion of cells when tumour antigen is present.
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Figure 4.3: Comparison of the models with experimental data of single
CTL tracking. Each figure displays the overlay of 50 cell tracks with aligned start-
ing positions. a Experimental observations from Boissonnas et al. (2007) of CTLs
when there is no tumour antigen. b Experimental observations from Boissonnas
et al. (2007) of CTLs in the presence of tumour antigen. c Cells undergoing a Le´vy
walk with a speed of 10µm min−1. d Cells moving via Brownian motion with a a speed
of 5µm min−1. e Cells moving via Brownian motion with a speed of 10µm min−1.
f Cells undergoing a Le´vy walk with a speed of 5µm min−1.
Figure 2B: Image 1, Image 3, used with permission, from (Boissonnas et al., 2007)
c© 2007 A Boissonnas et al. Journal of Experimental Medicine. 204(2):345-356. doi:
10.1084/jem.20061890
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4.5.3 Comparison of the key properties of Brownian motion
and Le´vy walk mechanisms
To allow for further understanding of the differences between using Brownian motion
and Le´vy walk mechanisms we investigate and compare some of the key properties
of each random walk.
The cover time of a random walk is defined to be the time taken for a random
walker to cover all points in the grid. Mathematical analysis and comparison of the
cover time of random walks has been described previously (Chupeau et al., 2015;
Koren et al., 2007; Yokoi et al., 1990), highlighting the dependence of the cover time
on the first passage time (Condamin et al., 2007; Tejedor et al., 2009). Through
these works, it can be suggested that a Le´vy walk should be more efficient, i.e. have
a faster cover time, than Brownian motion. We verify this by considering the cover
time of both mechanisms within our individual-based model. We placed one cell
on the grid defined previously and allowed it to perform either a Le´vy or Brownian
random walk. The cell continued until all grid positions have been covered. We
did this for both the Le´vy and Brownian mechanisms with two cell speeds, i.e.
5µm min−1 and 10µm min−1, and a range of values for the Le´vy exponent α. The
resulting cover times are shown in Figure 4.4. We ran each simulation ten times and
average the results to obtain a deeper understanding of the cover time of each walk
process. We first compare the case where α=1.15 in the Le´vy walk mechanisms and
Brownian motion, i.e. the red and black results in Figure 4.4. Our results suggest
that independent of cell speed, the Le´vy walk mechanism is generally more efficient
than the process of Brownian motion. By considering the standard deviations of
these results, we find that in general the Le´vy walk mechanism appears to have
more consistent cover times. The Brownian motion mechanism, on the other hand,
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has a larger standard deviation suggesting that there is greater variability in the
cover time of this method. These results indicate that the Le´vy walk response is
more consistent in terms of reproducibility. We can also compare the cover time of
the Le´vy walk with increasing values of α. From the results displayed in Figure 4.4
we observe a general increase in cover time with the increase of α for both cell
speeds investigated. When comparing the two cell speeds we observe an decrease
in the cover time for all cases when we increase the cell speed from 5µm min−1 to
10µm min−1. However, the decrease in cover time appears to be more prominent
in the Brownian motion case compared to the Le´vy walk cases. Furthermore, for
several cases the standard deviation between runs is smaller for the larger cell speed
indicating that the a faster cell speed leads to more consistent results.
The outcomes of our model suggest that following a Le´vy walk allows cells to
spread further in the domain. To investigate this further, we consider the maximum
distance that any cell travels from its starting position. We allowed cells to move
via the two distinct random walk processes and then calculated their distance from
the origin, i.e. their starting position, at each time-step. We tested both the Le´vy
walk with exponent α=1.15 and the Brownian motion for the two cell speeds. Each
parameter setting was tested ten times with the average results being displayed in
Figure 4.5. The simulation results suggest that the Le´vy walk allows cells to move
further from the origin than Brownian motion. Generally, the result indicate that
the distance travelled is also more varied when using the Le´vy walk, as can be seen
from the standard deviation lines in Figure 4.5.
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Figure 4.4: Comparison of the cover time of each walk mechanism. The
cover time is calculated as the time taken to visit all 1681 positions of the grid.
The squares represent the average cover time for each chosen cell motion and the
lines represent the standard deviation over ten runs of the simulations. The top
panel displays the results for the case where cells move at the speed 5µm min−1
and the lower panel displays the results for the case where cells move at the speed
10µm min−1. Results are displayed for Brownian motion (black) and a Le´vy walk
with increasing values of the exponent α (blue) with the results for α=1.15 highlighted
in red.
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Figure 4.5: Comparison of the maximum distance from the origin of cells
using each walk mechanism. Bars represent the maximum distance travelled of
the Le´vy walk (blue) and Brownian motion (red) for two different cell speeds. The
error bars represent the standard deviation between ten runs of the simulations.
4.6 Concluding remarks and discussion
In this chapter we have developed a discrete individual-based model of immune cell
motion which takes into account the difference of motion in regard to the presence of
tumour antigen. Our simulation results demonstrate that the strategies we adopted
to modelling cell motion make it possible to qualitatively reproduce trajectories of
cytotoxic T lymphocytes (CTLs) observed in experimental data (Boissonnas et al.,
2007). In particular, the Le´vy walk provides a good representation of CTLs’ motion
when the antigen is not present, whilst Brownian motion captures the movement of
CTLs in the presence of a tumour antigen. Due to the similar cell motions observed
in dendritic cells by Engelhardt et al. (2012), we assume that dendritic cells will
respond to tumour antigen in the same way.
Furthermore, systematic comparisons can be made between the two random walk
methodologies. We consider the cover time of both processes and demonstrate that,
generally, the Le´vy walk process is more efficient than the Brownian motion process.
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This is supported by previous mathematical analysis of both walk mechanisms (Chu-
peau et al., 2015; Koren et al., 2007; Yokoi et al., 1990). Additionally, our results
suggest that the smaller the walk exponent α the faster the cover time. Furthermore,
exploration into the maximum distance that cells can travel from their original pos-
ition allows us to confirm that the Le´vy walk allows cells to spread further into the
domain compared to Brownian motion.
Overall, our results suggest that it would be appropriate to model the movement
of inactive immune cells using a Le´vy walk, whereas the movement of active immune
cells can be modelled using Brownian motion. Through comparing the results of the
two different cell speeds, we can observe that the resulting dynamics of cells will
be similar when using faster or slower cell speeds. Therefore, for simplicity, we can
allow both inactive and active immune cells to have the same speed. In the following
chapter, we develop an individual-based model of tumour-immune competition and
utilise the random walk methods described in this chapter to describe immune cell
motion. We do this by introducing a solid tumour into the system and, in turn,
considering the interactions between the immune cells and the cancer cells.
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Chapter 5
An individual-based modelling
approach to describe
tumour-immune interactions
5.1 Overview
In this chapter, we will develop an individual-based (IB) model to describe tumour-
immune competition. We do this by utilising the IB approach described in Chapter 4
to model the movement of the immune cells. Furthermore, we include a solid tumour,
made up of tightly packed cancer cells, and consider the interactions between the
tumour cells and the immune cells in the surrounding microenvironment. Once the
model is set up, we tune certain parameters to investigate their role in the removal
of solid tumours by the immune system. The computational simulation results
of the model highlight which mechanisms control the outcome of tumour-immune
competition indicating that they may be potential targets in the development of new
immunotherapies. The model described in this chapter and several of the results
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shown have been published in Macfarlane et al. (2018).
5.2 Model development
We consider the interactions, in an in vitro situation, between three cell types:
cancer cells, dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs) through
individual-based modelling techniques. The total numbers of these cells will be
denoted by NT , ND and NC , respectively.
As in Chapter 4, the IB model is posed on a 2D spatial grid of spacing ∆x in the
x direction and ∆y in the y direction. To incorporate the biophysical constraints
upon the cells, we make the assumption that only one cell of any type is allowed on
each grid position at any time-step of duration ∆t.
5.2.1 Tumour cell population growth and migration
Tumour cell division: Initially, we consider a tumour consisting of tightly packed
cancer cells with a circular geometry. The solid tumour can expand over time
through cell division. Specifically, each cancer cell can divide at the rate λ, forming
two progeny cells. One progeny cell will occupy the parent cell’s grid position and
the other shall be placed at an unoccupied neighbouring position - see Figure 5.1a.
This method ensures that only cancer cells which have free grid positions in their
neighbourhood can divide (i.e. cancer cells in the centre of the solid tumour will
not divide).
Tumour cell death: It can be assumed that the rate of natural tumour cell death
will be much lower compared to the rate of tumour cell division, therefore we omit
tumour cell death from the model.
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Figure 5.1: A schematic overview of the biological and immunological
mechanisms that are considered in the individual-based model. Three
cell types: cancer cells, dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs)
and the inactive/active states of both immune cells are included in the model (key
subpanel). a Division of each tumour cell can occur at the rate λ, provided a neigh-
bouring grid position is unoccupied. b Through contact with tumour cells, DCs can
become activated at the rate DAct. c At the rate CAct, CTLs can become activ-
ated through interactions with activated DCs. d Once activated, CTLs can remove
tumour cells at the rate µ, through cell-cell interactions.
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Tumour cell migration: We do not consider migration of the tumour cells as
we assume that the tumour is in the early stages of development and, therefore, has
not yet initiated the invasion and metastasis processes (for more detail we direct the
reader to Section 2.3). This means that spreading of the tumour throughout the
domain is controlled by cell division only.
5.2.2 Immune cell migration and activation
Movement of inactive immune cells: At the start of the simulations, we as-
sume that only inactive immune cells are present and we assume that they are
randomly distributed throughout the domain. Both the inactive DCs and inactive
CTLs will migrate within the domain following a Le´vy random walk mechanism that
was developed in Chapter 4.
Activation of dendritic cells: While moving within the domain, each inactive
DC can interact with a tumour cell if they are positioned on neighbouring grid-
sites. At the rate DAct, we allow the DC to become activated by the tumour cell -
see Figure 5.1b. For most simulations, we assume that once each DC has become
activated it will remain activated over the time-frame considered. However, we will
also consider an exhaustion limit in some simulations, where each DC can only
activate a certain number of CTLs. Once it has reached the exhaustion limit it will
become an exhausted DC, i.e. it will move around like an active DC but will be
unable to interact with CTLs.
Activation of cytotoxic T lymphocytes: Inactive CTLs can become activated
via cell-cell interactions with activated DCs. If an active DC and an inactive CTL
are situated on neighbouring grid positions then they can interact and the CTLs
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can become activated at the rate CAct - see Figure 5.1c. We assume, in the model,
that each DC can then go on to activate an infinite number of CTLs, although an
exhaustion process is considered later in the chapter. As with the DCs, for most
simulations we assume that once each CTL has become activated it will remain
activated over the time-frame considered. However, we will also consider an exhaus-
tion limit in some simulations, where each CTL can only interact with a certain
number of tumour cells. Once it has reached the exhaustion limit it will become an
exhausted CTL, i.e. it will move around like an active CTL but will be unable to
interact with tumour cells.
Movement of activated immune cells: Upon activation, the immune cells will
alter their form of cell migration from a Le´vy walk to the Brownian motion mech-
anism developed in Chapter 4.
Immune cell number and proliferation: We use reflective boundary conditions
to ensure that all cells remain within the domain, to replicate an in vitro situation,
i.e. there will be no additional cells entering the domain and no cells leaving the
domain. We additionally omit the effects of cell division and cell death on both
immune cell populations for simplicity. Therefore, their respective cell numbers
will remain constant over the time-frame considered. Furthermore, as mentioned in
Chapter 2, there can be mechanisms where the tumour cells can damage and remove
immune cells directly, however we will not consider these mechanisms in this work.
5.2.3 Tumour cell removal by CTLs
Once activated, each CTL has the capability to interact with and remove tumour
cells. If an active CTL and a tumour cell occupy neighbouring grid positions, the
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Table 5.1: The average diameters of human cell types considered in the IB model
Cell Type Average Diameter Reference
Cytotoxic T lymphocyte 9-16 µm (Rozenberg, 2011)
Dendritic cell ∼ 7µm (Goya et al., 2008)
Melanoma cell ∼ 12.5 µm (Christophe et al., 2015)
CTL can instantly remove the tumour cell from the system at the rate µ - see
Figure 5.1d. We then allow each CTL to continue to interact with an infinite number
of other tumour cells in the system, that is, no exhaustion or deactivation process
occurs. Note that we will briefly discuss the effect of an exhaustion process later in
this chapter.
5.3 Individual-based model set up and results
5.3.1 Model parameterisation and numerical set up
Using biologically relevant values, from published data where possible, we paramet-
rise the IB model developed in Section 5.2.
Set up of the 2D grid: To determine an appropriate domain for the model, we
consider the average size of our three cell types where we choose the cancer cells to
be melanoma cells - see Table 5.1. To allow for simplicity, we take an average and
set the length of each grid position to be 10 µm in both the x and y directions. This
translates to setting,
∆x = 10 µm and ∆y = 10 µm. (5.1)
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As in the previous chapter, since we consider the diagonal neighbourhoods of cells
the grid-spacing can increase if moving diagonally to
√
2 ∆x/y, with these values
still within the biological ranges of immune cell diameter. Additionally, we define
our domain in such a way that we obtain a two-dimensional 100×100 position grid,
representing a 1 mm2 in vitro sample of tissue.
Setting the time-step of simulations: Each time-step is of length ∆t, the value
of which we can assign by considering the speed of moving immune cells. Referring
to the biological data used to model immune cell motion in Chapter 4, the average
speed of CTLs has been found to be approximately 10 ± 5µm min−1 (Boissonnas
et al., 2007). For simplicity, we assume an average cell speed of 10µm min−1 for
both inactive and active immune cells and choose a time-step of length,
∆t = 1 min, (5.2)
i.e. we allow each cell to move one grid-step per time-step.
Division of tumour cells: Christophe et al. (2015) calculated the average doub-
ling time of a melanoma cell to be 1000 mins which translates to a cell division rate
of,
λ = 0.001 min−1, (5.3)
which we choose in our numerical simulations of our IB model.
Movement of inactive immune cells: Harris et al. (2012) studied the migration
of CTLs in the brains of infected mice in response to the pathogen Toxoplasma gondii
and found that they followed a Le´vy walk with exponent of 1.15. Therefore, as in
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Chapter 4, we choose the Le´vy exponent
α = 1.15. (5.4)
Activation of dendritic cells: We choose the activation rate of dendritic cells
to be the same as that found by Bianca et al. (2012), that is
DAct = 0.07 cells min
−1. (5.5)
Activation of cytotoxic T lymphocytes: From the experimental work of En-
gelhardt et al. (2012), it can be calculated that it takes on average around 562 secs
for a single DC to activate a CTL through antigen presentation. This corresponds
to an activation rate of
CAct ≈ 0.12 cells min−1, (5.6)
which we choose in our numerical simulations of our IB model.
Tumour cell removal by CTLs: In addition to the cell division rate, the rate
at which active CTLs can remove melanoma cells was described in the experimental
work of Christophe et al. (2015) and was found to be
µ = 0.038 cells min−1. (5.7)
The full list of parameter values is displayed in Table 5.2, and unless stated
otherwise these are the values used in numerical simulations of the IB model. The
code was developed and the simulations were run in Matlab. Furthermore, all
simulation results were averaged over three separate runs with the same parameter
settings to ensure reliability of results. Examples of the spatial distributions of
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Table 5.2: Model parameters and related values used in computational simulations.
Symbol Description Value/ Units References
∆t time-step of simulations 1 min (Boissonnas et al., 2007)
∆x(y) grid spacing in the x (y) direction 10 µm Calculated
NT total number of tumour cells initial values: 400 or 1200 cells (Christophe et al., 2015)
NC total number of CTLs 400 cells (Christophe et al., 2015)
ND total number of DCs 400 cells Estimated
µ rate at which a CTL kills a tumour cell 0.03 cells min−1 (Christophe et al., 2015)
λ tumour cell division rate 0.001 min−1 (Christophe et al., 2015)
DAct DC activation rate 0.07 cells min
−1 (Bianca et al., 2012)
CAct CTL activation rate ≈ 0.12 cells min−1 (Engelhardt et al., 2012)
α Le´vy walk exponent 1.15 (Harris et al., 2012)
the cells over the simulation time are provided in Appendix A, Figure A.1 and
Figure A.2.
5.3.2 Increasing the number of DCs can cause overcrowding
and lead to longer tumour removal times
As mentioned in Section 2.6, a potential aim of adoptive cell therapies is to increase
the number of activated DCs or CTLs within the tumour microenvironment. To
investigate this further, using our IB model, we can consider the effect that increasing
either the number of DCs and/or CTLs has on the immune response to a solid
tumour. We ran each simulation over a 72 hr time-frame, in line with the work
of Christophe et al. (2015), or until all tumour cells were removed from the system.
Each simulation was carried out with the parameter values displayed in Table 5.2
and we considered a range of 40 values for the total number of DCs, ND, and/or the
total number of CTLs, NC , within the system. We consider a range of cell numbers,
from 60 cells to 2400 cells, of each cell type and we consider three situations: either
only the number of CTLs is varied, only the number of DCs is varied or both immune
cell numbers are varied. The resulting dynamics are described in Figure 5.2. The
left panels display heat maps showing the evolution of the tumour cell number over
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time for each given value of NC and/or ND and the right panels display the resulting
tumour cell number over time for four chosen values of NC and/or ND (i.e. values
of 60, 420, 1200 and 2400 cells). When we increase the number of CTLs, NC , in
the system the results shown in Figure 5.2a,b suggest a corresponding decrease in
the time it takes to remove the tumour from the system. However, upon further
inspection the tumour removal time does not decrease as strongly for increasing NC
when the value is sufficiently large, e.g. the results when NC = 1200 and NC = 2400
are similar. Varying the number of DCs within the system, through the parameter
ND, does not appear to be correlated to the time it takes for the immune system to
remove a tumour, as seen in the results displayed in Figure 5.2c,d. Particularly, we
note that in some cases a larger value of ND can result in a longer tumour removal
time, e.g. the time taken to remove the tumour when ND = 1200 is longer than the
tumour removal time when ND = 420, as displayed in Figure 5.2d. Interestingly,
when we increase both NC and ND, the results displayed in Figure 5.2e,f, suggest a
correlation between increasing cell number and a decreasing tumour removal time,
as was observed in the case where only NC was varied. To ensure that the results
obtained were not unique to the case of a relatively small tumour we also consider
a larger tumour, where initially NT = 1200, and observe similar resulting dynamics,
as shown in Appendix A, Figure A.3. One key observation of the results displayed
in Figure 5.2 is the emergence of situations where a larger number of CTLs, DCs or
both cell types can lead to a longer tumour removal time. These observed dynamics
could be explained by an overcrowding effect whereby a larger number of cells within
the system leads to limited immune access to the tumour site. We consider this in
more detail by calculating the average distance of CTLs from the centre of the
tumour for the three situations investigated previously: i.e. varying NC only, ND
only or both NC and ND. We compare the average distance of CTLs from the centre
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of the tumour for two larger values of NC and/or ND where the resulting tumour cell
number over time for each value is displayed in Figure 5.3. When considering the
number of CTLs only, the results shown in Figure 5.3a suggest that when NC = 2400
the CTLs cannot travel as close to the centre of the tumour compared to when
NC = 1200. Similarly, when we vary both NC and ND the activated CTLs appear
to be limited in their capacity to migrate closer to the tumour centre as shown by
the results in Figure 5.3c. Interestingly, if only ND is varied the larger number of
DCs present, again, prevents the activated CTLs from travelling towards the centre
of the tumour, as the results shown by Figure 5.3b suggest. In particular, when
ND = 2400 it appears that the CTLs are not only prevented from travelling towards
the centre of the tumour but appear to be pushed even further from the tumour
centre over time.
5.3.3 The ratio between the removal rate of tumour cells
by CTLs and the tumour cell division rate is a crucial
parameter in tumour removal
The rate at which a CTL can successfully remove tumour cells has previously been
highlighted as a key parameter which controls the outcome of tumour-immune com-
petition (Matzavinos et al., 2004). To investigate this further we examine the effect
of varying the parameter µ. Additionally, we consider the effects of varying the
tumour cell division rate λ. As in the previous subsection, each simulation was run
over a 72 hr period or until all of the tumour cells were removed from the system.
Each simulation was carried out with the parameter values shown in Table 5.2 and
we considered a range of 40 values of µ and/or λ. The values of these parameters
were scaled ranging from a half to twenty times the original values, which are given
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Figure 5.2: Increasing the number of DCs can lead to longer tumour
removal times. The heat maps show the evolution of the tumour cell number over
time for each given value of NC and/or ND (left panels). We select four simulation
results for cell numbers, of 60, 420, 1200 and 2400 cells, and compare the tumour
cell number over time for each parameter setting (right panels). In each case, we
begin the simulations with 400 tumour cells and test for varying values of: a,b NC
only, c,d ND only and e,f NC and ND. All values displayed are an average over
three simulation runs.
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Figure 5.3: Increasing the number of DCs can cause overcrowding. Plots
displaying the average distance of the CTLs from the centre of the domain ( i.e. the
initial centre of the tumour). We test for varying values of: a NC only, b ND only
and c NC and ND. In each case we compare the results of simulations for two values
of the varied parameter(s), choosing values of 1200 cells (red line) or 2400 cells (blue
line). All values displayed are an average over three simulation runs.
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in Table 5.2. The resulting dynamics are described in Figure 5.4. The left panels
display heat maps to show the evolution of the tumour cell number over time for
each given value of µ and/or λ. In the right panels of Figure 5.4, we display the
results of using values of a half, one, ten and twenty times the original parameter
values and compare the tumour cell number over time for each parameter setting.
Through increasing µ only a decrease in tumour removal time is observed in the
results shown in Figure 5.4a,b. However, when multiplying our original value of µ
by ten or twenty there is no significant difference in the resulting tumour removal
time. As expected when we only increase λ, as the results shown in Figure 5.4c,d,
we observe an increase in tumour removal time and eventually we encounter situ-
ations where the tumour grows too large and cannot be removed in the time-frame
considered. However, by increasing both λ and µ we observe a general decrease
in tumour removal time, although slightly slower than the cases where only µ is
altered, as shown in Figure 5.4e,f. Once again, to ensure that the results obtained
were not specific the case of a relatively small tumour we also consider a larger tu-
mour, where initially NT = 1200, and observe similar resulting dynamics, as shown
in Appendix A, Figure A.4..
5.3.4 Increasing the activation rates of DCs and CTLs has
little effect on tumour removal
Through the biological experiments of immune cells within the tumour microenvir-
onment, the role of immune cell activation through antigen presentation has been
highlighted (Boissonnas et al., 2007). Therefore, we consider the effect of altering
the activation rate of both CTLs and DCs, CAct and DAct, respectively. As in the
previous subsections, each simulation was run over a 72 hr period or until all of the
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Figure 5.4: The ratio between the removal rate of tumour cells by CTLs
and the tumour cell division rate is a crucial parameter in tumour re-
moval. The heat maps show the evolution of the tumour cell number over time for
each given value of µ and/or λ (left panels). We select four values of µ and/or
λ and compare the tumour cell number over time for each parameter setting (right
panels). In each case, we begin the simulations with 400 tumour cells and test for
varying values of: a,b µ only, c,d λ only and e,f µ and λ. All values displayed are
an average over three simulation runs.
73
tumour cells were removed from the system. Each simulation was carried out with
the parameter values shown in Table 5.2 and we considered a range of 40 values
of CAct and/or DAct. To compare results we considered two initial tumour sizes: a
smaller tumour made up of 400 cells at the beginning of simulations (results shown
in Figure 5.5) and a larger tumour made up of 1200 tumour cells at the beginning
of simulations (results shown in Figure 5.6). The values of DAct and/or CAct were
scaled ranging from a half to twenty times the original parameter values and the
resulting dynamics are described in Figure 5.5 and Figure 5.6. The left panels dis-
play heat maps to show the evolution of the tumour cell number over time for each
given value of CAct and/or DAct. In the right panels of Figure 5.5 and Figure 5.6, we
select results of simulations that used a half, one, ten and twenty times the original
values of DAct and/or CAct, and compare the tumour cell number over time for each
parameter setting. In both the initially larger and initially smaller tumour situations
there appears to be no clear correlation between altering either CAct and/or DAct
and tumour removal time, which can be inferred by the fluctuating results displayed
by the heat maps. Interestingly, when we considered the initially larger tumour we
can obtain results whereby higher activations rates lead to a slower tumour removal
time, e.g. the results shown in the right panels of Figure 5.6. This was not observed
in the case of a initially smaller tumour, e.g. the results shown in the right panels
of Figure 5.5.
74
Figure 5.5: Increasing the activation rates of DCs and CTLs has little
effect on the removal of an initially smaller tumour. The heat maps show the
evolution of the tumour cell number over time for each given value of CAct and/or
DAct (left panels). We select four values of CAct and/or DAct and compare the
tumour cell number over time for each parameter setting (right panels). In each
case, we begin the simulations with 400 tumour cells and test for varying values of:
a,b DAct only, c,d CAct only and e,f DAct and CAct. All values displayed are an
average over three simulation runs.
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Figure 5.6: Increasing the activation rates of DCs and CTLs has little
effect on the removal of an initially larger tumour. The heat maps show the
evolution of the tumour cell number over time for each given value of CAct and/or
DAct (left panels). We select four values of CAct and/or DAct and compare the
tumour cell number over time for each parameter setting (right panels). In each
case, we begin the simulations with 1200 tumour cells and test for varying values of:
a,b DAct only, c,d CAct only and e,f DAct and CAct. All values displayed are an
average over three simulation runs.
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5.3.5 For large exhaustion limits, immune cell exhaustion
does not impact the outcomes of tumour immune com-
petition
It has been suggested that immune cells can be limited in their activity through
exhaustion, whereby they can only interact with a certain number of cells (Chris-
tophe et al., 2015). Hence, we investigated the role of immune cell exhaustion on
the outcomes of tumour-immune competition by limiting the number of CTLs that
a single DC can activate and limiting the number of tumour cells that a single CTL
can remove from the system. As in the previous subsections, each simulation was
run over a 72 hr period or until all of the tumour cells were removed from the system.
Furthermore, each simulation was carried out with the parameter values shown in
Table 5.2 for a range of values for the limiting cell number that causes exhaustion.
Values of this limit were chosen to range from 1 cell to an infinite number of cells,
with suitable intermediate values investigated. The resulting evolutions of the tu-
mour cell number over time are shown in Figure 5.7 where each line represents the
tumour cell density over time for the tested parameter setting. In the case where
each immune cell can only interact with one cell, we observe that the tumour cell
number steadily increases over time. For limits of either two or three cells we observe
a slight decrease in tumour mass, before the tumour cell number increases again.
For a limit of four cells we observe a steady decrease in the tumour cell number with
very few cells remaining at the end of simulations. For all higher exhaustion limit
values we observe that the tumour can be removed and for larger values (i.e. over
twenty cells) the tumour removal times are very similar.
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Figure 5.7: For large exhaustion limits, immune cell exhaustion does not
impact the outcomes of tumour immune competition. Line plots showing
the evolution of the number of tumour cells over time for eleven different limits of
immune cell exhaustion. The limit shown in the legend indicates how many cells
both single DCs and single CTLs can interact with over the time-frame considered.
All values displayed are the average over three simulation runs.
5.3.6 Using a switch in immune cell motion decreases tu-
mour elimination time
In the model, immune cells switch their form of motion from a Le´vy walk to Brownian
motion upon activation. However, another modelling approach is to simply use
Brownian motion for both inactive and active immune cells. To investigate the
impact of the inclusion of the switch in cell motion we run simulations whereby both
inactive and active immune cells undergo Brownian motion and compare the results
to those from previous sections here immune cells switched from Le´vy to Brownian
motion. As in the previous subsections, each simulation was run over a 72 hr period
or until all of the tumour cells were removed from the system. Furthermore, each
simulation was carried out with the parameter values shown in Table 5.2. We
compare the tumour elimination time and numbers of active/inactive immune cells
with the case where the cells switched motion in Figure 5.8. The bars display the
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Figure 5.8: Using a switch in immune cell motion decreases tumour elim-
ination time. We compare the case where both inactive and active immune cells
undergo Brownian motion (blue) and the case where the immune cells switch from
a Le´vy walk to Brownian motion upon activation (pink). We compare the number
of tumour cells at the end of simulation, the time taken to remove the tumour and
the numbers of inactive/active immune cells within the system. The bars display the
mean value of ten runs of the simulation and the error lines represent the standard
deviation between these ten runs.
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mean value of ten runs of the simulation and the error lines represent the standard
deviation between these ten runs. We observe that the tumour elimination time for
the case with no switch (Brownian only) is larger than that when the cells switch
from a Le´vy walk to Brownian motion upon activation. In the case of Brownian
motion the number of active and inactive immune cells at the end of simulations is
similar to the results of the case where cell switch from a Le´vy walk to Brownian
motion upon activation.
5.4 Concluding remarks and discussion
In this chapter we have developed a stochastic individual-based (IB) spatial model of
tumour-immune competition focussing on cell-cell interactions between cancer cells,
dendritic cells and cytotoxic T lymphocytes.
The results of numerical simulations of this IB model recapitulate the findings
of experimental work which highlighted that a (limited) beneficial effect on the
immune response to cancer can be induced through enhancing the number of CTLs
in the tumour microenvironment (Spranger, 2016). Furthermore, in agreement with
the experimental results presented in Li et al. (2010) and Ye et al. (2011) – where
the authors showed that cellular overcrowding can hamper immune action – our
computational results indicate that higher numbers of DCs can lead to overcrowding
and prevent activated CTLs from reaching the tumour resulting in reduced success
of tumour removal. This may be useful in explaining instances of unsuccessful
dendritic cell therapy (Ahmed et al., 2014; Butterfield, 2013; Garg et al., 2017; Lim
et al., 2007) and suggests that increasing CTL numbers may be a better objective
for immunotherapy rather than increasing DC numbers.
As expected, when we increase the division rate of the tumour cells we observe
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that tumour growth could no longer be controlled by the immune system and could
eventually lead to situations of exponential tumour growth. However, if the capab-
ility of CTLs to remove tumour cells is also enhanced, in agreement with previous
theoretical works (d’Onofrio and Ciancio, 2011; Frascoli et al., 2014; Matzavinos
et al., 2004), our model predicts that tumour eradication can be re-established.
Such results illustrate how the ratio between the tumour proliferation rate and the
immune cell’s tumour kill rate (i.e. the ratio between λ and µ) is a crucial determ-
inant of the outcome of anti-tumour immune action.
The outcomes of this initial model demonstrate that, in general, increasing the
activation rates of CTLs and DCs has very little effect on removal of the tumour, in
the parameter settings we have considered . Taken together, our results testify to
the idea that choosing the activation rates of CTLs and DCs as designated targets
in adoptive cell therapy, or other forms of immunotherapy, may not enhance the
efficacy of the immune response against solid tumours.
Through investigation of the immune cell exhaustion process, our model indicates
that the exhaustion limit of immune cells does not greatly impact the tumour-
immune competition, unless the immune cells are limited to interacting with less
than five cells. Experimentally, it has been shown that T cells can have an exhaustion
limit of around 5 cells (Christophe et al., 2015) and there is evidence that this
limit is closer to 10 cells (Halle et al., 2016), both of which our model suggests
would still result in the same dynamics as the case where there was no exhaustion
limit. Therefore, this mechanism can be easily omitted from our model to allow for
simplicity and to focus on more influential processes and parameter settings.
We compare the case where all immune cells undergo Brownian motion, to our
model where immune cells switch from a Le´vy walk mechanism to Brownian motion
upon activation by tumour antigen. Our results suggest that including this switch
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in cell motion does not alter the resulting dynamics of the system, but does result
in a faster tumour removal time, for the parameter setting considered. This further
supports the results of Chapter 4 where the Le`vy walk mechanism was found to be
more efficient than the Brownian motion walk mechanism.
In the individual-based model described in this chapter we have considered a
homogeneous tumour, where all tumour cells are of the same phenotype. However,
a tumour can be heterogeneous in relation to the antigens which each tumour cell
expresses. This individual-based model will be further developed in Chapter 6 to
incorporate such tumour antigens and their effect on the immune response.
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Chapter 6
An individual-based model to
describe the role of tumour
heterogeneity in tumour-immune
competition
6.1 Overview
In the previous chapter, we developed an individual-based (IB) model of tumour-
immune competition to describe the interactions between dendritic cells (DCs),
cytotoxic T lymphocytes (CTLs) and tumour cells. In the model, we considered
a homogeneous tumour, i.e. all tumour cells exhibited the same antigenic profile.
However, the antigenic composition of solid tumours can be heterogeneous. There-
fore, each cell within the tumour mass may have an antigen profile characterised by
different expression levels of tumour antigens which may vary over time through epi-
mutations or mutations. In light of these considerations, in this chapter we extend
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the IB model described in Chapter 5 further to explicitly capture tumour antigen
expression and recognition by the immune system. In this extended model, each
cancer cell is characterised by an antigen profile which can change over time due to
either epimutations or mutations. The immune response towards the cancer cells is
initiated by the DCs that recognise the tumour antigens and present them to the
CTLs. Consequently, CTLs become activated against the tumour cells which ex-
press such antigens and can subsequently remove them from the system. The model
described in this chapter and several of the results shown have been submitted for
publication (Macfarlane et al., 2019).
6.2 The mathematical model
The model developed in this chapter is based upon the individual-based model de-
scribed in Chapter 5. Therefore, we again consider three cell types: tumour cells,
dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs) and use an individual-
based approach to describe the interactions between these three cell types. Fur-
thermore, the model is again posed on a 2D spatial grid of spacing ∆x in the x
direction and ∆y in the y direction, with the constraint that only one cell of any
type is allowed at each grid-site at any time-step of duration ∆t.
As in the previous chapter, initially, inactive immune cells are randomly dis-
tributed on the spatial grid, while the cancer cells are tightly packed in a circular
configuration positioned at the centre of the grid, to reproduce the geometry of a
solid tumour. We again assume that, at the start of simulations, there are no ac-
tivated immune cells. Throughout the simulations, we allow the tumour to grow
through cell division. In agreement with the previous model, a cancer cell divides
at the rate λ into two progeny cells of which one occupies the position of the parent
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cell while the other is positioned at an unoccupied neighbouring grid-site. This en-
sures that only cancer cells with free grid-sites in their neighbourhood can divide,
that is, cells with no free neighbouring grid sites will not proliferate. In line with
the previous models we have described, inactive immune cells update their position
according to a Le´vy walk and can become activated via interactions with other cells
which initiates a change in motion, i.e. activated immune cells follow a Brownian
walk. Furthermore, DCs are activated at the rate DAct upon contact with tumour
cells, and CTLs become activated at the rate CAct upon contact with active DCs.
Once again, we let active CTLs remove tumour cells, upon contact, at the rate µ.
For simplicity, we again omit the effects of natural death of tumour cells and the
proliferation of both DCs and CTLs, i.e. the total numbers of DCs and CTLs are
constant over time. Chapter 5 contains a detailed description of these modelling
strategies.
In this chapter, we develop each of these modelling strategies further to include:
the antigen profiles of cancer cells and their possible variation, the immune recogni-
tion of tumour antigens by DCs, and the targeted activation of CTLs against specific
tumour antigens. We incorporate antigen expression into our model by letting each
tumour cell express eleven different antigens, to represent the eleven MAGE-A an-
tigens that, as mentioned in Section 2.3, have a key role in tumour development
(Coulie et al., 2014). The eleven antigens are reported in Table 6.2 and we label
them by an index i = 1, . . . , 11. In the model, we assume there is no correlation
between the expression of the eleven MAGE-A antigens (Roch et al., 2010), there-
fore each antigen is expressed independently of the others. The modelling strategies
used to take into account such additional layers of biological complexity are de-
scribed in detail in the following subsections, and are also schematically illustrated
in Figure 6.1 and Figure 6.2.
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Figure 6.1: Schematic representation of the mechanisms and processes
included in the individual-based model. Key We consider three cell types in
the model: tumour cells, DCs and CTLs, along with their corresponding antigen and
receptor profiles. a Initially the tumour is composed of tumour cells characterised
by different antigenic profiles. The standard deviation of the initial tumour antigen
profiles from the experimental profile is determined by the parameter VT . b Tumour
cells divide at the rate λ. c Tumour cells may undergo epimutations with probability
θE. The standard deviation of the epimutation altered tumour antigen profiles from
the original profile is determined by the parameter VE. d DCs become activated upon
contact with tumour cells at the rate DAct. The standard deviation of the antigen
profiles recognised by DCs from the tumour antigen profiles is determined by the
parameter VD. e Upon contact, active DCs present the antigen profile they have
recognised to inactive CTLs. This leads to the targeted activation of CTLs against
specific tumour antigens at the rate CAct. f Activated CTLs remove tumour cells,
upon contact, at the rate µ, on the condition that the tumour cells express a sufficient
amount of the antigens corresponding to the CTL receptors. The binding affinity of
the CTLs is measured by the parameter β.
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6.2.1 Mathematical modelling of antigen expression
We denote by NT (t) the number of tumour cells in the system at time t = h∆t,
with h ∈ N0, and we label each cell by an index n = 1, . . . , NT (t). There can be high
variability in MAGE-A antigen expression between patients with the same type of
cancer (Hartmann et al., 2016; Mu¨ller-Richter et al., 2009; Urosevic et al., 2005)
and even within cancer cell samples from the same patient (Hartmann et al., 2016;
Mu¨ller-Richter et al., 2009; Urosevic et al., 2005). Therefore, at each time instant
t, we characterise the antigen profile of the nth tumour cell by means of a vector
ATn(t) = (A
(1)
Tn(t), . . . , A
(11)
Tn (t)),
with A
(i)
Tn(t) representing the expression level of antigen i. As schematically illus-
trated in Figure 6.1, for each tumour cell n we define the initial expression of the
ith antigen as
A
(i)
Tn(0) = (Mi + VT Ri)+, i = 1, . . . , 11. (6.1)
In equation (6.1), the parameter Mi denotes a mean expression level of antigen
i taken from published experimental data, the values of which are reported in
Table 6.2. The value of Ri is sampled from a standard normal distribution centred
at zero. We take the positive part of equation (6.1) to ensure nonnegativity of the
antigen expression level. As Ri is taken from a standard normal distribution, the
parameter VT can be described as the standard deviation of the initial antigen pro-
file from the experimental value Mi (Kenney and Keeping, 1962). Therefore the
parameter VT determines how close the value of A
(i)
Tn(0) will be to the value of Mi -
see the scheme in Figure 6.1a.
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6.2.2 Modelling variations in antigen expression
At each time-step, we let the tumour cells divide at the rate λ, as shown in the
schemes in Figure 6.1b, and allow their antigen profile to vary either through epi-
mutations or through mutations. We assume that epimutations can occur at any
time during the lifespan of a cell - see the schemes in Figure 6.1c and Figure 6.2a.
On the other hand, mutations take place during cell division and may cause the
antigen profile of one progeny cell to be different from that of the parent cell - see
the scheme in Figure 6.2b. We allow epimutations and mutations to occur with
probabilities θE and θM , respectively.
Epimutations: A variation in the level of expression of the ith antigen of the nth
tumour cell at the time instant t due to an epimutation is modelled according to
the following equation
A
(i)
Tn(t+ ∆t) = (A
(i)
Tn(t) + VE Ri)+, i = 1, . . . , 11. (6.2)
In equation (6.2), the value of Ri is sampled from a normal distribution centred
at zero. We take the positive part of equation (6.2) to ensure nonnegativity of the
antigen expression level. Following on from the definition of the parameter VT , since
Ri is taken from a standard normal distribution, the parameter VE can be described
as the standard deviation of the updated antigen profile from the previous expression
profile (Kenney and Keeping, 1962). Therefore, VE determines how close the value
of A
(i)
Tn(t+ ∆t) will be to the value of A
(i)
Tn(t).
Mutations: Upon division at the time instant t, the nth tumour cell is replaced
by two cells, one labelled by the index n and the other one labelled by the index
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NT (t) + 1. If mutations do not occur, the progeny cells inherit the antigen profile
of the parent cell, i.e. A
(i)
Tn(t + ∆t) = A
(i)
Tn(t) and A
(i)
T NT (t)+1
(t + ∆t) = A
(i)
Tn(t).
Conversely, if a mutation occurs, the antigen profile of the progeny cells will be
given by the following equations
A
(i)
Tn(t+ ∆t) = A
(i)
Tn(t), i = 1, . . . , 11 (6.3)
and
A
(i)
T NT (t)+1
(t+ ∆t) = (A
(i)
Tn(t) + VM Ri)+, i = 1, . . . , 11. (6.4)
Equations (6.3) and (6.4) rely on notation analogous to that of equation (6.2) and
therefore VM can be described as the standard deviation of the progeny antigen
profiles from the parent antigen profiles (Kenney and Keeping, 1962). Therefore,
the value of VM determines how close the value of A
(i)
T NT (t)+1
(t+ ∆t) will be to the
value of A
(i)
Tn(t).
Clearly, in the absence of changes in antigen expression, i.e. if θE = 0 and
θM = 0, the antigen profiles of the tumour cells will remain constant over time, that
is, ATn(t) = ATn(0) for all t > 0 and n = 1, . . . , NT .
6.2.3 Activation of immune cells
Activation of DCs: We denote by ND the number of DCs, which we assume to
be constant, and we label each DC by an index k = 1, . . . , ND. Activation of each
DCs occurs, at the rate DAct, through contact with a tumour cell. There is biological
evidence supporting heterogeneity within the antigen presentation process where a
less prevalent antigen may be recognised presented by DCs (Boes et al., 2002; Fehres
et al., 2014; Ljunggren et al., 1990). Additionally, it is known that the MAGE-A
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Figure 6.2: Schematic comparison of the modelling strategies used to
describe changes in antigen expression induced by epimutations and
mutations within tumour cells. a Antigenic variations due to epimutations
can occur, with probability θE, at any time during the life of a tumour cell. The
standard deviation of the new antigen profile from the original one is determined by
the parameter VE. b Mutations can take place, with probability θM , only during cell
division, which occurs at the rate λ. Due to mutations, one progeny cell may exhibit
an antigen profile different from that of the parent cell. The standard deviation
between the parent and progeny cell antigen profiles is determined by the parameter
VM .
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genes have similar homology (Roch et al., 2010; Zajac et al., 2017) and therefore there
is a potential that they could be mis-recognised as each other (Graff-Dubois et al.,
2002; Linette et al., 2013; Raman et al., 2016; Schueler-Furman et al., 1998; Tong
et al., 2004). Therefore, we incorporate variability into the DC activation process
whereby the DCs may recognise different expression levels of the tumour antigen
from this actually present. At any time instant t, the kth DC is characterised by a
recognised antigen profile
ADk(t) = (A
(1)
Dk(t), . . . , A
(11)
Dk (t)).
We let all DCs be initially inactive and thus assume
A
(i)
Dk(0) = 0, i = 1, . . . , 11,
for all k = 1, . . . , ND. As schematically described by Figure 6.1d, we consider the
case where there may be potential variation in the antigen recognition process. To
capture this idea, upon activation through contact with the nth tumour cell at the
time instant t, we assign the recognised antigen profile of the kth DC using the
following equation
A
(i)
Dk(t+ ∆t) = (A
(i)
Tn(t) + VD Ri)+, i = 1, . . . , 11. (6.5)
In equation (6.5), the value of Ri is sampled from a normal distribution centred
at zero. We take the positive part of equation (6.5) to ensure nonnegativity of the
antigen expression level. We can describe VD as the standard deviation of the antigen
profile recognised by each DC from the actual tumour antigen profile (Kenney and
Keeping, 1962). Therefore, VD determines how close the value of A
(i)
Dk(t + ∆t) will
91
be to the value of A
(i)
Tn(t). We note that biologically, VD captures the potential of
the immune system to target an antigen which is not the highest expressed by the
tumour cell. Therefore, introducing VD allows the dendritic cells to have variation
in which antigens they present to the CTLs and thus determines the diversity of
the T cell receptor expression within the CTL population. The results we have
discussed previously in Chapter 5, indicate that realistic exhaustion limits of cells
would not change the outcome of tumour immune competition, compared to no limit
of exhaustion. Therefore, once activated, the DCs remain activated against their
recognised tumour antigen profile.
Activation of CTLs: We denote by NC the number of CTLs, which we assume
to be constant, and we label each CTL by an index m = 1, . . . , NC . As schematically
described by Figure 6.1e, activation of CTLs occurs, at the rate CAct, through contact
with activated DCs. At any time instant t, each CTL m has a receptor profile
ACm(t) = (A
(1)
Cm(t), . . . , A
(11)
Cm (t)).
We let all CTLs be initially inactive and thus assume
A
(i)
Cm(0) = 0, i = 1, . . . , 11,
for all m = 1, . . . , NC . While DCs can recognise multiple types of antigens, CTLs
can produce copies of one antigen receptor only (Brenner et al., 2008; Coico and
Sunshine, 2015). This means that each CTL can only be activated against one of
the eleven MAGE-A antigens. To capture this fact, upon activation through contact
with the kth DC at the time instant t, we let the mth CTL become activated against
the most prevalent antigen within the tumour antigen profile recognised by the kth
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DC, i.e. we assign the receptor profile of the mth CTL using the following equation
A
(i)
Cm(t) =

1 for i = iˆ,
0 for i 6= iˆ,
with iˆ = arg max
j
A
(j)
Dk(t), (6.6)
where the index iˆ specifies the target antigen of the activated CTL. Note that, if
| arg maxj A(j)Dk(t)| > 1, then we arbitrarily choose iˆ = min arg maxj A(j)Dk(t). Again,
the results we have discussed previously in Chapter 5, indicate that realistic exhaus-
tion limits of cells would not change the outcome of tumour immune competition,
compared to no limit of exhaustion. Therefore, once activated, a CTL remains
activated against the same tumour antigen.
6.2.4 Removal of tumour cells by activated CTLs
Upon contact, each activated CTL can induce death of the tumour cells which
express a sufficiently high level of the CTL’s target antigen (Coulie et al., 2014;
Stone et al., 2009), which we assume to be given by the mean antigen expression
levels reported in Table 6.2. In particular, as schematically described by Figure 6.1f,
when the mth CTL interacts with the nth tumour cell at time t, we compare the
receptor profile ACm(t) with the antigen profile ATn(t) and let the tumour cell be
removed from the system at the rate µ provided that
A
(i)
Tn(t) ≥ (Mi − β) for i such that A(i)Cm(t) = 1. (6.7)
In equation (6.7), the parameter β describes the binding affinity of the CTLs, which
determines the range of tumour cells that each CTL can interact with. If β is
larger, then the CTL can recognise tumour cells with a lower level of expression of
93
Table 6.1: Model parameters and related values used in computational simulations.
Note, standard deviation has been abbreviated to StD.
Symbol Description Value(s) Reference
∆t time-step 1 min (Boissonnas et al., 2007)
∆x,y grid spacing in the x or y direction 10 µm (Macfarlane et al., 2018)
NT (0) initial number of tumour cells 400 cells (Christophe et al., 2015)
NC total number of CTLs 400 cells (Christophe et al., 2015)
ND total number of DCs 400 cells (Macfarlane et al., 2018)
n Index identifier of each tumour cell n = 1, . . . , NT -
k Index identifier of each DC k = 1, . . . , ND -
m Index identifier of each CTL m = 1, . . . , NC -
M Antigen profile from experimental data see Table 6.2 (Hartmann et al., 2016)
ATn(t) Antigen profile of tumour cell n at time t values ≥ 0 -
ADk(t) Recognised antigen profile of DC k at time values ≥ 0 -
ACm(t) Antigen receptor profile of CTL m at time values of 0 or 1 -
λ tumour cell division rate 0.001 min−1 (Christophe et al., 2015)
θ∗E Average probability of epimutations 0.23 (De Smet et al., 1996)
µ removal rate of tumour cells by CTLs 0.03 cells min−1 (Christophe et al., 2015)
DAct DC activation rate 0.07 cells min
−1 (Bianca et al., 2012)
CAct CTL activation rate ≈ 0.12 cells min−1 (Engelhardt et al., 2012)
α Le´vy walk exponent 1.15 (Harris et al., 2012)
β T cell binding affinity 0 → 0.2 (Schmid et al., 2010)
VT StD of the initial tumour antigen profiles from experimental profile M 0 → 1 -
VD StD of the antigen profiles recognised by DCs from the tumour antigen profiles 0 → 1 -
VE/M StD of the tumour antigen profiles after epimutations/mutations same as VT -
the antigen that they target. Independent of the outcome of the interaction, the
CTL can interact with further tumour cells following the same process.
6.3 Computational simulations and results
6.3.1 Model parametrisation and simulation set up
In line with the IB model developed in Chapter 5, we use 100 grid points both
in the x and in the y direction, which correspond to a 2D spatial domain of size
1 mm2. The code was developed and the simulations were run in Matlab, for an
appropriate number of time-steps, with one time-step chosen to be ∆t = 1 min, to
allow for the resulting dynamics of the system to be investigated. Chapter 5 contains
a detailed description of the parametrisation of the original model, and we describe
here the way in which the additional components of the model are calibrated using
the parameter values reported in Table 6.1.
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Initial tumour antigen expression levels: Hartmann et al. (2016) investigated
the levels of expression of the eleven MAGE-A antigens in oral squamous cell cancers
of 38 patients. The mean antigen expression levels were taken to be values between 0-
12 arbitrary units as an immune-reactivity score, which are normalised and reported
in Table 6.2. In our model the initial expression level of each antigen for each tumour
cell is defined by using equation (6.1) along with the values of Mi from Table 6.2.
To determine the value of (VT Ri) in equation (6.1) we consider the properties of
Ri, which is a random value taken from a standard normal distribution. A standard
normal distribution with mean 0 and standard deviation 1, has a 95% confidence
interval of ±1.96 (Kenney and Keeping, 1962). Therefore, for 95% of values, we
expect -1.96 ≤ Ri ≤1.96 with the majority of the values being close to the mean
value, zero. We then use the parameter VT to control the minimum and maximum
value of (VT Ri), i.e when VT=1 then (VT Ri) ∈ {−1.96, 1.96}, for most values.
However, if VT is lower, e.g. VT=0.1, then the values of (VT Ri) will also be lower,
e.g. (VT Ri) ∈ {−0.196, 0.196}. To consider a wide range of biological situations,
in regards to the initial heterogeneity between tumour antigen profiles, we use a
range of values, between 0 and 1, for the parameter VT . As the experimental data
in Table 6.2 is unitless, we also consider VT to be unitless.
Probabilities of epimutations and mutations: De Smet et al. (1996) found
that cancer cell lines expressing the MAGE-A1 antigen were 23% more likely to
undergo demethylation events than tumour cell lines that did not express this an-
tigen. Such values are supported by other studies that consider the likelihood of
DNA demethylation in various cancers (Chalitchagorn et al., 2004; Ehrlich, 2002).
We make the assumption that this holds true for the other ten MAGE-A antigens,
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Table 6.2: Average levels of expression of the MAGE-A antigens in human oral
squamous cell cancer cell lines. The experimental values were taken from (Hartmann
et al., 2016) and then normalised by dividing by 12.
Antigen (i) Mean Expression, Mi
MAGE-A1 (1) 0.10
MAGE-A2 (2) 0.25
MAGE-A3 (3) 0.41
MAGE-A4 (4) 0.24
MAGE-A5 (5) 0.36
MAGE-A6 (6) 0.35
MAGE-A8 (7) 0.17
MAGE-A9 (8) 0.16
MAGE-A10 (9) 0.38
MAGE-A11 (10) 0.06
MAGE-A12 (11) 0.32
and let the average probability of epimutations in our model be
θ∗E = 0.23.
In the model we consider the effect of increase or decreasing the probability of
epimutations or mutations by setting θE and θM , respectively, as multiples of θ
∗
E.
The parameters VE and VM control how much the antigen expression of a tumour cell
can change through epimutations or how much the antigen expression of a daughter
tumour cell can change through mutations - see equations (6.2) and (6.3). The
values of VM and VE are chosen to match the values of VT , that is we assume that
the antigenic profiles of cells will only be able to evolve according to the levels of
heterogeneity in the antigen expression levels between initial antigen profiles. As
the experimental data in Table 6.2 is unitless, we also consider VE and VM to be
unitless.
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Antigen recognition process: In line with the choice of values for the para-
meter VT , to consider a wide range of biological situations, in regards to the antigen
recognition process, we use a range of values, between 0 and 1, for the parameter
VD - see equation (6.5). As the experimental data in Table 6.2 is unitless, we also
consider VD to be unitless.
T cell binding affinity: The binding affinity of a T cell is related to the associ-
ation rate, that is the inverse of the dissociation rate KD. In general this value is
between 0.005 µM−1 and 1 µM−1 for all natural T cells (Davis et al., 1998; Slansky
and Jordan, 2010). Furthermore, the MAGE-A T cell receptors association rates
have been found to be even larger than this range, e.g. for MAGE-A3 the values are
between 0.018 µM−1 and 5.917 µM−1 (Tan et al., 2015). However, Schmid et al.
(2010) have shown that an association rate of 0.2 µM−1 or higher did not improve
the binding affinity and therefore higher binding affinities may have a limited ef-
fect. We take Mi to be the minimal binding and allow the likelihood of binding to
increase depending on β. In line with the experimental evidence, we investigate a
range of unitless values between 0 and 0.2 for the parameter, β, that models the T
cell receptor binding affinity - see equation (6.7).
6.3.2 Variability between the initial tumour antigen profiles
determines the effectiveness of the immune response
To investigate how the immune response is affected by variability in the initial
tumour antigen profiles, we test for three increasing values of the parameter VT , i.e.
VT = 0.001, VT = 0.01 and VT = 0.1. We choose β = 0.01 and we let the tumour
cell antigen profiles remain constant over time, i.e. we choose θE = θM = 0. For
each value of VT considered, we also explore the effect of increasing the value of
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Figure 6.3: Variability between the initial tumour antigen profiles de-
termines the effectiveness of the immune response. Plots displaying the
number of tumour cells remaining after 1000 time-steps for increasing values of the
parameter VT : a VT = 0.001, b VT = 0.01 and c VT = 0.1. For each value of VT
a range of values of the parameter VD are tested. The tumour cell numbers presen-
ted have been obtained as the average over 5 simulations and the error bars display
the related standard deviation. Here, β = 0.01, θE = θM = 0, and all the other
parameter values are reported in Table 6.1.
98
the parameter VD. In all cases, we carried out simulations for 1000 time-steps. As
shown by Figure 6.3a, when there is a small difference between the initial tumour cell
antigen profiles, very few tumour cells remain in the system after 1000 time-steps
for all considered values of VD. Conversely, the results presented in Figure 6.3c show
that if we allow VT to be relatively large, there is a significant number of remaining
tumour cells after 1000 time-steps for all values of VD. Moreover, as shown by
Figure 6.3b, for an intermediate level of initial antigen variability, there appears to
be a correlation between the number of tumour cells remaining after 1000 time-steps
and the parameter VD. In particular, larger values of the parameter VD correspond
to smaller numbers of the remaining tumour cells after 1000 time-steps. These
results suggest that for tumours characterised by intermediate levels of VT , higher
levels of variability between the antigen profile recognised by DCs and the actual
antigen profile of tumour cells may result in a more effective immune response. This
is further illustrated by the computational results presented in the next subsection.
6.3.3 Increasing variability between the antigen profile re-
cognised by DCs and the actual antigen profile of tu-
mour cells results in immune escape, chronic dormancy
or immune clearance of the tumour
The results discussed in the previous subsection illustrate how different cell dynamics
can be observed for increasing values of the parameter VD. We test this further by
using the parameter setting of Figure 6.3b, i.e. VT = 0.01, θE = 0 and β = 0.01, and
comparing the dynamics obtained for three different values of VD, i.e. VD = 0.001,
VD = 0.05 and VD = 0.1. In Figure 6.4, we compare the average antigen profile of
the tumour cells at the end of simulations with the average antigen profile recognised
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Figure 6.4: Increasing VD can result in immune escape or chronic
dormancy or immune clearance of the tumour. Plots in panels a-c display
the average antigen profile of tumour cells (blue) and the average antigen profile
recognised by the DCs (green) at the end of simulations. The black lines describe the
standard deviation between 5 runs of the simulation. Plots in panels d-f display the
time evolution of the tumour cell number with an example of the observed cell spatial
distributions at the final time-step shown in the insets. Values are taken to be the
average over five simulation runs. Tumour cells are blue, DCs are green, CTLs are
red and inactive immune cells are darker green and red, respectively. Three values
for the parameter VD are tested: a,d VD = 0.001, b,e VD = 0.05 and c,f VD = 0.1.
Here, VT = 0.01, β = 0.01, θE = θM = 0, and all the other parameter values are
reported in Table 6.1.
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by the DCs, and we show the corresponding time evolution of the number of tumour
cells. The insets also display the spatial cell distributions observed at the end of
simulations to allow for a clearer understanding of the resulting dynamics. We
observe that VD is a bifurcation parameter whereby three distinct situations result
from choosing increasing values of VD. In particular, Figures 6.4a,d refer to the case
where the value of VD is relatively low, i.e. VD = 0.001, and show that there is
a small difference between the average antigen profile of the tumour cells and the
average recognised antigen profile at the end of simulations. Moreover, after an
initial decrease, the tumour cell number increases steadily over time resulting in a
relatively large final number of tumour cells. Furthermore, Figures 6.4b,e refer to
the case where an intermediate value of VD is considered, i.e. VD = 0.05, and show
that there is a larger difference between the average antigen profile of the tumour
cells and the average recognised antigen profile at the end of simulations. Moreover,
after a steep decrease, the tumour cell number remains at a low, almost constant,
level for the remainder of the simulation time interval. Finally, Figures 6.4c,f refer
to the case where the value of VD is relatively large, i.e. VD = 0.1, and show
that the difference between the average antigen profile of the tumour cells and the
average recognised antigen profile at the end of simulations is even larger than in
the previous cases. Moreover, the number of tumour cells decreases steadily over
time and eventually the tumour is completely removed.
6.3.4 Increasing the T cell receptor binding affinity can be-
nefit the immune system response to cancer
To explore the effect of altering the T cell receptor binding affinity, we test for three
increasing values of the parameter β, i.e. β = 0, β = 0.0001 and β = 0.001. We
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Figure 6.5: Increasing the T cell receptor binding affinity can benefit the
immune system response to cancer. Plots displaying the number of tumour
cells remaining after 1000 time-steps for increasing values of the parameter β: a
β = 0, b β = 0.0001 and c β = 0.001. For each value of β a range of values of
the parameter VD are tested. The tumour cell numbers presented have been obtained
as the average over 5 simulations and the error bars display the related standard
deviation. Here, VT = 0.0001, θE = θM = 0, and all the other parameter values are
reported in Table 6.1.
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Figure 6.6: Increasing the T cell receptor binding affinity can benefit the
immune system response to cancer. Plots in panels a-c display the average
antigen profile of tumour cells (blue) and the average antigen profile recognised by
the DCs (green) at the end of simulations. The black lines describe the standard
deviation between 5 runs of the simulation. Plots in panels d-f display the time
evolution of the tumour cell number with an example of the observed cell spatial
distributions at the final time-step shown in the insets. Values are taken to be the
average over five simulation runs. Tumour cells are blue, DCs are green, CTLs are
red and inactive immune cells are darker green and red, respectively. Three values
for the parameter VD are tested: a,d VD = 0.001, b,e VD = 0.05 and c,f VD = 0.1.
Here, VT = 0.0001, β = 0.0001, θE = θM = 0, and all the other parameter values
are reported in Table 6.1.
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choose VT = 0.0001 and we let the tumour cell antigen profiles remain constant over
time, i.e. we choose θE = θM = 0. For each value of β considered, we also explore
the effect of increasing the value of the parameter VD. In all cases, we carried out
simulations for 1000 time-steps. As shown by Figure 6.5a, for β = 0, a considerable
number of tumour cells remain inside the system at the end of simulations for all
values of VD. Conversely, the results presented in Figure 6.5c show that when β is
sufficiently high, very few tumour cells remain in the system after 1000 time-steps
for all values of VD. Moreover, as shown by Figure 6.5b, for intermediate values of
β, there appears to be a correlation between the number of tumour cells remaining
after 1000 time-steps and the parameter VD. In particular, larger values of the
parameter VD correspond to smaller numbers of the remaining tumour cells after
1000 time-steps. These results suggest that the T cell receptor binding affinity plays
a key role in the immune response to tumour cells. In the same way as Figure 6.4,
Figure 6.6 shows that, under the parameter choice of the computational simulations
related to Figure 6.5b, increasing the value of the parameter VD leads to immune
escape or chronic dormancy or immune clearance of the tumour.
6.3.5 Increasing the probability of epimutations can lead to
variations in the immune response to tumour cells
So far we have considered only the situation where the antigen profile of each tu-
mour cell remains constant over time, i.e. the probability at which epimutations
and mutations, leading to antigenic variations, occur are θE = 0 and θM = 0. To
investigate the effect of epimutations on the success of the immune response against
tumour cells, we consider the parameter setting that we have used in the compu-
tational simulations shown either in Figures 6.4a,d or in Figures 6.6c,f but now we
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Figure 6.7: Increasing the probability of epimutations can lead to vari-
ations in the immune response to tumour cells. Panels a and b display
the time evolution of the tumour cell number for increasing values of θE (cf. the
legend below the panels). For the numerical results reported in panel a we use the
parameter setting of the simulations whose results are displayed in Figures 6.4a,d
and VE = 0.01, while for the numerical results reported in panel b we use the para-
meter setting of the simulations whose results are displayed in Figures 6.6c,f and
VE = 0.0001. Values are taken to be the average over five simulation runs.
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allow the antigen profiles of tumour cells to change through epimutations, i.e. we
choose θE > 0. We consider eight specific values of θE defined as fractions or mul-
tiples of the average probability of epimutations θ∗E, given in Table 6.1. In all cases,
we carried out simulations for 8640 time-steps and we report on tumour cell numbers
obtained as the average over 5 simulations. Figure 6.7a displays the time evolution
of the tumour cell number for the parameter setting of Figures 6.4a,d. These results
show that increasing values of θE correspond to decreasing numbers of tumour cells
inside the system at the end of simulations. In summary, by increasing the prob-
ability of epimutations the dynamics of tumour cells change from immune escape,
through to chronic dormancy to immune clearance. On the other hand, Figure 6.7b
displays the time evolution of the tumour cell number for the parameter setting of
Figures 6.6c,f. These results show that for sufficiently small values of θE there are
no tumour cells left inside the system at the end of simulations, whereas for larger
values of θE a small number of tumour cells persist at the final time-step. Generally,
by increasing the probability of epimutations the dynamics of tumour cells change
from immune clearance to chronic dormancy. The range we consider, 0 ≤ θE ≤ 0.92,
is above the range of De Smet et al. (1996), where the largest value was 0.45 and
lowest 0.12. However values up to 2θ∗E are within the biological range and as from
our results we expect larger θE to exhibit the same dynamics as 2θ
∗
E. Therefore, the
results we observe would be viable in a biological setting.
6.3.6 Mutations have a weaker impact on the immune re-
sponse to tumour cells compared to epimutations
We now compare the impact of mutations and epimutations on the immune response
to tumour cells. Following what we have done in the subsection above, we consider
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the parameter setting used in the computational simulations shown either in Fig-
ures 6.4a,d or in Figures 6.6c,f but now we allow the antigen profiles of tumour cells
to change through mutations, i.e. we choose θM > 0. We consider eight specific val-
ues of θM defined as fractions or multiples of the average probability of epimutations
θ∗E, given in Table 6.1. In all cases, we carried out simulations for 8640 time-steps
and we report on tumour cell numbers obtained as the average over 5 simulations.
Figure 6.8a displays the time evolution of the tumour cell number for the parameter
setting of Figures 6.4a,d and shows that immune escape occurs for all values of θM
considered. On the other hand, Figure 6.8b displays the time evolution of the tu-
mour cell number for the parameter setting of Figures 6.6c,f and shows that immune
clearance occurs for all values of θM considered. Comparing these results with those
displayed in Figure 6.7a and Figure 6.7b, respectively, we reach the conclusion that
mutations have a weaker impact on the immune response to tumour cells compared
to epimutations.
6.4 Concluding remarks and discussion
Spatial interactions between cancer and immune cells, as well as the recognition
of tumour antigens by cells of the immune system, play a key role in the immune
response against solid tumours. The existing mathematical models generally focus
only on one of these key aspects. We have presented, in this chapter, a spatially
explicit stochastic individual-based model that incorporates the adaptive processes
driving tumour antigen recognition. Our model takes explicitly into account the
dynamical heterogeneity of tumour antigen expression, and effectively captures the
way in which this affects the immune response against the tumour.
Our computational simulation results show that the standard deviation of the
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Figure 6.8: Mutations have a weaker impact on the immune response
to tumour cells compared to epimutations. panels a and b display the time
evolution of the tumour cell number for increasing values of θM (cf. the legend below
the panels). For the numerical results reported in panel a we use the parameter
setting of the simulations whose results are displayed in Figures 6.4a,d and VM =
0.01, while for the numerical results reported in Panel b we use the parameter setting
of the simulations whose results are displayed in Figures 6.6c,f and VM = 0.0001.
Values are taken to be the average over five simulation runs.
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initial antigen expression profiles of cancer cells within the tumour, i.e. the para-
meter VT , has a crucial impact upon the outcome of the immune response. In the
situation of an almost homogeneous tumour, i.e. where all tumour cells have a
similar antigen profile, immune clearance occurs. Conversely, when the antigenic
composition between cancer cells is highly heterogeneous the tumour may be able
to escape the immune system response and continue growing. Interestingly, for mod-
erate levels of initial antigenic heterogeneity our results demonstrate that the fate
of the tumour is determined by the specificity of the cellular immune response.
The computational outcomes of our model indicate that the parameter con-
trolling the specificity of the antigen recognition process of the dendritic cells, i.e.
the parameter VD, ultimately dictates which receptors are produced by the cyto-
toxic T lymphocytes. A larger value of this parameter brings about a more diverse
receptor repertoire of the CTLs, and in turn results in a better immune response.
This suggests that it is advantageous for the T cell population to be multi-specific,
whereby several different antigen receptors are simultaneously expressed by the CTL
population. In this respect, the outcomes of our model recapitulate the conclusions
of experimental papers showing the success of a more diverse T cell repertoire in
response to cancer (Carreno et al., 2015; Gerdemann et al., 2011; Ott et al., 2017;
Sahin et al., 2017; Schumacher and Hacohen, 2016; Sharma and Allison, 2015).
Moreover, our computational results support the idea that varying the specificity
of the immune response can result in three distinct scenarios, from immune escape,
through to chronic dormancy to immune clearance of the tumour. The importance of
tumour dormancy controlled by the immune system, i.e. immunological dormancy,
has been highlighted by previous experimental and theoretical work (Kuznetsov
et al., 1994; Lorenzi et al., 2015; Matzavinos et al., 2004; Wu et al., 2018). In par-
ticular, immunological dormancy can explain situations where there is an extended
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period of time before the occurrence of tumour relapse (Aguirre-Ghiso, 2007; Gomis
and Gawrzak, 2017; Manjili, 2018; Teng et al., 2008; Wang and Lin, 2013; Yeh and
Ramaswamy, 2015). In this regard, our model suggests the existence of a possible
relationship between the specificity of the immune response and the emergence of
prolonged immunological dormancy. Furthermore, in recent years, new experimental
techniques have been developed which allow for the specificty of T cell receptors to
be altered (Smith et al., 2014). One particular approach is to use gene editing, in
vitro, to modify which antigen the T cell receptors will respond to (Albers et al.,
2019). These approaches would allow for greater control over which tumour antigens
the T cells target.
We have also explored the way in which altering the binding affinity of the
CTLs, i.e. the parameter β, to their corresponding tumour antigen may change
the immune response to the tumour. Our results indicate that a stronger binding
affinity leads to a more effective immune response, as the CTLs have a wider range
of tumour cells that they can interact with. Previously, Gerdemann et al. (2011)
found experimentally that a strong T cell binding affinity to tumour antigens played
a key role in the overall immune response to the disease. Integrating the outcomes
of our model and such experimental findings suggests that enhancing the binding
affinity of T cells, e.g. through the modification of the receptors that the T cells of
a patient can produce, could be a potential target of adoptive T cell therapy.
Furthermore, the results from our computational simulations suggest that changes
in the antigenic expression of tumour cells due to epimutations can be either bene-
ficial or detrimental to the immune response to a solid tumour. In more detail, we
have found that in some cases increasing the frequency of epimutations could trans-
form situations of immune escape into tumour dormancy and eventually tumour
removal. These findings are interesting in light of cancer therapy as they suggest
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that the efficacy of the immune response against solid tumours could be enhanced
by increasing the frequency of epimutations. In regards to this, the loss of DNA
methylation was the first epimutation to be identified in cancer cells (Feinberg and
Tycko, 2004) and several experimental and clinical works found that the expres-
sion of MAGE antigens could be increased through demethylation (Chinnasamy
et al., 2011; Gerdemann et al., 2011; Graff-Dubois et al., 2002; Wischnewski et al.,
2006). Taken together, the outcomes of our model suggest that by combining a
T cell therapy targeting multiple MAGE genes – e.g. using approaches similar to
those of Gerdemann et al. (2011) – and increasing the probability of epimutations
through demethylating agents, e.g. using methods similar to those of Chinnasamy
et al. (2011) and Wischnewski et al. (2006), a stronger immune response could be
induced. However, in other cases, we have observed that increasing the frequency of
epimutations can turn instances of tumour removal into scenarios whereby a small
number of tumour cells persisted over time. These contrasting results were also
suggested previously through experimental research, where epimutations could be
either beneficial or detrimental to tumour development (Chen and Mellman, 2017;
Yarchoan et al., 2017).
We have additionally studied the effect of changes in the antigenic expression
of tumour cells caused by mutations. In all parameter settings we have considered,
increasing the frequency of mutations did not change the resulting dynamics of
the tumour-immune response. This suggests that mutations have a weaker effect
on tumour-immune competition than antigenic variations caused by epimutations.
This finding is coherent with experimental observations indicating that epimuta-
tions generally occur more frequently than mutations in tumour development (Fein-
berg, 2004; Peltoma¨ki, 2012). Hence our results demonstrate the importance of
understanding the underlying causes of antigenic variations in tumour cells when
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considering tumour-immune competition.
In a variety of contexts the benefit of relating stochastic individual-based models
to deterministic continuum models has been highlighted (Champagnat et al., 2006;
Chisholm et al., 2016, 2015; Deroulers et al., 2009; Painter and Hillen, 2015; Pen-
ington et al., 2011; Stevens, 2000). Combining such modelling approaches makes
it possible to integrate computational simulations with analytical results, thus en-
abling a more extensive exploration of the model parameter space. However, our
individual-based model described in this chapter (and those described in Chapter 4
and Chapter 5) includes various complex mechanisms. These mechanisms, such as
the Le´vy walk mechanisms and antigenic expression modelling, will be challenging
to capture using continuum methods. With the aim of achieving a continuum form
of the discrete individual-based models presented, we initially consider a simpler
biological scenario. In the following chapter we present a stochastic individual-
based model describing motion and proliferation of cell populations and derive the
continuum version of this model to allow for mathematical analysis.
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Chapter 7
Deriving continuum models from
individual-based models
7.1 Overview
In general, individual-based (IB) models are useful for observing emergent dynam-
ics from these interactions they can be computationally time consuming and do not
allow for analysis to be completed on the model. Considering the continuum coun-
terpart of our stochastic discrete IB models would allow for mathematical analysis.
In the previous chapters we have developed IB models to describe tumour immune
competition including the antigen recognition process and evolution of the tumour
through changes in antigenic expression. In these models we also describe the change
in cell motion of cytotoxic T cells (CTLs) and dendritic cells (DCs) due to the pres-
ence of tumour antigen. Due to the complexity approaches used in the previous
chapters to model the antigen recognition process and the movement of immune
cells, the derivation of a continuum version of these models would be potentially
challenging. The derivation of a continuum description of Le´vy walk mechanisms
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has been studied (Fedotov, 2016; Fedotov and Korabel, 2017; Gan et al., 2015; Go-
lovin et al., 2008; Hanert, 2012; Stage et al., 2016), however the methods used are
complex and may not be applicable to interacting populations. Therefore, to gain an
understanding of the process of deriving a continuum limit from individual-based
models, in this chapter, we consider a simpler biological situation to investigate
whether deriving continuum models from the IB schemes can still result in the same
numerical results and provide opportunities for the study of interesting mathemat-
ical properties. The work described in this chapter has been published in Chaplain
et al. (2019).
7.2 Motivation
For a population of cells whose growth rate depends on the local pressure (Bru´ et al.,
2003; Byrne and Preziosi, 2003; Drasdo and Hoehme, 2012; Ranft et al., 2010), a
prototypical example of such models was proposed by Byrne and Drasdo (2009),
that is,
∂tρ− µ div (ρ∇p) = G(p)ρ. (7.1)
This is a conservation equation for the cell density function ρ(t, x) ≥ 0 at position
x ∈ Rd, with d = 1, 2, 3 in the biologically relevant cases, and time t ∈ R+. In
this case, the function p stands for the cell pressure and the term G is the net
growth rate of the cell density. In analogy with the classical Darcy law for fluids,
the parameter µ > 0 is the cell mobility coefficient, which is defined as the quotient
between the permeability of the porous medium in which the cells are embedded
(e.g. the extracellular matrix) and the cellular viscosity.
The pressure-driven movement, which is modelled by the second term on the
left-hand side of equation (7.1), dictates that cells tend to move towards regions of
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lower local pressure where they feel less compressed. That is, we assume cells exert
pressure on each other through physical interactions, and therefore when there are
a large number of cells then the pressure will be greater through compression of
space. The definition of this term builds on the seminal paper of Greenspan (1976)
and subsequent work of Byrne and Chaplain (1997).
Pressure-limited growth, i.e. cell division and cell death, of the cell population
is determined by the term on the right-hand side of equation (7.1). From a math-
ematical perspective, the effect of this pressure-limited growth can be captured by
assuming that G(p) is a smooth function which satisfies,
∂G
∂p
< 0, G(P ) = 0. (7.2)
In the assumptions given by equation (7.2), the parameter P > 0 stands for the
pressure at which cell death exactly compensates cell division. The term homeostatic
pressure has been coined to indicate such a critical pressure (Basan et al., 2009).
In order to close equation (7.1) the pressure p must be defined. Several works
consider a barotropic relation p ≡ Π(ρ). Typically, the function Π(ρ) is identically
zero for ρ ≤ ρ∗ and is monotonically increasing for ρ > ρ∗, with 0 < ρ∗ < Π−1(P )
being the density below which cells do not exert any force upon one another (Tang
et al., 2014). For instance, it is common to assume Π is a smooth function of ρ that
satisfies the following assumptions
Π(0) = 0,
∂Π
∂ρ
> 0 for ρ > 0. (7.3)
In the attempt to reduce the biological problem to its essentials while ensuring
analytical tractability of the mathematical model, Perthame et al. (2014b) have
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proposed the following definition of Π(ρ), which satisfies the assumptions given by
equation (7.3):
Π(ρ) = Kγ ρ
γ with γ > 1 and Kγ > 0. (7.4)
In the definition given by equation (7.4), the parameter γ provides a measure of the
stiffness of the barotropic relation and Kγ is a scale factor. Interestingly, the limit
γ → ∞ corresponds to the case where cells behave like an incompressible fluid. In
this asymptotic regime, it has been proven that models of the form of equation (7.1)
converge to free-boundary problems of Hele-Shaw type (Kim and Pozˇa´r, 2018; Kim
et al., 2016; Mellet et al., 2017; Perthame et al., 2014a).
The model given by equation (7.1) can be generalised to the case of multiple
cell populations with different biophysical properties, i.e. different mobilities and
growth rates, as follows
∂tρh − µh div (ρh∇p) = Gh(p)ρh, h = 1, . . . ,M. (7.5)
The system of coupled equations (7.5) contains notation, and relies on assumptions,
analogous to those underlying equation (7.1). In particular, the coefficient µh > 0
measures the mobility of cells in the hth population and the pressure p is given by a
barotropic relation p ≡ Π(ρ), where ρ stands for the total cell density, i.e.
ρ(t, x) =
M∑
h=1
ρh(t, x). (7.6)
The function Π satisfies the conditions given by equation (7.3) and the net growth
rate Gh(p) can be assumed to be a smooth function of the cell pressure that satisfies
the assumptions given by equation (7.2) for all h = 1, . . . ,M .
For example, building on the computational results presented by Drasdo and
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Hoehme (2012), Lorenzi et al. (2017) considered the following system of equations,
 ∂tρ1 − µ1 div (ρ1∇p) = G(p)ρ1,∂tρ2 − µ2 div (ρ2∇p) = 0, (7.7)
complemented with the barotropic relation given by equation (7.4). The system
of equations (7.7) describes the interaction dynamics between a population of pro-
liferating cells, i.e. population 1, and a population of nonproliferating cells, i.e.
population 2, with different mobilities.
As detailed in Section 3.3.1, the derivation of continuum models from stochastic
IB models can allow for a more robust description of biological phenomena. However,
with the exception of the qualitative comparisons of growth dynamics carried out
by Byrne and Drasdo (2009) and Fozard et al. (2010), and the study of long-time
behaviour by Motsch and Peurichard (2018) for the case of one single cell population,
little prior work has investigated the relation between single-cell-based models and
continuum models in the form of equation (7.1) and the system of equations (7.7).
In this chapter, we develop a simple stochastic individual-based model for the
dynamics of growing cell populations. Our model is based on a branching ran-
dom walk that takes into account the effects of pressure-driven cell movement and
pressure-dependent cell proliferation. We show that equation (7.1) and the system
of equations (7.5) can be formally derived from the branching random walk that
underlies our discrete model. Furthermore, we carry out a systematic quantitative
comparison between the individual-based model and its continuum counterparts,
both in the case of one single cell population and in the case of multiple cell popula-
tions with different biophysical properties. Specifically, we construct travelling-wave
solutions both for equation (7.1) and for the system of equations (7.7). Finally, we
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present numerical solutions that illustrate the results of the travelling-wave analysis,
and compare such numerical solutions with the results of computational simulations
of the individual-based model. Comparison of the models indicates that simple IB
models can lead to the emergence of complex spatial patterns of population growth
observed in continuum models.
7.3 An individual-based model for growing cell
populations
To allow for multiple biological situations to be considered we examine a multicel-
lular system made up of M cell populations, where we index each population with
h = 1, . . . ,M . Each cell within the system is modelled as an agent which occu-
pies a lattice position on the real line R. Although in this chapter we will focus
on a one dimensional situation, there is little additional difficulty extending these
ideas to higher dimensions. Each cell can undergo pressure-driven movement and
pressure-limited growth according to a set of simple rules that result in a discrete-
time branching random walk.
To set up our individual-based (IB) model we begin by discretising the time
variable t ∈ R+ as tk = kτ with k ∈ N0. We additionally discretise the space
variable x ∈ R as xi = iχ with i ∈ Z where 0 < τ, χ 1. From these discretisations
we obtain a time-step of length τ and grid spaces of length χ .
At any chosen time-step k, we denote the number of cells in population h =
1, . . . ,M at the lattice position i to be denoted as nkhi ∈ N0, and from this can
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calculate the total cell density as,
ρh(tk, xi) = ρ
k
hi = n
k
hi χ
−1 and ρ(tk, xi) = ρki =
M∑
h=1
ρh(tk, xi). (7.8)
Additionally, at each lattice site i and time-step k we calculate the cell pressure
p(tk, xi) = p
k
i , which is defined through a barotropic relation p
k
i ≡ Π(ρki ). We assume
that Π is a function of the total cell density that satisfies the conditions given by
equation (7.3). At each time-step, we allow every cell to undergo pressure-limited
growth and pressure-driven movement according to a set of algorithmic rules, which
are shown schematically in Figure 7.1. Note that, unlike the individual-based models
we have developed in the previous chapters, we allow multiple cells to inhabit each
grid position where the total number is limited by the pressure.
Pressure-limited population growth: At each time-step each cell may divide,
die or remain quiescent with probabilities which depend on the local pressure. If a
cell divides, two daughter cells are formed and replace the parent cell on the original
lattice position of the parent cell. Furthermore, any cells that undergo cell death are
removed from the system. In particular, we incorporate pressure-limited cell growth
into our model by assuming that at the kth time-step a focal cell of population h on
the lattice site i can divide with probability
τ Gh(p
k
i )+ where Gh(p
k
i )+ = max{0, Gh(pki )} (7.9)
or die with probability
τ Gh(p
k
i )− where Gh(p
k
i )− = −min{0, Gh(pki )} (7.10)
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or remain quiescent with probability
1− (τ Gh(pki )+ + τ Gh(pki )−) = 1− τ |Gh(pki )|. (7.11)
Here, we let the rate Gh be a function of the local pressure that satisfies the as-
sumptions given by equation (7.2) for all values of h. Moreover, the length of each
time-step τ is chosen to be sufficiently small to ensure that the quantities given by
equations (7.9)-(7.11) are all between 0 and 1. The assumptions that we consider
on the growth function Gh, given by equation (7.2), are such that if p
k
i > P then
each cell within the population h at the position i can only die or remain quiescent
at the kth time-step. This can be summarised by the conditions,
pki ≤ p for all (k, i) ∈ N0 × Z, with p = max
{
max
i∈Z
p0i , P
}
. (7.12)
Pressure-driven cell movement: We model pressure-driven cell movement, i.e.
the tendency of cells to move down pressure gradients, as a biased random walk. We
consider that the probabilities of movement depend on the difference between the
pressure at the site occupied by a cell and the pressure at the neighbouring sites. In
particular, for a cell of population h on the lattice site i at the time-step k, we define
the probability of moving to the lattice site i−1, i.e. the probability of moving left,
as
JLh (p
k
i − pki−1) = νh
(pki − pki−1)+
2 p
, (7.13)
where (pki − pki−1)+ = max{0, (pki − pki−1)}. Similarly, we model the probability of
moving to the lattice site i+ 1, i.e. the probability of moving right, as
JRh (p
k
i − pki+1) = νh
(pki − pki+1)+
2 p
, (7.14)
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Figure 7.1: Schematic representation of the simple algorithmic rules gov-
erning cell dynamics in our stochastic individual-based model. Pressure-
limited cell growth is modelled by letting the probabilities of a cell dividing, dying
and remaining quiescent be dependent on the local pressure (left panel). Pressure-
driven cell movement is modelled by letting the movement probabilities depend on
the difference between the pressure at the site occupied by a cell and the pressure at
the neighbouring sites (right panel).
where (pki −pki+1)+ = max{0, (pki −pki+1)}. Therefore we can calculate the probability
of remaining stationary on the lattice site i as
1− JLh (pki − pki−1)− JRh (pki − pki+1). (7.15)
In the above equations, the coefficient 0 < νh ≤ 1 is directly proportional to the
mobility of cells in population h and the parameter p is defined in equation (7.12).
We note that, the definitions given by equations (7.13)-(7.15) are such that the
cells will move down pressure gradients, i.e. they will favour positions with lower
pressure values. Moreover, the assumptions given by equation (7.12) guarantee that
the quantities given by equations (7.13)-(7.15) are all between 0 and 1.
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7.4 Formal derivation of continuum models
In this section, we show how continuum models of growing cell populations of the
form of equation (7.1) and of the system of equations (7.5) and (7.7) can be derived
as formal limits of the branching random walk that underlies our individual-based
model.
For a multicellular system whose dynamics are governed by the algorithmic rules
for cell movement and cell proliferation, that are presented in Section 7.3, the prin-
ciple of mass balance gives
ρk+1hi = νh
(pki−1 − pki )+
2 p
[
2τGh(p
k
i−1)+ +
(
1− τ |Gh(pki−1)|
)]
ρkh i−1
+νh
(pki+1 − pki )+
2 p
[
2τGh(p
k
i+1)+ +
(
1− τ |Gh(pki+1)|
)]
ρkh i+1
+
[
1− νh (p
k
i − pki−1)+
2 p
− νh (p
k
i − pki+1)+
2 p
]
×
[
2τGh(p
k
i )+ +
(
1− τ |Gh(pki )|
) ]
ρkhi,
and after a little algebra we find
ρk+1hi = νh
(pki−1 − pki )+
2 p
(
τGh(p
k
i−1) + 1
)
ρkh i−1
+νh
(pki+1 − pki )+
2 p
(
τGh(p
k
i+1) + 1
)
ρkh i+1
+
[
1− νh (p
k
i − pki−1)+
2 p
− νh (p
k
i − pki+1)+
2 p
] (
τGh(p
k
i ) + 1
)
ρkhi.
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The above equation simplifies to
ρk+1hi − ρkhi = τGh(pki )ρkhi
+
νh
2 p
[
ρkh i−1(p
k
i−1 − pki )+ + ρkh i+1(pki+1 − pki )+
]
− νh
2 p
[
ρkhi(p
k
i − pki−1)+ + ρkhi(pki − pki+1)+
]
+
νhτ
2 p
[
ρkh i−1Gh(p
k
i−1)(p
k
i−1 − pki )+ + ρkh i+1Gh(pki+1)(pki+1 − pki )+
]
−νhτ
2 p
[
ρkhiGh(p
k
i )(p
k
i − pki−1)+ + ρkhiGh(pki )(pki − pki+1)+
]
. (7.16)
Using the fact that the following relations hold for τ and χ sufficiently small
tk ≈ t, tk+1 ≈ t+ τ, xi ≈ x, xi±1 ≈ x± χ,
ρkhi ≈ ρh(t, x), ρk+1hi ≈ ρh(t+ τ, x), ρkh i±1 ≈ ρh(t, x± χ),
pki ≈ p(t, x), pki±1 ≈ p(t, x± χ),
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we rewrite equation (7.16) in the following approximate form:
ρh(t+ τ, x)− ρh(t, x) ≈ τGh(p)ρh(t, x)
+
νh
2 p
[ρh(t, x− χ)(p(t, x− χ)− p(t, x))+]
+
νh
2 p
[ρh(t, x+ χ)(p(t, x+ χ)− p(t, x))+]
− νh
2 p
[ρh(t, x)(p(t, x)− p(t, x− χ))+]
− νh
2 p
[ρh(t, x)(p(t, x)− p(t, x+ χ))+]
+
νhτ
2 p
[ρh(t, x− χ)Gh(p(t, x− χ))(p(t, x− χ)− p(t, x))+]
+
νhτ
2 p
[ρh(t, x+ χ)Gh(p(t, x+ χ))(p(t, x+ χ)− p(t, x))+]
−νhτ
2 p
[ρh(t, x)Gh(p(t, x))(p(t, x)− p(t, x− χ))+]
−νhτ
2 p
[ρh(t, x)Gh(p(t, x))(p(t, x)− p(t, x+ χ))+] . (7.17)
Throughout the remainder of this section we will assume
ρh ∈ C2(R+ × R), h = 1, . . . ,M. (7.18)
Since the function ρh(t, x) is twice continuously differentiable for all values of h, we
can approximate the terms ρh(t+τ, x), ρh(t, x−χ) and ρh(t, x+χ) in equation (7.17)
by their second order Taylor expansions about the point (t, x). Under the assump-
tion given by equation (7.18), since p ≡ Π(ρ) with Π being a smooth function of ρ,
the pressure p(t, x) is twice continuously differentiable w.r.t the variable x as well.
Therefore, we can also approximate the terms p(t, x − χ) and p(t, x + χ) in equa-
tion (7.17) by their second order Taylor expansions about the point (t, x). After a
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little algebra, we find that
τ ∂tρh(t, x) +
τ 2
2
∂2ttρh(t, x) ≈ τGh(p(t, x))ρh(t, x) +
νhχ
2
2 p
ρh(t, x)∂
2
xxp(t, x)
+
νhχ
2
2 p
[
(∂xp(t, x))+ − (−∂xp(t, x))+
]
∂xρh(t, x)
+
νhτ
2 p
ρh(t, x)Gh(p(t, x− χ)) (−χ∂xp(t, x))+
+
νhτ
2 p
ρh(t, x)Gh(p(t, x+ χ)) (χ∂xp(t, x))+
−νhτ
2 p
ρh(t, x)Gh(p(t, x)) (χ∂xp(t, x))+
−νhτ
2 p
ρh(t, x)Gh(p(t, x)) (−χ∂xp(t, x))+ ,
which implies
τ ∂tρh(t, x) +
τ 2
2
∂2ttρh(t, x) ≈ τGh(p(t, x))ρh(t, x)
+
νhχ
2
2 p
(
ρh(t, x)∂
2
xxp(t, x) + ∂xρh(t, x)∂xp(t, x)
)
+
νhτχ
2 p
F (t, x), (7.19)
with
F (t, x) =
[
Gh(p(t, x− χ)) (−∂xp(t, x))+ +Gh(p(t, x+ χ)) (∂xp(t, x))+
]
ρh(t, x)
− [(∂xp(t, x))+ + (−∂xp(t, x))+]Gh(p(t, x))ρh(t, x).
Dividing both sides of the resulting equation by τ we obtain
∂tρh(t, x) +
τ
2
∂2ttρh(t, x) ≈ Gh(p(t, x))ρh(t, x)
+
νhχ
2
2 pτ
(
ρh(t, x)∂
2
xxp(t, x) + ∂xρh(t, x)∂xp(t, x)
)
+
νhχ
2 p
F (t, x). (7.20)
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Letting both τ → 0 and χ→ 0 in equation (7.20) in such a way that
νhχ
2
2 p τ
→ µh as τ → 0 and χ→ 0, for h = 1, . . . ,M (7.21)
we formally obtain the following system of coupled conservation equations
∂tρh = Gh(p)ρh + µ
(
ρh ∂
2
xxph + ∂xρh ∂xph
)
, h = 1, . . . ,M,
which can be rewritten as the system of equations (7.5), that is,
∂tρh − µh ∂x (ρh ∂xp) = Gh(p)ρh, h = 1, . . . ,M. (7.22)
Remark 1. We note that condition (7.21) is a natural counterpart of the usual
parabolic scaling of Brownian motion. Hence, our formal derivation does not im-
pose any additional assumptions than those commonly employed for the asymptotic
investigation of random walks.
In the case of one single cell population, letting M = 1 and dropping the index
h we formally obtain equation (7.1). Moreover, we formally obtain the system of
equations (7.7) by choosing M = 2, labelling the two populations by h = 1 and
h = 2, and setting G1 ≡ G and G2 ≡ 0.
7.5 Comparison between individual-based and con-
tinuum models
In this section, we aim to quantitatively compare the outcomes of the IB model and
the derived continuum models, for both a single population case and the case where
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we have two cell populations. Firstly, we look for travelling wave solutions of the
continuum models given by equation (7.1) and the system of equations (7.7) - see
Section 7.5.1. Following this, we construct numerical solutions of the model equa-
tions, which support our findings from the travelling-wave analysis, and compare
these results to numerical simulations of our IB model - see Section 7.5.2.
7.5.1 Travelling-wave analysis of the continuum models
We first consider the continuum model given by equation (7.1) and we look for
one-dimensional travelling-wave solutions of the form
ρ(t, x) = ρ(z) with z = x− ct and c > 0,
that satisfy the following asymptotic conditions
ρ(z) −−−−→
z→−∞
Π−1(P ) and ρ(z) −−−→
z→∞
0. (7.23)
Therefore, we study the existence of pairs (ρ, c) that satisfy the problem defined by
the differential equation
−c ρ′ − µ (ρ p′)′ = G(p) ρ, (7.24)
complemented with the asymptotic conditions given by equation (7.23). Our main
results are summarised by the following theorem.
Theorem 1. Under the assumptions given by equations (7.2) and (7.3), there exists
c > 0 such that the travelling-wave problem defined by equation (7.24) complemented
with the asymptotic conditions given by equation (7.23) admits a nonnegative and
nonincreasing solution ρ.
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Proof. We divide the proof of Theorem 1 into two steps. First we prove that for
c > 0 fixed equation (7.24) complemented with the asymptotic conditions given by
equation (7.23) admits a nonnegative and nonincreasing solution ρ (Step 1). Then
we show that there exists a unique value of the wave speed c that satisfies the
travelling-wave problem (Step 2).
Step 1. Multiplying both sides of equation (7.24) by
∂p
∂ρ
we obtain the following
boundary-value problem for p:
−p′ (c+ µ p′)− µ p′′ ρ ∂p
∂ρ
= G (p) ρ
∂p
∂ρ
, (7.25)
p(z) −−−−→
z→−∞
P and p(z) −−−→
z→∞
0. (7.26)
Let z∗ be a critical point of p in R. Using the differential equation (7.25) we see
that
p′′(z∗) = − 1
µ
G (p(z∗))
and, under assumptions (7.2) and conditions (7.26), using the strong maximum
principle we conclude that p < P in R and that p cannot have a local minimum in
R, i.e.
p′(z) < 0 for all z ∈ R. (7.27)
Hence the solution p of the differential equation (7.25) subject to conditions (7.26)
is a nonnegative and nonincreasing function that satisfies
0 < p(z) < P for all z ∈ R. (7.28)
Since p ≡ Π(ρ) and Π is a smooth monotonically increasing function of ρ, we can
then conclude that the cell density ρ is a nonnegative and nonincreasing function as
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well.
Step 2. We prove that p is a monotonically decreasing function of the parameter
c. This guarantees that given the cell density ρ the wave speed c can be uniquely
identified through a monotonicity argument. Differentiating equation (7.24) w.r.t.
z yields
−c (ρ′)′ − µ [(p′)′′ ρ+ p′′ ρ′ + (p′)′ρ′ + p′(ρ′)′] = ∂G
∂p
p′ ρ+G (p) ρ′, (7.29)
while differentiating equation (7.24) w.r.t. c gives
−c
(
∂ρ
∂c
)′
− µ
[(
∂p
∂c
)′′
ρ+ p′′
∂ρ
∂c
+
(
∂p
∂c
)′
ρ′ + p′
(
∂ρ
∂c
)′]
=
∂G
∂p
∂p
∂c
ρ+G (p)
∂ρ
∂c
+ ρ′.
(7.30)
Using the fact that p′ =
∂p
∂ρ
ρ′, we rewrite equations (7.50) and (7.51), respectively,
as
−c (ρ′)′ − µ
[
(p′)′′ ρ+ p′′ρ′ + (p′)′ρ′ +
∂p
∂ρ
ρ′ (ρ′)′
]
=
∂G
∂p
p′ ρ+G (p) ρ′ (7.31)
and
−c
(
∂ρ
∂c
)′
− µ
[(
∂p
∂c
)′′
ρ+ p′′
∂ρ
∂c
+
(
∂p
∂c
)′
ρ′ +
∂p
∂ρ
ρ′
(
∂ρ
∂c
)′]
=
∂G
∂p
∂p
∂c
ρ+G (p)
∂ρ
∂c
+ ρ′.
(7.32)
Since
∂p
∂ρ
> 0, we have
ρ′ = p′
(
∂p
∂ρ
)−1
and
∂ρ
∂c
=
∂p
∂c
(
∂p
∂ρ
)−1
.
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Hence, introducing the following definitions
k0 =
(
∂p
∂ρ
)−1
, k1 = ρ, k2 = p
′′
(
∂p
∂ρ
)−1
, k3 = ρ
′,
k4 = ρ
′ ∂p
∂ρ
, k5 =
∂G
∂p
ρ+G (p)
(
∂p
∂ρ
)−1
,
along with the notations f = p′ and g =
∂p
∂c
, we rewrite equations (7.52) and (7.53),
respectively, as
−c (k0 f)′ − µ
[
k1 f
′′ + k2 f + k3 f ′ + k4 (k0 f)
′] = k5 f, (7.33)
and
−c (k0 g)′ − µ
[
k1 g
′′ + k2 g + k3 g′ + k4 (k0 g)
′] = k5 g + ρ′. (7.34)
Since
ρ′(z) −−−−→
z→−∞
0, p(z) −−−−→
z→−∞
P, G(p(z)) −−−−→
z→−∞
0,
Equation (7.24) gives
p′′(z) −−−−→
z→−∞
0.
Therefore, we impose the following asymptotic conditions
f(z) −−−−→
z→−∞
0, f ′(z) −−−−→
z→−∞
0. (7.35)
Moreover, we have that
g(z) −−−−→
z→−∞
0, g′(z) −−−−→
z→−∞
0. (7.36)
Noting that ρ′ < 0, we conclude that if g solves the problem defined by equa-
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tion (7.56) complemented with the asymptotic conditions given by equation (7.57)
and f solves the problem defined by equation (7.54) complemented with the asymp-
totic conditions given by equation (7.55), then g < f . This result together with the
fact that f = p′ < 0 demonstrates that g =
∂p
∂c
< 0, which concludes the proof of
Theorem 1.
We now turn to the travelling-wave analysis of the system of equations (7.7). We
consider one-dimensional travelling-wave solutions of the form
ρ1(t, x) = ρ1(z) and ρ2(t, x) = ρ2(z), with z = x− ct and c > 0,
that satisfy the following conditions
ρ1(z)
 > 0, for z < 0,= 0, for z ≥ 0, ρ2(z)

= 0, for z < 0,
> 0, for z ∈ [0, `),
= 0, for z ≥ `,
(7.37)
for some ` > 0, along with the asymptotic condition
ρ1(z) −−−−→
z→−∞
Π−1(P ). (7.38)
Hence, we study the existence of triples (ρ1, ρ2, c) along with ` > 0 that satisfy the
problem defined by the following system of differential equations
 −c ρ
′
1 − µ1 (ρ1 p′)′ = G(p)ρ1,
−c ρ′2 − µ2 (ρ2 p′)′ = 0,
(7.39)
complemented with the conditions given by equations (7.37) and (7.38). Notice that
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the principle of mass conservation gives
∫ `
0
ρ2(z) dz = N2, (7.40)
for some N2 > 0 that represents the number of cells in population 2. Our main
results are summarised by the following theorem.
Theorem 2. Under the assumptions given by equations (7.2) and (7.3), for any
N2 > 0 given, there exists c > 0 and ` > 0 such that the system of equations (7.39)
complemented with the conditions given by equations (7.37) and (7.38) admits a
component-wise nonnegative solution (ρ1, ρ2) with ρ1 nonincreasing, and ρ2 nonin-
creasing and satisfying the condition given by equation (7.40). Moreover, the pres-
sure p has a “kink” at z = 0 with
sgn(p′(0+)− p′(0−)) = sgn(µ2 − µ1). (7.41)
Proof. Building upon the method of proof presented by Lorenzi et al. (2017) for
the case of the barotropic relation given by equation (7.4), we prove Theorem 2 in
five steps. We fix the parameter c > 0 and first prove that, for N2 > 0 given, the
problem under study admits a component-wise nonnegative solution (ρ1, ρ2) with ρ2
nonincreasing and with the value of ` being determined by the condition given by
equation (7.40) (Step 1), and with ρ1 nonincreasing (Step 2). Then we prove that
the pressure p is continuous on (−∞, `) (Step 3) and the jump condition given by
equation (7.41) holds (Step 4). Finally, we show that there exists a unique value of
the wave speed c that satisfies the travelling-wave problem (Step 5).
Step 1. Integrating the second equation in equation (7.39) between a generic point
z ∈ [0, `] and ∞, and using the fact that both p′(z)→ 0 and ρ2(z)→ 0 as z →∞,
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we find
p′(z) = − c
µ2
< 0 for all z ∈ [0, `]. (7.42)
Integrating equation (7.42) between a generic point z ∈ [0, `) and `, and using the
fact that p(`) = 0, gives
p(z) =
c
µ2
(`− z) for z ∈ [0, `], (7.43)
which implies that
p(0) =
c `
µ2
. (7.44)
Since ρ1 ≡ 0 on [0, `], under the assumptions given by equation (7.3), we have
that p is a monotonically decreasing function of ρ2 in [0, `]. Hence, the results
given by equations (7.42) and (7.43) allow us to conclude that ρ2 is decreasing in
(0, `). Moreover, for N2 > 0 given, since the value of ρ2(z) is uniquely determined
for all z ∈ [0, `], the value of ` is uniquely fixed by the integral identity given by
equation (7.40).
Step 2. Since ρ2 ≡ 0 on (−∞, 0) and, therefore, ρ1 ≡ ρ on (−∞, 0), multiplying both
sides of the differential equation (7.39)1 by
dp
dρ
we obtain the following boundary-
value problem for p
−p′ (c+ µ1 p′)− µ1 p′′ ρ dp
dρ
= G (p) ρ
dp
dρ
, (7.45)
p(z) −−−−→
z→−∞
P and p(0) =
c `
µ2
. (7.46)
Hence, using a method similar to that used in Step 1 of the proof of Theorem 1 one
can prove that ρ1 is decreasing in (−∞, 0).
Step 3. The results proved in Step 1 and Step 2 guarantee that p is nonincreasing
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and continuous in (−∞, 0) and in (0, `). To show that p is continuous in z = 0, we
add the two equations in equations (7.39) to obtain
−c (ρ1 + ρ2)′ − [(µ1ρ1 + µ2ρ2) p′]′ = G(p)ρ1. (7.47)
Multiplying both sides of the above equation by p and using the fact that
p [(µ1ρ1 + µ2ρ2) p
′]′ = [p (µ1ρ1 + µ2ρ2) p′]
′ − (µ1ρ1 + µ2ρ2) (p′)2,
we achieve
(µ1ρ1 + µ2ρ2) (p
′)2 = G(p)ρ1 + c p (ρ1 + ρ2)
′ + [p (µ1ρ1 + µ2ρ2) p′]
′
.
Integrating both sides of the latter equation between a generic point z∗ < 0 and
`, and estimating the right-hand side from above by using the fact that −∞ <
(ρ1 + ρ2)
′ (z) ≤ 0 for all z ∈ [z∗, `), p(`) = 0 and ρ2(z∗) = 0, yields
∫ `
z∗
(µ1ρ1 + µ2ρ2) (p
′)2 dz ≤
∫ `
z∗
G(p)ρ1 dz − µ1 ρ1(z∗) p(z∗) p′(z∗) <∞.
Using the above integral inequality we find that p′ ∈ L2loc(R). This result together
with the fact that p ∈ L∞(R) allow us to conclude that p is continuous in z = 0.
Since p ≡ Π(ρ) and Π is a smooth monotonically increasing function of ρ, we have
that the total cell density ρ is continuous in z = 0 as well.
Step 4. Integrating equation (7.47) between a generic point z < ` and ` and using
the fact that ρ1(`) = ρ2(`) = 0 yields
c (ρ1(z) + ρ2(z)) + (µ1ρ1(z) + µ2ρ2(z)) p
′(z) =
∫ `
z
G(p)ρ1 dz
′.
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Letting z → 0− and using the fact that ρ1(0−) = ρ(0−) and ρ1 ≡ 0 on [0, `] we find
that
c ρ(0−) + µ1 ρ(0−) p′(0−) = 0. (7.48)
Similarly, letting z → 0+ and using the fact that ρ2(0+) = ρ(0+) and ρ1 ≡ 0 on [0, `]
gives
c ρ(0+) + µ2 ρ(0
+) p′(0+) = 0. (7.49)
Since ρ(z) is continuous in z = 0, combining equations (7.48) and (7.49) we obtain
µ1 p
′(0−) = µ2 p′(0+) =⇒ p′(0−) = µ2
µ1
p′(0+).
This result along with the expression (7.42) for p′(0+) gives
p′(0−) = − c
µ1
and p′(0+)− p′(0−) = c
µ1 µ2
(µ2 − µ1) .
From the above equation, noting that p′(0+) < 0, we deduce the condition given by
equation (7.41).
Step 5. We prove that p is a monotonically decreasing function of the parameter
c on (−∞, 0). This ensures that given the cell density ρ1 the wave speed c can
be uniquely identified through a monotonicity argument. Recalling that ρ2 ≡ 0 on
(−∞, 0) and, therefore, ρ1 ≡ ρ on (−∞, 0), differentiating equation (7.39)1 with
respect to z we find
−c (ρ′)′ − µ1
[
(p′)′′ ρ+ p′′ ρ′ + (p′)′ρ′ + p′(ρ′)′
]
=
dG
dp
p′ ρ+G (p) ρ′ (7.50)
with
p′(z) −−−−→
z→−∞
0 and p′(0) = − c
µ1
.
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On the other hand, differentiating equation (7.39)1 with respect to c gives
−c
(
∂ρ
∂c
)′
− µ1
[(
∂p
∂c
)′′
ρ+ p′′
∂ρ
∂c
+
(
∂p
∂c
)′
ρ′ + p′
(
∂ρ
∂c
)′]
=
dG
dp
∂p
∂c
ρ+G (p)
∂ρ
∂c
+ ρ′
(7.51)
with
∂p
∂c
(z) −−−−→
z→−∞
0 and
(
∂p
∂c
)′
(0) = − 1
µ1
.
Using the fact that p′ =
dp
dρ
ρ′, we rewrite the differential equations (7.50) and (7.51),
respectively, as
−c (ρ′)′ − µ
[
(p′)′′ ρ+ p′′ρ′ + (p′)′ρ′ +
dp
dρ
ρ′ (ρ′)′
]
=
dG
dp
p′ ρ+G (p) ρ′ (7.52)
and
−c
(
∂ρ
∂c
)′
− µ
[(
∂p
∂c
)′′
ρ+ p′′
∂ρ
∂c
+
(
∂p
∂c
)′
ρ′ +
∂p
∂ρ
ρ′
(
∂ρ
∂c
)′]
=
dG
dp
∂p
∂c
ρ+G (p)
∂ρ
∂c
+ ρ′.
(7.53)
Since
dp
dρ
> 0, we have
ρ′ = p′
(
dp
dρ
)−1
and
∂ρ
∂c
=
∂p
∂c
(
dp
dρ
)−1
.
Hence, introducing the notation f = p′, g =
∂p
∂c
and
k0 =
(
dp
dρ
)−1
, k1 = ρ, k2 = p
′′
(
dp
dρ
)−1
, k3 = ρ
′,
k4 = ρ
′ dp
dρ
, k5 =
dG
dp
ρ+G (p)
(
dp
dρ
)−1
,
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we rewrite the differential equations (7.52) and (7.53), respectively, as
−c (k0 f)′ − µ
[
k1 f
′′ + k2 f + k3 f ′ + k4 (k0 f)
′] = k5 f (7.54)
with
f(z) −−−−→
z→−∞
0, f(0) = − c
µ1
(7.55)
and
−c (k0 g)′ − µ
[
k1 g
′′ + k2 g + k3 g′ + k4 (k0 g)
′] = k5 g + ρ′ (7.56)
with
g(z) −−−−→
z→−∞
0, g′(0) = − 1
µ1
. (7.57)
Since f(z) < 0 for all z ∈ (−∞, 0) and f ′(0) < 0, noting that both f(z) → 0 and
g(z) → 0 as z → −∞ and the right-hand side of the differential equation (7.56)
contains the additional term ρ′ < 0 compared to the right-hand side of the differ-
ential equation (7.54), we deduce that g =
∂p
∂c
< 0, which concludes the proof of
Theorem 2.
Remark 2. Based on the jump condition (7.41), we expect the travelling-wave solu-
tion of Theorem 2 to be unstable if µ1 > µ2. In fact, a small perturbation of ρ1(z)
that is greater than zero on [0, `) will propagate with approximate speed −µ1 p′(0+).
Noting that when µ1 > µ2 the jump condition (7.41) gives −µ1 p′(0+) > −µ1 p′(0−),
we deduce that such a perturbation will separate from the rest of the travelling wave
ρ1(z).
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7.5.2 Quantitative comparison between individual-based and
continuum models
One cell population
We consider the computational simulation results of our individual-based model in
the case of one cell population and compare them to numerical solutions of equa-
tion (7.1). To ensure consistency, we let M = 1 and drop the index h from the
functions and from the parameters of the individual-based model. A complete de-
scription of the parameter choices and setup of numerical simulations is given in
Appendix B.1.1 and Appendix B.2.1. In particular, we define the growth rate G as,
G(p) =
1
2pi
arctan(β (P − p)) with β > 0, (7.58)
so that the assumptions given by equation (7.2) are satisfied.
Travelling fronts: Figure 7.2 demonstrates that there is an excellent quantit-
ative match between the numerical solutions of equation (7.1) (dashed lines) and
the computational simulation results of our individual-based model (solid lines). In
agreement with the results established by Theorem 1, the cell density is nonincreas-
ing and connects the homogeneous steady state ρ ≡ Π−1(P ) to the homogeneous
steady state ρ ≡ 0. Accordingly, the cell pressure is nonincreasing and connects the
homogeneous steady state p ≡ P to the homogeneous steady state p ≡ 0.
Higher values of β lead to higher speed of invasion: Figure 7.3 indicates
that, as one would expect, increasing the value of the parameter β in the definition of
the rate G(p) given by equation (7.58) accelerates the growth of the cell population,
thus leading to a faster speed of invasion.
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Figure 7.2: Travelling fronts. Comparison between the computational simula-
tion results of our individual-based model in the case of one population (solid lines)
and the numerical solutions of the continuum model given by equation (7.1) (dashed
lines). The left and right panel display, respectively, the pressure and the cell density
at three successive time instants, i.e. t = 10 (left curves), t = 15 (middle curves)
and t = 20 (right curves). Values of the pressure and the cell density are in units of
104 and were taken as an average from three runs of the simulations. Simulations
were carried out using a definition for the pressure that satisfies the assumptions
given by equation (7.3). The definition of G(p) is given by equation (7.58), with
the homeostatic pressure P = 120 × 104 and the coefficient β = 4 × 10−6. A com-
plete description of the numerical simulation setup is given in Appendix B.1.1 and
Appendix B.2.1.
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Figure 7.3: Higher values of β lead to higher speed of invasion Com-
parison between the computational simulation results of our individual-based model
in the case of one cell population (solid lines) and the numerical solutions of the
continuum model given by equation (7.1) (dashed lines). The left and right panel
display, respectively, the pressure and the cell density at the time instant t = 15 for
increasing values of the parameter β in the definition of the rate G(p) given by equa-
tion (7.58), i.e. β = 1.5× 10−6 (light grey and yellow lines), β = 4× 10−6 (middle
grey and red lines) and β = 4 × 10−5 (dark grey and brown lines). Values of the
pressure and the cell density are in units of 104 and were taken as an average from
three runs of the simulations. Simulations were carried out with pressure defined in
a way that satisfies the assumptions given by equation (7.3) with the homeostatic
pressure P = 120 × 104. A complete description of the numerical simulation setup
is given in Appendix B.1.1 and Appendix B.2.1.
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Differences between the outcomes of individual-based and continuum
models in the presence of sharp transitions from high to low cell dens-
ities: The results presented so far indicate that there is an excellent agreement
between the computational simulation results of our individual-based model and
the solutions of the corresponding continuum models. However, due to extinction
phenomena related to stochasticity effects that occur in the individual-based model
for low cell densities, we expect differences between the outcomes of the two mod-
elling approaches to emerge in the presence of sharp transitions from high to low
total cell densities. In order to verify this hypothesis, exploiting the asymptotic
results of Perthame et al. (2014b), who have shown that under the barotropic rela-
tion given by equation (7.4) higher values of the parameter γ lead equation (7.1) to
develop sharper invasion fronts, we compare the computational simulation results
of our individual-based model in the case of one cell population with the numerical
solutions of equation (7.1) under the barotropic relation given by equation (7.4) for
increasing values of γ. A complete description of the setup of numerical simulations
is given in Appendix B.1.1 and Appendix B.2.1. The results obtained are summar-
ised by Figure 7.4 which shows that larger values of the parameter γ can bring about
sharper invasion fronts, which come along with more abrupt variations in the cell
density, thus leading to more evident differences between the computational simu-
lation results of the stochastic individual-based model and the numerical solutions
of equation (7.1) at the front of invasion. Ultimately, this causes the invasion front
of the individual-based model to travel at the same speed but behind the front of
the corresponding continuum model. This is further clarified in Figure B.1 in Ap-
pendix B, where we compare the PDE and IB models at four consecutive time-steps
for the simulations with γ = 2 whose results are shown in Figure 7.4.
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Figure 7.4: Differences in the outcomes of individual-based and con-
tinuum models in the presence of sharp transitions from high to low
cell densities. Comparison between the computational simulation results of our
individual-based model in the case of one cell population (solid lines) and the nu-
merical solutions of the continuum model given by equation (7.1) (dashed lines). The
left and right panel display, respectively, the pressure and the cell density at the time
instant t = 15 for increasing values of the parameter γ in the barotropic relation
given by equation (7.4), i.e. γ = 1.2 (light grey and yellow lines), γ = 1.5 (middle
grey and red lines) and γ = 2 (dark grey and brown lines). Values of the pressure
and the cell density are in units of 105. Magnifications of the curves near the inva-
sion fronts are shown in the insets. Simulations were carried out using the definition
of G(p) given by equation (7.58), with the homeostatic pressure P = 120× 105 and
the coefficient β = 4 × 10−5. A complete description of the numerical simulation
setup is given in Appendix B.1.1 and Appendix B.2.1.
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Two cell populations
We now turn to the case of two cell populations and we compare computational
simulation results of our individual-based model with numerical solutions of the
system of equations (7.7). For consistency, we choose M = 2, and we set G1 ≡ G
and G2 ≡ 0 in the individual-based model. Full details of the setup of numerical
simulations can be found in Appendix B.1.2 and Appendix B.2.2 (for the results
reported in Figures 7.5 and 7.6), and Appendix B.1.3 and Appendix B.2.3 (for the
results reported in Figures 7.7 and 7.8). In particular, we use the definition of the
rate G(p) given by equation (7.58) with the homeostatic pressure P = 10× 104 and
we let the population of nonproliferating cells, i.e. population 2, be ahead of the
population of proliferating cells, i.e. population 1, at the initial time t = 0.
Figures 7.5 and 7.6 demonstrate that there is an excellent quantitative match
between the numerical solutions of the system of equations (7.7) (dashed lines) and
the computational simulation results of our individual-based model (solid lines),
both in the case where µ1 ≤ µ2 and when µ1 > µ2. In both cases, the number of
nonproliferating cells, i.e. the integral of the cell density ρ2, is conserved. Over
time, the pressure p converges to the homeostatic pressure P while the cell density
ρ1 converges to the corresponding value Π
−1(P ).
Travelling fronts and spatial segregation between the two cell populations:
If µ1 ≤ µ2, i.e. if ν1 ≤ ν2, in agreement with the results established by Theorem 2,
spatial segregation occurs and the two cell populations remain separated by a sharp
interface - see Figure 7.5. The population of nonproliferating cells stays ahead of the
population of proliferating cells and, over the regions where they are greater than
zero, the cell densities are nonincreasing. The pressure itself is continuous across the
interface between the two cell populations, whereas its first derivative jumps from a
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Figure 7.5: Travelling fronts and spatial segregation between the two
cell populations. Comparison between the computational simulation results of our
individual-based model in the case of two cell populations (solid lines) and the numer-
ical solutions of the continuum model given by the system of equations (7.7) (dashed
lines), for µ1 ≤ µ2, i.e. ν1 ≤ ν2. The left and right panel display, respectively,
the pressure and the cell densities of population 1 (red lines) and population 2 (blue
lines) at three successive time instants, i.e. t = 300 (left curves), t = 450 (middle
curves) and t = 600 (right curves). Values of the pressure and the cell densities
are in units of 104. Simulations were carried out using a barotropic relation that
satisfies the assumptions given by equation (7.3) and the definition of G(p) given
by equation (7.58), with the homeostatic pressure P = 10 × 104 and the coefficient
β = 4× 10−5. A complete description of the numerical simulation setup is given in
Appendix B.1.2 and Appendix B.2.2.
lower negative value to a larger negative value, i.e. the sign of the jump coincides
with sgn(µ2 − µ1) - see the jump condition given by equation (7.41).
Mixing between the two cell populations: If µ1 > µ2, i.e. if ν1 > ν2, the cell
population 2 is left behind by the cell population 1, which ultimately propagates
alone - see Figure 7.6. This is consistent with the heuristic argument provided
in Remark 2, which suggests that the travelling-wave solutions of Theorem 2 are
unstable in the case where µ1 > µ2.
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Figure 7.6: Mixing between the two cell populations. Comparison between
the computational simulation results of our individual-based model in the case of two
cell populations (solid lines) and the numerical solutions of the continuum model
given by the system of equations (7.7) (dashed lines), for µ1 > µ2, i.e. ν1 > ν2. The
left and right panel display, respectively, the pressure and the cell densities of pop-
ulation 1 (red lines) and population 2 (blue lines) at three successive time instants,
i.e. t = 100 (left curves), t = 150 (middle curves) and t = 190 (right curves).
Values of the pressure and the cell densities are in units of 104. Simulations were
carried out using a barotropic relation that satisfies the assumptions given by equa-
tion (7.3) and the definition of G(p) given by equation (7.58), with the homeostatic
pressure P = 10 × 104 and the coefficient β = 4 × 10−5. A complete description of
the numerical simulation setup is given in Appendix B.1.2 and Appendix B.2.2.
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Numerical simulations for more realistic barotropic relations for the defin-
ition of the pressure: In this chapter, so far we have focused on barotropic
relations defining the local pressure, which satisfy the assumptions given by equa-
tion (7.3). However, as mentioned earlier in Section 7.1, more realistic barotropic
relations satisfy the following conditions
Π(ρ) = 0 for ρ ∈ [0, ρ∗) and ∂Π
∂ρ
> 0 for ρ > ρ∗, (7.59)
with 0 < ρ∗ < Π−1(P ). Figures 7.7 and 7.8 display the computational simulation
results of our stochastic individual-based model and the numerical solutions of the
system of equations (7.7) obtained under a barotropic relation that satisfies the
more general assumptions given by equation (7.59) - see Appendix B.1.3 and Ap-
pendix B.2.3 for a complete description of the numerical simulation setup. These
computational results and numerical solutions clearly share the same properties as
those of Figures 7.5 and 7.6. This supports the conclusion that the essentials of
the results obtained using barotropic relations of the form given by equation (7.3)
remain intact even under the more realistic assumptions given by equation (7.59).
7.6 Concluding remarks and discussion
In this chapter, we have developed a simple, yet effective, stochastic individual-based
(IB) model for the spatial dynamics of multicellular systems whereby cells undergo
pressure-driven movement and pressure-limited population growth. From the con-
struction of our simple IB model, nonlinear partial differential equations (PDEs)
commonly used to model the spatial dynamics of growing cell populations can be
formally derived. Through comparison of both models we find that the results of
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Figure 7.7: Numerical simulations for more realistic barotropic relations.
Comparison between the computational simulation results of our individual-based
model in the case of two cell populations (solid lines) and the numerical solutions
of the continuum model given by the system of equations (7.7) (dashed lines), for
µ1 ≤ µ2, i.e. ν1 ≤ ν2. The left and right panel display, respectively, the pressure and
the cell densities of population 1 (red lines) and population 2 (blue lines) at three suc-
cessive time instants, i.e. t = 300 (left curves), t = 450 (middle curves) and t = 600
(right curves). Values of the pressure and the cell densities are in units of 104. Sim-
ulations were carried out using a barotropic relation that satisfies the assumptions
given by equation (7.59) and the definition of G(p) given by equation (7.58) with
the homeostatic pressure P = 10 × 104 and the coefficient β = 4 × 10−5. A com-
plete description of the numerical simulation setup is given in Appendix B.1.3 and
Appendix B.2.3.
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Figure 7.8: Numerical simulations for more realistic barotropic relations.
Comparison between the computational simulation results of our individual-based
model in the case of two cell populations (solid lines) and the numerical solutions
of the continuum model given by the system of equations (7.7) (dashed lines), for
µ1 > µ2, i.e. ν1 > ν2. The left and right panel display, respectively, the pressure and
the cell densities of population 1 (red lines) and population 2 (blue lines) at three suc-
cessive time instants, i.e. t = 100 (left curves), t = 150 (middle curves) and t = 200
(right curves). Values of the pressure and the cell densities are in units of 104. Sim-
ulations were carried out using a barotropic relation that satisfies the assumptions
given by equation (7.59) and the definition of G(p) given by equation (7.58) with
the homeostatic pressure P = 10 × 104 and the coefficient β = 4 × 10−5. A com-
plete description of the numerical simulation setup is given in Appendix B.1.3 and
Appendix B.2.3.
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computational simulations of the individual-based model faithfully mirror the qual-
itative and quantitative properties of the solutions to the corresponding nonlinear
PDEs. This highlights the fact that simple IB models can lead to the emergence
of complex spatial patterns of population growth observed in continuum models,
e.g. travelling waves with composite shapes and sharp interfaces corresponding to
spatial segregation between cell populations with different biophysical properties.
Although the models described in this chapter have been general in nature, they
could be adapted to biologically represent situations of tumour cell growth and in-
vasion into healthy tissue. This could be done by considering the cancer cells as
the proliferating cell population and normal healthy tissue to be the nonproliferat-
ing cell population. Other possible scenarios such as wound healing and embryonic
development are also envisaged.
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Chapter 8
Conclusions and potential future
directions
In the past decade, the advancement in cell imaging techniques has allowed for in-
sight into the mechanisms that underpin the immune response to solid tumours.
Understanding these mechanisms of tumour removal by immune cells, and how tu-
mours can evade this response, has promoted the development of immunotherapy
techniques. However, the development of new cancer treatments can be time con-
suming and expensive. Through the use of mathematical models potential therapy
techniques may be tested in a timely and inexpensive manner. In this thesis, we have
developed mathematical models to describe tumour-immune competition with the
aim to investigate the biological settings which allow for successful immune action.
We began this thesis by describing the key biological processes and mechanisms
which have been discovered by experimentalists, historically and in recent years. In
particular, we focused on the role of two immune cell types: dendritic cells (DCs)
and cytotoxic T lymphocytes (CTLs), where DCs can collect protein antigens from
cancer cells and present them to naive CTLs to allow for CTL activation. The CTLs
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can then actively target and destroy tumour cells which express the targeted protein
antigen. Along with a description of this immune response to cancer, we considered
ways in which tumours can evade the immune response and current immunotherapy
techniques used to try and restore these processes.
Mathematical modelling techniques have been used extensively in the past to
describe cell motion, tumour development and tumour-immune competition. We
provided a short review of these techniques and their applications, with a focus on
discrete individual-based (IB) models and continuous partial differential equation
(PDE) models.
Recent advances in cell imaging technology have allowed for the single cell track-
ing of immune cells in the tumour microenvironment. In particular, experimental
works have highlighted that CTLs, and DCs alter their migration patterns upon ex-
posure to tumour antigens. To describe these movement patterns, mathematically,
we have developed a simple individual-based model of immune cell motion using
two random walk methods based on a 2D lattice. We chose a Le´vy walk to replicate
the movement of inactive immune cells, where they can travel in one direction for
an extended period of time before choosing a new one. Additionally, for the active
immune cells we considered Brownian motion, where at each time instant the cell
could move to any neighbouring grid position with equal probability. Results from
our computational simulations were able to reproduce qualitatively the spatial tra-
jectories of immune cells observed in the experimental data of single cell tracking.
Looking to the future, the T cell experiments completed in Boissonnas et al. (2007)
consider cell movement in the z direction as well as x and y directions and there-
fore it may be appropriate to consider the model in three dimensions. The effects
of changing the spatial domain from 2D to 3D on the two forms of random walks,
Brownian motion and Le´vy walks, would need to be considered. It is probable that
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the change of dimension would alter the time it takes for cells moving via either
walk to reach their target cells. However the general properties of each walk and
their benefits in comparison to each other should be maintained (Bartumeus et al.,
2014; Detcheverry, 2017; Wosniack et al., 2017).
Using the modelling strategies to describe immune cell motion, we then developed
a spatially stochastic individual-based model describing the spatio-temporal inter-
actions between DCs, CTLs and tumour cells. We included the effects of tumour
recognition, immune activation, tumour growth and tumour destruction by the im-
mune system. Simulations of the model were run for the 2D case and parameter
settings of potential interest were investigated. The model results suggested that a
high density of CTLs within the tumour microenvironment would be beneficial to
tumour removal. However increased numbers of DCs could lead to an overcrowding
effect. Furthermore, the results of our model highlighted that situations of enhance
tumour growth could be control if CTLs had a strong capability of removing tumour
cells. However, the model also suggested that altering the activation rate of both
immune cells types or the exhaustion rate of the immune cells would not signific-
antly alter the outcome of tumour-immune competition, and therefore are not viable
targets for immunotherapy techniques. Immune cell exhaustion was also considered
where the immune cells were limited in the number of cells that they could interact
with. The results of the model suggested that as long as this limit was not small, e.g.
an exhaustion limit ≥ 10 cells, then the outcomes of tumour-immune competition
would be similar to those where there was no exhaustion limit. The effect of using
the switch in cell motion suggested in Chapter 4 was also investigated and it was
found that using this switch led to a faster tumour removal time than if Brownian
motion was used to describe the motion of all cell types. In this individual-based
model, for simplicity, it was assumed that the tumour was homogeneous, i.e. all
153
tumour cells expressed the same tumour antigens. However, tumours can be het-
erogeneous, where each cell may have a unique antigen profile.
To investigate this further, we extended the individual-based model to include the
effects of heterogeneity within and between tumour cells. Each tumour cell was char-
acterised by an antigen profile, which described the expression levels of the eleven
MAGE antigens expressed by the cell. Initially, the antigen profiles of tumour cells
were dependent on the total level of heterogeneity within the tumour. The antigen
profile of each cell was additionally allowed to vary over time due to the occurrence
of epimutations. The antigen expression of each tumour cell subsequently shaped
the cellular immune response, and ultimately determined the receptors produced by
the CTLs. Successful destruction of tumour cells by the CTLs then depended on
the level of antigen expressed by the tumour cell corresponding to the CTL’s T cell
receptor. Once again, simulations of the model were run for the 2D case and para-
meter settings of potential interest were investigated. Computational simulations of
this model clarified the conditions for the emergence of tumour clearance, dormancy
or escape, and allowed us to assess the impact of antigenic heterogeneity of cancer
cells on the efficacy of immune action. The model results also suggested that a
diverse T cell population, where multiple antigen receptors are produced, would be
advantageous in removal of the tumour. Furthermore, the model results indicated
that increasing the frequency of epimutations may be a beneficial approach to treat
cancer.
Ultimately, the results from both tumour-immune individual-based models high-
lighted the complex interplay between spatial interactions and adaptive mechanisms
that underpin the immune response against solid tumours, and suggests how this
may be exploited to further develop cancer immunotherapies. Looking to the fu-
ture, these individual-based models could be extended further by considering the
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effects of division and decay of the immune cells types or through describing pro-
cesses where tumour cells directly attack the lymphocytes. Normally Fas ligand
from the lymphocyte binds to the Fas receptor on the tumour cell surface, they
aggregate to form a Fas associated death domain which activates a caspase cascade
resulting in apoptosis of the tumour cell (Hersey and Zhang, 2001). However, tu-
mour cells can also produce FasL and activate apoptosis of the CTLs through their
Fas receptors (Stewart and Abrams, 2008). Furthermore, we have only described
tumour-immune competition in 2D, and therefore extending the model into 3D could
bring further understanding of the biological mechanisms underpinning the immune
response to solid tumours and the phenomena observed in the 2D model, such as
overcrowding.
As mentioned previously, individual-based models can be limited by their lack
of amenability to mathematical analysis techniques. To overcome this we aim to
derive the continuum counterparts of the individual-based models described previ-
ously. However, due to the inclusion of a Le´vy walk and other complex mechanisms,
we considered a simpler biological situation. We developed an individual-based
model describing a cell population, where cells were able to undergo pressure-driven
movement and pressure-dependent proliferation. From the discrete random branch-
ing walk that underlies the individual-based model we formally derived nonlinear
partial differential equations which have been commonly used to model the spatial
dynamics of growing cell populations. We subsequently carried out a systematic
comparison between the individual-based model and its continuum counterparts,
both in the case of one single cell population and in the case of multiple cell popula-
tions with different biophysical properties. The outcomes of our comparative study
demonstrated that the results of computational simulations of the individual-based
model we able to faithfully mirror the qualitative and quantitative properties of the
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solutions to the corresponding nonlinear partial differential equations. This is of po-
tential use when working on biologically motivated models, as the individual-based
approach may be easier to describe to biologists and other nonmathematicians, how-
ever through the continuum model a level of mathematical analysis can be retained.
Ultimately, these results illustrated how the simple rules governing the dynamics
of single cells in our individual-based model can lead to the emergence of complex
spatial patterns of population growth observed in continuum models. Similar meth-
ods could be used in the future to derive the corresponding continuum models of
more complex individual-based models, such as those we have developed to describe
tumour-immune competition. In this regard, many previous continuous models have
been used to describe Le´vy flights. However, in the case of Le´vy walks there is a gap
in the literature and this form of random walk is not well described in the context
of systems of equations.
Our cell population migration and growth model could be extended into higher
dimensions or used to describe biological situations such as cancer invasion. In
this regard, it would be interesting to use our stochastic individual-based model to
further investigate the formation of finger-like patterns of invasion observed for the
two population system of PDEs posed on a two dimensional spatial domain (Lorenzi
et al., 2017). Such spatial patterns resemble infiltrating patterns of cancer-cell in-
vasion commonly observed in breast tumours (Wang et al., 2012). An additional
development of our study would be to compare the results presented here with
those obtained from equivalent models defined on irregular (non-uniform) lattices,
as well as to investigate how our modelling approach could be related to off-lattice
models of growing cell populations (Drasdo, 2005; Motsch and Peurichard, 2018;
Van Liedekerke et al., 2015). Cell population models have also be used to con-
sider other modes of cell migration, for example chemotaxis, whereby cells follow
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a chemical signal. The continuum limit of stochastic chemotactic models has been
considered (Erban and Othmer, 2004; Stevens, 2000) and in a similar way our model
could be adapted to consider chemotaxis, whereby cells move up the chemoattract-
ant gradient, rather than down the pressure gradient.
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Appendix A
Appendix for Chapter 5
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Figure A.1: Example of spatial distributions of cells over time for a case of
tumour elimination. Initially, the simulations begin with 400 tumour cells (blue)
situated in the centre of the domain surrounded by inactive cytotoxic T lymphocytes,
CTLS, (pink) and inactive dendritic cells, DCs, (grey). Throughout the simulations
the DCs and CTLs can become activated (black and red, respectively) and interact
with tumour cells. In the parameter setting used here the tumour cell number reduces
until all cells are removed from the system at time t = 2505. For this simulation we
use the parameter values given in Table 5.2 with an exhaustion limit of 5 cells.
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Figure A.2: Example of spatial distributions of cells over time for a case of
tumour persistence. Initially, the simulations begin with 400 tumour cells (blue)
situated in the centre of the domain surrounded by inactive cytotoxic T lymphocytes,
CTLS, (pink) and inactive dendritic cells, DCs, (grey). Throughout the simulations
the DCs and CTLs can become activated (black and red, respectively) and inter-
act with tumour cells. In the parameter setting used here the tumour cell number
increases over the simulation time and the tumour increases in size. For this simu-
lation we use the parameter values given in Table 5.2 with an exhaustion limit of 1
cell.
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Figure A.3: Increasing the number of DCs can lead to longer tumour
removal times. The heat maps show the evolution of the tumour cell number over
time for each given value of NC and/or ND (left panels). We select four simulation
results for cell numbers, of 60, 420, 1200 and 2400 cells, and compare the tumour cell
number over time for each parameter setting (right panels). In each case, we begin
the simulations with 1200 tumour cells and test for varying values of: a,b NC only,
c,d ND only and e,f NC and ND. All values were averaged over three simulation
runs.
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Figure A.4: The ratio between the removal rate of tumour cells by CTLs
and the tumour cell division rate is a crucial parameter in tumour re-
moval. The heat maps show the evolution of the tumour cell number over time for
each given value of µ and/or λ (left panels). We select four values of µ and/or
λ and compare the tumour cell number over time for each parameter setting (right
panels). In each case, we begin the simulations with 1200 tumour cells and test for
varying values of: a,b µ only, c,d λ only and e,f µ and λ. All values were averaged
over three simulation runs
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Appendix B
Appendix for Chapter 7
B.1 Details of numerical simulations of the individual-
based model
We use a uniform discretisation of the interval [0, 100] that consists of 1001 points
as the spatial domain, i.e. the grid-step is χ = 0.1, and we choose the time-step
τ = 2 × 10−3. We implement zero-flux boundary conditions to prevent cells from
moving out of the spatial domain. For all simulations, we use the definition of
the rate G given by equation (7.44) and we perform numerical computations in
Matlab. Further details for each specific situation considered are provided in the
next subsections.
B.1.1 Setup of numerical simulations for the case of one cell
population
For consistency with equation (7.1), we set M = 1 and we drop the index h = 1
both from the functions and from the parameters of the individual-based model.
165
We define the rate G in equations (7.9)-(7.11) according to equation (7.44). We
set the homeostatic pressure P = 120 × 104 for the simulation results reported
in Figure 7.2 and Figure 7.3, while we choose P = 120 × 105 for the simulation
results of Figure 7.4. Moreover, we choose β = 4 × 10−6 for the simulation results
reported in Figure 7.2, β = 4 × 10−5 for the simulation results of Figure 7.4, and
β ∈ {1.5× 10−6, 4× 10−6, 4× 10−5} for the simulation results of Figure 7.3. We set
ν = 0.02 in equations (7.13)-(7.15) and we define the pressure pki according to the
following barotropic relation
Π(ρki ) = Kγ (ρ
k
i )
γ with Kγ =
γ + 1
γ
and γ > 1,
which satisfies the conditions given by equation (7.2). We let γ ∈ {1.2, 1.5, 2} for the
simulation results of Figure 7.4, while we choose γ = 1.2 for the simulation results
reported in Figure 7.2 and Figure 7.3. We impose compact support by using the
initial cell density
ρ0i =

A exp (−b x2i ) for xi ≤ 50
0 for xi > 50
with A = 2× 104 and b = 4× 10−3.
The results presented in Figure 7.2 and Figure 7.3 correspond to the average over
three simulations of our individual-based model, while the results in Figure 7.4
correspond to one single simulation when γ = 1.5 or γ = 2 and the average over two
simulations when γ = 1.2.
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B.1.2 Setup of numerical simulations for the case of two cell
populations
For consistency with the system of equations (7.7), we choose M = 2, and we
set G1 ≡ G and G2 ≡ 0 in equations (7.9)-(7.11), where G is defined according
to equation (7.44) with the homeostatic pressure P = 10 × 104 and the factor
β = 4 × 10−5. We set ν1 = 0.01 and ν2 = 0.5 in equations (7.13)-(7.15) for the
simulation results reported in Figure 7.5, while we consider ν1 = 0.5 and ν2 = 0.01
for the simulation results of Figure 7.6. We define the pressure pki according to the
following simplified barotropic relation
Π(ρki ) = K ρ
k
i with K = 2,
which satisfies the conditions given by equation (7.2). Here, we choose γ = 1 as the
results displayed in Section 7.5.2 and Figure 7.4 highlight that for large γ there can
be disagreement between the discrete and continuum models. We make use of the
initial cell densities
ρ01i = A1 exp
(−b1 x2i ) and ρ02i =

0, for xi ≤ 13,
A2 exp (−b2(xi − 14)2), for xi ∈ (13, 29),
0, for xi ≥ 29,
(B.1)
where
A1 = 1.25× 104, b1 = 0.06, A2 = 2.5× 104 and b2 = 6× 10−3.
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The results presented in Figure 7.5 and Figure 7.6 correspond to one single simula-
tion of our individual-based model.
B.1.3 Setup of numerical simulations for the case of two
populations with a redefined pressure function
For consistency with the system of equations (7.7), we choose M = 2, and we
set G1 ≡ G and G2 ≡ 0 in equations (7.9)-(7.11), where G is defined according
to equation (7.44) with the homeostatic pressure P = 10 × 104 and the factor
β = 4 × 10−5. We set ν1 = 0.01 and ν2 = 0.5 in equations (7.13)-(7.15) for the
simulation results reported in Figure 7.7, while we consider ν1 = 0.5 and ν2 = 0.01
for the simulation results of Figure 7.8. We define the pressure pki according to the
following barotropic relation
Π(ρki ) = q (ρ
k
i − ρ∗)+ where q = 10 and ρ∗ = r P with r = 10−3,
which satisfies the conditions given by equation (7.45). We choose this definition of
the pressure function as we now only depend on a linear function of the cell density
which may be a more biologically realistic description of cellular pressure. We make
use of the initial cell densities given by equation (B.1) with
A1 = 12.5× 104, b1 = 0.06, A2 = 25× 104 and b2 = 6× 10−3.
The results presented in Figure 7.8 and Figure 7.7 correspond to one single simula-
tion of our individual-based model.
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B.2 Details of numerical simulations of the con-
tinuum models
We let x ∈ [0, 100] and we construct numerical solutions for equation (7.1) and
for the system of equations (7.7) complemented with zero Neumann boundary con-
ditions. We use a finite volume method based on a time-splitting between the
conservative and nonconservative parts. For the conservative parts, transport terms
are approximated through an upwind scheme whereby the cell edge states are cal-
culated by means of a high-order extrapolation procedure (LeVeque, 2002), while
the forward Euler method is used to approximate the nonconservative parts. We
consider a uniform discretisation of the interval [0, 100] that consists of 1001 points
and we perform numerical computations in Matlab. For all simulations, we use the
definition of the rate G given by equation (7.44). Further details for each specific
situation considered are provided in the next subsections.
B.2.1 Setup of numerical simulations for the case of one cell
population
The rate G is defined according to equation (7.44) with the homeostatic pressure
P = 120×104 for the numerical solutions reported in Figure 7.2 and Figure 7.3, while
we choose P = 120 × 105 for the numerical solutions of Figure 7.4. Moreover, we
choose β = 4×10−6 for the numerical solutions reported in Figure 7.2, β = 4×10−5
for the numerical solutions of Figure 7.4, and β ∈ {1.5× 10−6, 4× 10−6, 4× 10−5}
for the numerical solutions reported in Figure 7.3. We define the pressure p according
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to the following barotropic relation
Π(ρ) = Kγ ρ
γ with Kγ =
γ + 1
γ
and γ > 1,
which satisfies the conditions given by equation (7.2). We let γ ∈ {1.2, 1.5, 2} for
the numerical solutions of Figure 7.4, while we choose γ = 1.2 for the numerical
solutions reported in Figure 7.2 and Figure 7.3. Given the parameter values used
for the individual-based model in the case of one single cell population, we choose
the mobility µ = 4.166×10−7 for the numerical solutions reported in Figure 7.2 and
Figure 7.3, while we set µ = 4.166× 10−8 for the numerical solutions of Figure 7.4.
In this way, both values of µ satisfy the condition given by equation (7.21) for h = 1.
We impose the initial condition
ρ(0, x) =

A exp (−b x2) for x ≥ 50
0 for x < 50
with A = 2× 104 and b = 4× 10−3.
B.2.2 Setup of numerical simulations for the case of two
populations
The rate G is defined according to equation (7.44) with the homeostatic pressure
P = 10×104 and β = 4×10−5. Given the parameter values used for the individual-
based model in the case of two cell populations, we choose the mobilities µ1 =
2.5× 10−7 and µ2 = 1.25× 10−5 for the numerical solutions reported in Figure 7.5,
and the mobilities µ1 = 1.25× 10−5 and µ2 = 2.5× 10−7 for the numerical solutions
of Figure 7.6. This guarantees that the conditions given by equation (7.21) for
h = 1, 2 are satisfied. We define the pressure p according to the following simplified
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barotropic relation
Π(ρ) = K ρ with K = 2,
which satisfies the conditions given by equation (7.2). Again, we choose γ = 1 as
the results displayed in Section 7.5.2 and Figure 7.4 highlight that for large γ there
can be disagreement between the discrete and continuum models. We impose the
initial conditions
ρ01(0, x) = A1 exp
(−b1 x2) and ρ02 =

0, for x ≤ 13,
A2 exp (−b2(x− 14)2), for x ∈ (13, 29),
0, for x ≥ 29,
(B.2)
where
A1 = 1.25× 104, b1 = 0.06, A2 = 2.5× 104 and b2 = 6× 10−3.
B.2.3 Setup of numerical simulations for the case of two
populations with a redefined pressure function
The rate G is defined according to equation (7.58) with the homeostatic pressure
P = 10×104 and β = 4×10−5. Given the parameter values used for the individual-
based model in the case of two cell populations, we choose the mobilities µ1 =
2.5× 10−7 and µ2 = 1.25× 10−5 for the numerical solutions reported in Figure 7.7,
and the mobilities µ1 = 1.25×10−5 and µ2 = 2.5×10−7 for the numerical solutions of
Figure 7.8. This guarantees that the conditions given by equation (7.21) for h = 1, 2
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Figure B.1: The invasion front of the individual-based model travels at
the same speed but behind the front of the corresponding continuum
model. The left and right panel display, respectively, the pressure and the cell
density at the time instants t = 10, t = 50, t = 150 and t = 250. Values of
the pressure and the cell density are in units of 104. Simulations were carried out
using the same parameter values as the results for γ = 2 displayed in Figure 7.4. A
complete description of the numerical simulation setup is given in Appendix B.1.1
and Appendix B.2.1.
are satisfied. We define the pressure p according to the following barotropic relation
Π(ρ) = q (ρ− ρ∗)+ where q = 10 and ρ∗ = r P with r = 10−3,
which satisfies the conditions given by equation (7.45). We impose the initial con-
ditions given by equation (B.2) with
A1 = 12.5× 104, b1 = 0.06, A2 = 25× 104 and b2 = 6× 10−3.
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